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ABSTRACT  
   
CD8+ T-lymphocytes (CTLs) are central to the immunologic control of infections and are currently 
at the forefront of strategies that enhance immune based treatment of a variety of tumors. 
Effective T-cell based vaccines and immunotherapies fundamentally rely on the interaction of 
CTLs with peptide-human leukocyte antigen class I (HLA-I) complexes on the infected/malignant 
cell surface. However, how CTLs are able to respond to antigenic peptides with high specificity is 
largely unknown. Also unknown, are the different mechanisms underlying tumor immune evasion 
from CTL-mediated cytotoxicity. In this dissertation, I investigate the immunogenicity and 
dysfunction of CTLs for the development of novel T-cell therapies. Project 1 explores the 
biochemical hallmarks associated with HLA-I binding peptides that result in a CTL-immune 
response. The results reveal amino acid hydrophobicity of T-cell receptor (TCR) contact residues 
within immunogenic CTL-epitopes as a critical parameter for CTL-self/nonself discrimination. 
Project 2 develops a bioinformatic and experimental methodology for the identification of CTL-
epitopes from low frequency T-cells against tumor antigens and chronic viruses. This 
methodology is employed in Project 3 to identify novel immunogenic CTL-epitopes from human 
papillomavirus (HPV)-associated head and neck cancer patients. In Project 3, I further study the 
mechanisms of HPV-specific T-cell dysfunction, and I demonstrate that combination inhibition of 
Indoleamine 2, 3-dioxygenase (IDO-1) and programmed cell death protein (PD-1) can be a 
potential immunotherapy against HPV+ head and neck cancers. Lastly, in Project 4, I develop a 
single-cell assay for high-throughput identification of antigens targeted by CTLs from whole 
pathogenome libraries. Thus, this dissertation contributes to fundamental T-cell immunobiology 
by identifying rules of T-cell immunogenicity and dysfunction, as well as to translational 
immunology by identifying novel CTL-epitopes, and therapeutic targets for T-cell immunotherapy. 
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CHAPTER 1 
INTRODUCTION 
 
The vertebrate immune system is composed of a constellation of diverse immune cell types, each 
with an exquisite ability to protect the host from infectious agents, cancers, and other 
immunopathologies. Central to the success of this elegant complex system is the arm of adaptive 
immunity, dominated by the effects of T-lymphocytes and B-lymphocytes. In terms of evolutionary 
history, an immunological “big bang” resulted in the adoption of T/B lymphocyte receptors as 
dominant anti-pathogen defense system by the vertebrate lineage (Flajnik, 2014; Pancer & 
Cooper, 2006). The result is the near virtual conservation of the adaptive lymphocyte lineage in 
jawed vertebrates, underscoring the importance of lymphocyte-mediated immune protection 
across the tree of life (Pancer & Cooper, 2006). T/B Lymphocytes have three fundamental 
hallmarks that make them indispensable for host defense: 1) antigen specificity that is critical for 
self/nonself discrimination limiting off-target effects 2) receptor diversity that ensures sufficient 
frequency of pre-existing pool of immune cells to effectively combat any unknown pathogen over 
the course of the host’s lifetime 3) the unique immunologic memory that issues recall responses 
against a previous pathogen, and forms the basis of all modern vaccines (Abbas, Lichtman, & 
Pillai, 2014; Moticka, 2016a). 
Our understanding of the hallmarks of the lymphocyte immune response and its 
protective effects dates back to the early days of variolation performed by the Chinese as an 
effective deterrent against smallpox (Leung, 2011; Moticka, 2016a). It wasn’t until Edward 
Jenner’s smallpox vaccination efforts in 1796, that a true appreciation for concept of 
immunological memory impact on modern medicine was truly felt (Stewart & Devlin, 2006). About 
hundred years later, in 1890, an American pathologist William B Coley observed that injecting 
sarcoma patients with heat inactivated bacteria into the tumors resulted in occasional prolonged 
remissions (Decker & Safdar, 2009). It is now believed that a combination of innate and adaptive 
immune response by trafficking immune cells into the tumor injected with “Coley’s toxins” resulted 
in tumor remission observed in these patients (Decker & Safdar, 2009). Today, close to 120 years 
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after Dr. Coley’s findings, cancer immune therapies have come to the forefront of therapeutic 
interventions of cancer (Couzin-Frankel, 2013).  
This chapter describes a broad historical account into the discovery of the major players 
in cell mediated immune response: MHC-restriction and T-cells, along with the foundations of 
self/nonself discrimination and cancer immunology. Particular focus is given to the last 50 years 
of research in T-cell immunology and tumor immunology. Finally, relevant unanswered questions 
specifically relating to this dissertation work, and contributions addressed by the investigations 
pursued in this dissertation are addressed.  
1.1 Discovery, structure and function of MHC 
1.1.1. Discovery of MHC 
The Major Histocompatibility complex (MHC) genes, also called human leukocyte antigen (HLA), 
make proteins that form the crux of adaptive cell mediated T-cell response. There is a deep 
historical relationship between tumor immunology and MHC, going back to early 1900s. During 
the early years of transplantation and tumor immunology, tumors in inbred and random outbred 
mice were commonly used to understand immune responses. In 1909, Ernest Tyzzer, an 
American pathologist, and a founding member of the American association of cancer research 
(AACR), studied the progression and rejection of tumors transferred between the inbred 
Japanese waltzing mice and the outbred albino mice (Moticka, 2016c). Tyzzer observed that 
spontaneous tumors from the Japanese waltzing mice were able to grow when implanted into 
other Japanese waltzing mice, but were rejected when implanted into the outbred albino mice 
(Moticka, 2016c). Along with another researcher in his lab, Clarence C. Little, Tyzzer also 
observed that while F1 hybrids crossed between the Japanese waltzing mice and inbred C57Bl 
mice accepted the transplanted tumors, almost 98% of the F2 generation hybrids rejected it 
(Little, 1914, 1920; Moticka, 2016c). These results indicated that there was a genetic basis of 
tumor rejection in these animals. The data from F2 hybrid mice seemed to indicate a non-
mendelian mode inheritance of tumor rejection, which they proposed in a 1914 paper (Little, 
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1914). Little and Tyzzer later reconciled their data by proposing that perhaps more than one gene 
(upto 12, according to their calculations) was involved in these tumor rejection experiments (Little, 
1914, 1920; Moticka, 2016c).  
 During World War 2, Peter Groer performed similar experiments to identify genetic traits 
underlying tumor rejection by outbred mice. Gorer proposed that blood group antigens might be 
the source of tumor rejection in the different mice receiving the transplantable tumors. He 
reasoned that if this was the case, they should bear antibodies (which were described years 
before by Paul Ehrlich) against red blood cells from tumor donor in the recipient (Moticka, 2016c). 
Gorer was able to show that three types of antibodies indeed developed against blood antigens in 
the different types of inbred and outbred mice receiving the transplanted tumors (Gorer, 1936). 
Gorer then collaborated with George D. Snell from Jackson Laboratory who was interested in 
“histocompatibility genes” by studying tumor rejection in outbred mice. Together, they showed 
that tumors transplanted from mice with one of the blood antigens Groer identified (antigen II), 
was immediately rejected by mice which lacked antibodies against antigen II (Gorer, Lyman, & 
Snell, 1948). Gorer and Snell renamed this gene as Histocompatibility gene 2 (H-2) and proposed 
rules for tumor rejection during transplantation (Gorer et al., 1948).    
 The severe need for medical research on transplantation, especially of skin grafts to help 
soldiers and civilians recover from their severe injuries peaked during World War 2 (Moticka, 
2016c). Therefore, under the direction of Medical research Council of UK,  Peter Medawar 
studied transplanting non-malignant tissue in mice models, performing experiments largely similar 
to Groer and Snell (Moticka, 2016c), and obtained similar results as the MHC-H-2 antigen 
researchers. Medawar also observed that the severity of rejection of skin grafts transplanted 
between between animals decreased as the the “relatedness” between the animals increased 
(Medawar, 1944). Medawar made the very astute observation that graft rejection was therefore 
an immunological process associated with the adaptive immunity based on 1) the speed of 
secondary rejection (vastly higher than preliminary rejections) similar to “immune memory” 2) the 
specificity of graft rejection with limited off-target effects (Medawar, 1944). Medawar and 
colleagues were further able to demonstrate that it was lymphocytes from draining lymph nodes 
  4 
in the transplanted animals that were responsible for the vigorous reaction against transplanted 
skin grafts (Brent, Brown, & Medawar, 1958; Medawar, 1944).  
Based on decades of previous research, in 1956, in a landmark study, the first ever 
successful kidney transplant was performed between monozygotic twins (Merrill, Murray, 
Harrison, & Guild, 1956). In the following years, Jean Dausset and Baruj Benacerraf identified the 
human MHC (HLA) protein and it was shown that tumor rejection antigens and transplant 
rejection antigens were the same, and they were linked to lymphocyte-mediated graft rejection 
(Benacerraf, 1981; Dausset, 1958). For their discovery of MHC, George Snell, Jean Dausset and 
Baruch Benacceraf were awarded the Nobel Prize for Physiology or Medicine in 1980 (Moticka, 
2016c). Peter Medawar shared the Nobel Prize with Sir Frank Burnett for their contributions to 
transplantation immunology in 1960 (Moticka, 2016c).  
1.1.2. Structure and function of MHC 
In the 1970s, there were several labs working on elucidating the structure of the transplant 
molecule - the MHC. Because Ethan Shevach had previously shown that antibodies raised 
against MHC could interfere with antigen induced lymphocyte proliferation (Shevach, 1972), Pete 
Cresswell and colleagues eluted and purified MHC from surface of lymphocytes (Cresswell, 
Turner, & Strominger, 1973). The results revealed the presence of two polypeptide fragments; a 
30 KD fragment and a 11 KD fragment (Cresswell et al., 1973). The smaller 11 KD fragment was 
later shown by by Howard Grey and Pete Cresswell to be the the Beta-2-microglobulin (β2M) 
protein (Figure 1B), which non-covalently associates with with MHC-I (Grey, 1973). Finally, in 
1987, the crystal structure of human MHC HLA-A*02:01-β2M complex was solved by Pamela J. 
Björkman, Don C. Wiley and Jack L. Strominger (Bjorkman et al., 1988). Figure 1A shows a 3D 
reconstructed model of the original crystal structure from Bjorkman et al., which demonstrated a 
clear cleft formed by the HLA’s α1, α2 domains for foreign antigen binding (later shown to be 
linear peptides). Figure 1B shows the orientation of an antigenic peptide from the Influenza virus 
A protein M1 forming non-covalent binding in the peptide binding cleft formed by α1-α2 domains. 
The MHC class II (HLA-II) structure, solved much later again from JL Strominger and DC Wiley’s 
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Figure 1-1. 3D protein structure of HLA-A*02:01 derived from Protein Database (PDB). (A) 
3D reconstruction of original x-ray crystal structure of the human-MHC HLA-A*02:01 complex 
(Bjorkman et al., 1988) showing α1-α3 domains of human HLA-A*02:01 heavy chain (green), and 
β2M (orange) complex derived from PDB (Rose et al., 2017). (B)  Top view of the HLA-A*02:01 
α1-α2 domains forming the antigen binding cleft in complex with a viral-antigenic peptide 
(GILGFVFTL in grey) from Influenza A virus matrix protein from (Celie et al., 2009) (PDB 2X70). 
 
 
groups showed that it was a heterodimer formed by an α chain and a β chain (Brown et al., 
1993). 
Functionally, MHCs contribute to host immune surveillance by binding and presenting 
small linear peptides derived from intracellular proteins on the cell surface (Blum, Wearsch, & 
Cresswell, 2013; Fernando et al., 2008). Encoded in the short arm of human chromosome 6, the 
MHC-locus encompasses a multi-gene region representing one of the most polymorphic locus of 
the human genome (Blum et al., 2013; Fernando et al., 2008; Murphy & Weaver, 2016). Variants 
in this locus contribute to the control and susceptibility to a wide range of immunologic diseases 
from autoimmunity, infectious diseases to transplantation, and tumor immunity (Blum et al., 2013; 
Fernando et al., 2008). Classical antigen processing machinery posits that MHC class I (or HLA-I) 
presents such intracellular peptides to CD8+ T-cells (CTLs) while MHC class II (HLA-II) does the 
same to CD4+ T-cells (Blum et al., 2013; Fernando et al., 2008). MHC class I is expressed in all 
nucleated cells except neurons and erythrocytes, while MHC class II proteins are expressed in 
specialized immune cells such as antigen presenting cells (APCs) (Moticka, 2016c; Murphy & 
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Weaver, 2016). The peptide products are primarily derived from intracellular proteolysis of 
cytosolic proteins through the proteasome for the MHC class I pathway, and from exogenous 
proteins into the lysosome for MHC class II (Blum et al., 2013). In MHC class I pathway, the focus 
of CTL-recognition in this dissertation, long peptides generated by proteasomal degradation are 
imported into the endoplasmic reticulum (ER) via the transporter associated with antigen 
processing (TAP)  molecules as shown in Figure 1-2 (Blum et al., 2013). Subsequently, these 
longer peptides are further trimmed by ER aminopeptidase (ERAAP) to short 9-11 amino acid 
linear peptides, and the short peptides with binding motifs for the respective MHC subsequently 
bind with strong affinity (Blum et al., 2013).  Peptide binding stabilizes the MHC-β2M complex, 
and subsequently the pMHC-β2M trimeric complex is exported through the Golgi complex onto 
the cell surface for CTL- evaluation (Figure 1-2) (Blum et al., 2013). Thus, in classical MHC Class 
I pathway, the predominant ligands/peptides presented on cell surface via MHC-binding are 
 
Figure 1-2. Classical MHC class I and II antigen processing pathways. Top: MHC class I 
pathway. Bottom: MHC Class II pathway. Note that MHC class I is expressed in all nucleated 
cells, while MHC class II is expressed predominantly in immune cells (APCs). Figure reproduced 
with permission from Cellular and Molecular Immunology, Chapter 6, pg 127-128, Eighth Edition, 
Abul K. abbas, Andrew H. Lichtman, Shiv Pillai. Copyright Elsevier 2015 (Appendix C1).  
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self-peptides. However, during a pathogenic infection for instance, non-self-proteins (as well as 
autoimmune, tumor associated proteins) are subject to the same rules, resulting in the 
presentation of non-self antigenic “epitopes” on MHC class I/I. These antigenic peptide-MHC 
complexes on both class I and class II pathways (pMHC-I, pMHC-II) ultimately leads to T-cell 
(CD8, CD4 respectively) recognition of the infected cell (Blum et al., 2013; Fernando et al., 2008). 
This process will be covered in subsequent sections. 
 
1.2 Discovery and function of T-Cells 
1.2.1. Discovery of T-Cells 
The earliest known indication of cell mediated immunity was observed when Ilya Metchnikov, a 
Russian zoologist showed that a rose thorn inserted into starfish larvae attracted cells (later 
shown to be macrophages performing phagocytosis) which surrounded, engulfed and dissolved 
the thorn (Metchnikoff, 1989; Moticka, 2016e). The relative importance between the types of 
immune response observed in infections between antibodies (demonstrated by Paul Ehrlich) and 
cellular responses (Ilya Metchnikov) was the subject of long dispute and debate, despite them 
sharing the Nobel prize for Physiology and Medicine in 1908 (Metchnikoff, 1989; Moticka, 2016e).  
In the early 1940s, Merrill Chase and Karl Landsteiner were researching on skin 
hypersensitivity and inflammation after synthetic chemical injections (Moticka, 2016e). Chase and 
Landsteiner showed that serum transfer from guinea pigs sensitized with picryl chloride (a 
synthetic chemical) injections failed to protect non-sensitized animals indicating that antibodies 
alone failed to protect against skin hypersensitivity (Landsteiner & Chase, 1942; Moticka, 2016e). 
However, other immunologists around the same time had shown that skin hypersensitivity 
matched a number of tenets of immunological memory as proposed by Peter Medawar (section 
1.1.1) including immunological memory that mediated a vigorous secondary response to 
hypersensitivity. After several failures to explain skin hypersensitivity, Chase accidentally used 
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serum contaminated with cell preparation which elicited skin hypersensitivity in normal guinea 
pigs (Landsteiner & Chase, 1942). Building on these fortuitous observations, in 1945, Chase 
demonstrated that peripheral blood cell preparations were able to transfer and initiate  skin 
sensitivity to chemicals and tuberculosis pathogen used in the previous studies (Chase, 1945), 
demonstrating what is perhaps one of the first  attempts at adoptive T-cell transfer therapy.  
 Around the same time, Peter Medawar was studying the immunologic basis on skin graft 
rejection (section 1.1.1, (Medawar, 1944)). Because of a substantial amount of antibodies in sera 
of animals and human undergoing graft rejection, Medawar assumed that serum antibodies were 
the cause (as opposed to the consequence) of skin graft rejection (Hildemann & Medawar, 1959). 
Building on Chase’s findings, in 1955, Avrion Mitchison, showed that lymphocytes from tumor 
draining lymph nodes were able to mediate the rejection of tumor grafts in syngeneic animals 
(Mitchison, 1955). Medawar, in a subsequent seminal study, then reasoned and showed that 
similar lymphocyte-mediated inflammatory reaction might also occur during non-malignant tissue 
transplantation using skin grafts (Brent et al., 1958).  
1.2.2. Discovery of T-Cell-MHC-restriction 
By 1956, it was established that antibodies are synthesized and secreted by cells that are found 
in the mature Bursa Fabricus of birds (and later in mammalian bone marrow) called B-cells (Glick 
& Sadler, 1961), but no such equivalent was found for the cell-mediated responses. In 1961, 
Jacques Miller, an Australian immunologist, discovered the function of the thymus (an organ rich 
with lymphocytes) by demonstrating that thymectomy dramatically reduced an animal’s ability to 
respond to subsequent antigen challenge (Miller, 1961). Subsequent experiments by James 
Gowans and colleagues clearly showed antigen-dependent proliferation of small lymphocytes and 
thymocytes (Gowans, Mcgregor, Cowen, & Ford, 1962). Furthermore, Rupert E. Billingham, a 
British immunologist in 1968 showed unequivocally that lymphocytes, not antibodies from skin 
graft recipient mice were able to transfer their reactivity to other untransplanted mice, 
demonstrating the true importance of lymphocyte mediated histo-incompatibility (Billingham, 
Silvers, & Wilson, 1963).  
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In subsequent years several studies indicated the link between T-cells and MHCs 
(section 1.1.1). For instance, a 1975 study by Peter Doherty and Rolf Zinkernagel demonstrated 
that activation of cytotoxic T-lymphocytes by LCMV-infected fibroblasts required MHC-
compatibility, was contingent on MHC H-2
k
 interaction and was abrogated in mice lacking MHC-
H-2
k
 molecules (R. M. Zinkernagel, 1975). Similar results of histocompatibility were observed 
using T-cells and Macrophages, T-cells and B-cells (Katz, 1973). This led Zinkernagel and 
Doherty to propose that either 1) there were two separate molecules on CTLs (one interacting 
with virus and other with MHC) - the “intimacy model”; or 2) the virus infection altered the MHC to 
provide a signal to CTLs-”the altered self” model (Rolf M. Zinkernagel & Doherty, 1974). The duo 
would later be awarded the Nobel Prize for Physiology or Medicine in 1996.  
1.2.3. T-Cell-receptor discovery and structure 
Studies on the nature of T-cell receptor (TCR) structure in early 1980s by several groups clearly 
put to rest the debate of altered self versus intimacy model proposed by Zinkernagel and Doherty 
(Allison, McIntyre, & Bloch, 1982; Haskins, 1983; Meuer, 1983). The studies indicated that the 
TCR directly interacts with the MHC-I, and the immunogenic antigen was a linear 8-11 amino acid 
stretch of peptides derived from the antigen. In essence, the altered self resulted from the 
presence of the short antigenic epitope from the antigen (virus or tumor-derived) while the TCR 
itself recognized the MHC-peptide complex. Emil R. Unanue, a Cuban-American immunologist, 
fluorescently labelled the peptide derived from hen egg lysozyme and visualized on cell surface in 
complex with MHC-I, and proved the specificity of MHC-I, but not MHC-II (B. P. Babbitt, 
Matsueda, Haber, Unanue, & Allen, 1986; Bruce P. Babbitt, Allen, Matsueda, Haber, & Unanue, 
2005). In 1984, Mark Davis and colleagues, and Tak Wah Mak’s group in two successive papers, 
identified the elusive T-cell receptor gene (TCR from αβ-TCR expressing T-cells) by subtracting 
T-cell mRNA from that of B-cells (Hedrick, Cohen, Nielsen, & Davis, 1984; Yanagi et al., 1984). 
Harvey Cantor and colleagues, and a little later, Edgar Engleman and colleagues, showed that 
MHC-I and MHC-II bound peptides stimulated the two major subpopulations of T-cells, CD4+ T-
cells and CD8+ T-cells respectively (Cantor & Boyse, 1975; Engleman, Benike, Grumet, & Evans, 
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1981). These results were further confirmed by the solved X-ray crystal structure of the MHC-
class I peptide complex (section 1.1.2). Lastly, Don Wiley’s group in 1996, again succeeded in 
solving the X-ray crystal structure of TCR in complex with human HLA-A*02:01-Viral peptide 
complex (Garboczi et al., 2010).  
 Wiley et al’s results largely confirmed decades of previous research. The TCR is a cell 
surface membrane disulfide linked heterodimer of the α-chain and β-chain belonging to the 
Immunoglobulin superfamily proteins (Garboczi et al., 2010; Wucherpfennig, Gagnon, Call, 
Huseby, & Call, 2010). Both chains have a constant (C) region proximal to the cell surface of the 
T-cell, while the variable (V) region interacts with the MHC-peptide complex (Wucherpfennig et 
al., 2010). In general, the TCR interacts diagonally with the MHC-peptide complex (Figure 1.3), 
with different loops within the Vα and Vβ domains making contact with the antigenic peptide, or 
the MHC, or both (Garboczi et al., 2010; Wucherpfennig et al., 2010).  The V and C regions of 
αβTCRs as well as Igs from B-cells, are generated by the process of somatic recombination, 
discovered in 1978 by Susumu Tongeawa (Tonegawa, 1983). This process, referred to as V(D)J 
recombination, results in the generation of the incredible diversity of TCR-repertoire which can in 
theory, can generate up to 10
15
 to 10
20
 TCR-clonotypes (Laydon, Bangham, & Asquith, 2015). 
The diagonal placement of the TCR over pMHC complex ensures that the hypervariable 
complementarity determining region 3 (CDR3) of Vα and Vβ domains (CDR3α & CDR3β) are 
responsible for interacting with the center of the antigenic peptide (Wucherpfennig et al., 2010). 
The CDR1 and CDR2 of Vα and Vβ domains in turn interact with the N or C-terminal of the 
antigenic peptide, with the CDR2 also thought to be interacting with the presenting MHC, 
contributing to the TCR-MHC-restriction (Wucherpfennig et al., 2010). Recent studies have now 
pointed that TCRs although cross-reactive, have very similar recognition motifs across the 
different antigenic epitopes (Birnbaum et al., 2014; Cole et al., 2016).  Despite the generalizable 
properties of TCR-pMHC interaction, individual residues contributing a TCR’s recognition of an 
antigenic peptide-MHC complex is highly dependent on the specific antigenic peptide-MHC 
complex, giving high specificity and sensitivity to the sampling methodology for T-cells 
encountering infected/malignant cells throughout a host’s lifetime.  
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Figure 1-3. 3D protein structure of the 1E6-TCR-pHLA complex. 1E6-TCR in complex with 
preproinsulin peptide-HLA-A*02:01, derived from a patient with Type 1 diabetes (T1D). 3D 
reconstruction of X-ray Crystal structure of human-TCR 1E6 binding to the preproinsulin epitope 
AQWGPDPAAA-HLA-A*02:01 complex (Cole et al., 2016) obtained from PDB. The pMHC 
complex (right side) and the TCR (left side) are shown, colored by subunits within each protein. 
The 1E6 TCR also has cross-reactivity with several microbial peptides and is considered to be 
active in T1D patients by antigen mimicry (Cole et al., 2016; Stadinski, Obst, & Huseby, 2016). 
 
 
1.2.4. Function of T-Cells 
T-cells are the master mediators of the adaptive cell mediated immunity against infected, 
malignant cells. While antibodies secreted by B-lymphocytes (B-cells) function predominantly to 
protect an infection from getting established (by “neutralization” and other mechanisms), T-cells 
function by eliminating infected cells once an infection/malignant cell has already been 
established (Murphy & Weaver, 2016). When TCR-pMHC interaction is achieved, the membrane 
proximal Cα and Cβ constant domains region of TCR associate with cell surface CD3 proteins 
(CD3ϒ, CD3δ, and CD3 ) (Abbas et al., 2014). Subsequently, a number of signal transducing 
molecules are recruited to the TCRs, such as the SRC family kinase (SFK) member LCK which 
phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3ϒ, CD3δ, 
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and CD3  (Brownlie & Zamoyska, 2013). Following ITAM phosphorylation, a series of 
phosphorylation events occur via ZAP70 (ζ-chain associated protein kinase of 70 kDa) by LCK, 
LAT (linker for activation of T cells) by ZAP70, and subsequently assembles a multiprotein 
complex termed LAT-signalosome (Brownlie & Zamoyska, 2013). The phenotypic outcome of this 
diverse signaling network is the upregulation of genes necessary for sustained growth, effector 
functions (e.g. target cell cytolysis by CTLs), secretion of canonical cytokines (e.g. Interleukin-2 
by CTLs), cell adhesion molecules (e.g. CD62L for lymph node homing), and other functions 
associated with the memory state of the T-cell (e.g. Naive vs memory).  
 Although there are other types of T-cells (e.g. 𝛄𝛅 T-cells, NKT cells etc.), the primary 
focus of this dissertation will be on CTLs (and to some extent CD4+ T-cells and regulatory T-
cells). Functionally the two major subsets of T-cells, CD4+ T-cells and CD8+ T-cells (CTLs) play 
different yet complementing roles in cell mediated immunity. CD4+ T-cells, termed helper T-cells 
are stimulated by antigenic peptide-MHC class II complexes are involved in 1) secreting pro-
inflammatory cytokines (Th1, Th2 and Th17) that can either directly or indirectly eliminate 
intracellular, extracellular pathogens; 2) providing T-cell help to B-cells, CTLs to carry out their 
effector function (Abbas et al., 2014). CTLs, also known as cytotoxic T-cells, are stimulated by 
antigenic peptide-MHC class I complexes presented by proteasomal processing of antigen by 
professional APCs (Abbas et al., 2014). Once primed, effector CTLs home to the periphery or the 
site of infection and directly cause target cell (infected cell or malignant cells) apoptosis (Abbas et 
al., 2014). Target cell apoptosis by CTLs occur via the effector molecules secreted by CTLs such 
as Perforin and Granzyme, or via Fas-ligand (FasL) on CTLs binding to Fas on target cells 
(Abbas et al., 2014). CTLs that recognize target cells via their TCR-pMHC-I interaction, there is 
massive microtubule reorganization, and secretory granules containing Granzyme B and Perforin 
traffic towards the immunologic synapse (Voskoboinik, Whisstock, & Trapani, 2015). The 
secretory granules are then secreted by the CTLs at the immunologic synapse, along with 
directionally secreted cytokines onto the target cell (Huse, Lillemeier, Kuhns, Chen, & Davis, 
2006; Voskoboinik et al., 2015). A second sub-dominant but independent mechanism of CTL-
mediated killing involved the ligation of Fas ligand (FasL) on CTLs to Fas protein expressed on 
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target cells (C. Janeway, 2005). This directional secretion of effector molecules provide high 
sensitivity and specificity of target cell killing by CTLs, and are exploited in this dissertation 
(Chapter 5).  
1.3 Primer on self/nonself-discrimination 
The idea of individuality has been an exercise in intellectual debate beginning with philosophers 
such as Aristotle, and in the last century has morphed into the phenomenology of biological 
identity by evolutionary biologists (Clarke, 2010; Thomas Pradeu, 2012; Smith & Szathmary, 
1997). At its core, immunology aims to provide mechanistic and conceptual understanding to the 
biological identity of an organism by its differentiation of self from nonself. Immunologic 
self/nonself discrimination vigorously protects the biological identity of a living entity by preserving 
its lifespan, and by extension, its genetic makeup.  
 The concept of the immunological self pervades the tree of life, from prokaryotes all the 
way up to vertebrates. The elegant CRISPR system in bacteria and archaea for example, is a 
prokaryotic adaptive immune mechanism aimed at protecting the bacterial “self” against invading 
bacteriophages (“nonself”) and other viruses (Barrangou et al., 2007). Regardless of the species 
and complexity of the immune system, there are commonalities to the conceptual immunological 
self. First, the immunological self has evolved mechanisms that are almost always harmful for an 
organism/entity that is perceived as the nonself (Cohn, 2010; Thomas Pradeu, 2012). For 
instance, in jawed vertebrates, as explained in previous sections, CTLs specifically target and kill 
infected and malignant cells with great precision (Section 1.2.4). Second, because the 
mechanism of defection by the immunological self is harmful, there must be a way for the 
immunological self to prevent itself from its own adverse actions, and reduce “off-target” effects 
mounted by an immune response against the immunological self to avoid debilitating conditions 
such as autoimmunity (Cohn, 2010). An example of this limiting self-reactivity  criterion can be 
seen in the vertebrate adaptive immune system, where majority of autoreactive T-cells are 
eliminated via a process called negative selection during thymic development  (Starr, Jameson, & 
Hogquist, 2003). This results in the dramatic reduction of the diversity in self-reactive TCRs (Yu et 
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al., 2015). Lastly, the immunological self must maintain cooperation and a status quo with other 
perceived foreign entities that are not harmful (and are in some cases beneficial) to the host.  
Examples of this type of interaction are the extension of T-cell tolerance against gut microbiome 
that is beneficial for humans (Round & Mazmanian, 2009).  
 In the last century, there have been several attempts to develop unifying immunological 
theories of self/nonself discrimination. Based on decades of previous research on transplantation 
and tumor immunology, Frank Burnett, conceptualized one of the earliest known thesis on 
immunologic self/nonself by proposing that early during development, an organism’s immune 
system acquires the knowledge of self vs. nonself causing immunologic tolerance (F. M. Burnet, 
1961; Ebert, 1970; C. A. Janeway Jr, Goodnow, & Medzhitov, 1996). These theories would later 
spur Peter Medawar’s landmark experiments on transplanting donor splenocytes to neonatal 
mice to acquire immunological tolerance (section 1.1.1) (Billingham, Brent, & Medawar, 1953). 
This self/nonself theory which dominated the landscape of immune theories over much of the last 
century proposes that during development, the immune system actively learns to distinguish self 
and makes an immune response against the nonself foreign entity (C. A. Janeway Jr, 1992; 
Langman & Cohn, 2000). However, many foreign entities do not garner immune responses (gut 
microbiota for instance), insofar as there are immune responses often initiated against the self, 
observed in autoimmunity and immunopathologies (C. A. Janeway Jr et al., 1996). Furthermore, 
Matzinger and colleagues in 1996 were able to show that neonatal mice can make an immune 
response to foreign grafts using appropriate signals (derived from dendritic cells) in an apparent 
contradiction to Medawar’s experiments (Ridge, Fuchs, & Matzinger, 1996).  
These experiments challenged the notion that tolerance did not depend on the source of 
the nonself foreign antigen, but rather the context under which the nonself was visible to the self 
(Ridge et al., 1996).  To address these limitations, Polly Matzinger proposed the “danger model” 
of immune system, which theorized that the immune system does not learn to distinguish self vs. 
nonself, but rather responds to the perceived presence or absence of danger (Matzinger, 1994, 
2002). The danger theory invited much enthusiasm and critique, with respect to the definition of 
what constitutes molecular danger, and the notion that the immune system is pre-programmed to 
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respond to pathogen associated molecular patterns (PAMPs) along with the antigenic stimulus 
(Charles A. Janeway Jr, Goodnow, & Medzhitov, 1996; Thomas Pradeu & Cooper, 2012). 
Recently, a third theory, put forth by Pradeau and colleagues, tries to unify these theories by 
proposing that irrespective of the source of immune response (danger vs. self/nonself) it is the 
breakdown of non-antigenic patterns upon routine surveillance by immune cells such as CTLs, 
that an immune response can be made (T. Pradeu & Carosella, 2006; Thomas Pradeu & Cooper, 
2012). This theory thus abandons the idea of the context of immune response, or the semantical 
definition of what constitutes self vs. nonself, but rather defines an entity (organism, antigen, or 
epitope) as immunogenic, if it constitutes a distinct pattern that is normally not encountered by the 
immune system, innate or adaptive (T. Pradeu & Carosella, 2006).  
Regardless of the interpretation of these theories, any definition of what constitutes as 
nonself, or as danger, or as immunogenic, can only be conceptualized when the underlying 
biological parameters that make an immune response by the adaptive immune system are 
comprehensively elucidated. In context of human CTLs, the hallmarks of antigenic epitopes that 
contribute to a CTL immune response have not been fully discovered. In Chapter 2, I explore the 
biochemical parameters of epitopes from a variety of sources (pathogenic as well as self) that 
underlie what T-cells determine as worthy of an immune response. Understanding this 
phenomenon is particularly relevant when developing T-cell based therapies that target diseases 
of foreign, as well as of the self (such as autoimmunity, solid tumors). 
 
1.4 Brief history of tumor immunology 
Many of the fundamental immunology discoveries on tolerance and autoimmunity and infectious 
disease response were uncovered based on investigations into tumor immune response 
(examples in previous sections). This section will describe the history of cancer immunotherapy, 
major discoveries in the last decade, and current developments in the field.  
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1.4.1. Coley’s toxins 
William B. Coley (1862–1936), was an American pathologist and a physician at the Memorial 
Sloan Kettering cancer center (Moticka, 2016d). During the course of his treatments, Coley noted 
that occasionally patients would have their tumors regress following a high fever from a bacterial 
infection (Coley, 1891). Coley through a literature search found that there were close to 47 
previous cases of physicians documenting occasional regression of tumors in patients following 
bacterial fevers (Coley, 1891). Based on these reports, Coley reasoned that the regression was 
perhaps due to the fever in response to the infection, although the biological mechanism under 
which that happened remained understandably obscure. Coley started injecting end stage cancer 
patients (in most cases with inoperable sarcomas) by injecting heat killed Streptococcus 
pyogenes directly into the tumors (Coley, 1898a).  
 The results of Coley’s clinical trials were mixed (Moticka, 2016d). Coley was able to 
induce tumor regression by his method in several patients, although two patients died of the 
infection itself (Coley, 1891). Because of the danger of using S.pyrogenes strains in cancer 
patients, Coley also experimented with second less dangerous Enterobacter bacteria, Serratia 
marcescens in combination with S.pyrogenes. A subset (~ 10%) of patients in these trials 
benefitted from regression (Coley, 1895), with some patients succumbing to either the treatment 
or the disease (Coley, 1898b). However, because Coley did not maintain consistency with 
respect to preparation of the heat killed bacteria (up to 13 different mixture of strains were used), 
and administration or the toxins (intravenous vs. intramuscular vs. intratumoral), other physicians 
had difficulties replicating these trials and treatments (McCarthy, 2006). This resulted in criticism 
of his experiments, with other physicians and scientists suggesting that the response observed 
might just be natural regression rates, which prompted Coley to defend his techniques (Coley, 
1895). One interesting observation in Coley’s response was his remark that some of these 
patients with inoperable tumors (presumably late-stage metastatic disease) had complete long 
term benefit (by today’s standards) after the administration of his toxins (Coley, 1895). In 1895, 
Coley wrote “One of my cases has gone three and one-half years. This was a twice recurrent 
sarcoma of the neck and tonsil, with the patient in a most desperate condition, with no chance of 
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living more than a few months” (Coley, 1895). Based on current knowledge of anti-tumor 
immunity, it has been proposed that a combination of a strong intratumoral innate inflammatory 
response mediated by proinflammatory cytokines such as interferon-α (IFNα), tumor necrosis 
factor α (TNFα), and interleukin 12 (IL-12) (Tsung & Norton, 2006), and cross reactive T-cells 
targeting neo-epitopes were recruited into these patient tumors causing sustained tumor 
regression (Snyder et al., 2014).  
 Despite these occasional but significant response observed in his patients, Coley’s toxins 
were outcompeted by the ever growing prominence and usage of radiation therapy, and 
subsequently chemotherapy to treat cancers (McCarthy, 2006). In contrast to Coley’s toxins 
which primarily worked best in sarcomas, radiation therapy, using X-rays discovered by Wilhelm 
Röntgen in 1895, caused therapeutic regression (although short term) of many different types of 
tumors consistently (Holsti, 1995; McCarthy, 2006). Despite these issues, Coley’s studies 
ushered in early research on factors secreted by immune system in response to pathogenic 
infections that could have beneficial effects (Kienle, 2012; Tsung & Norton, 2006). For instance, 
bacterial lipopolysaccharide (LPS) and tumor necrosis factor α (TNFα) were discovered by 
conducting research on induced sarcoma in mice models (Carswell et al., 1975; Kienle, 2012). 
Post 1940, Coley’s toxins were empirically tested in retrospective analyses, which indicated 
benefit for up to 57% of the patients treated with heat killed bacterial vaccines (Kienle, 2012). 
However, these studies did not rigorously undertake spontaneous remission rates to truly 
delineate the beneficial effects of Coley’s toxins. Coley’s early immunotherapy was also 
empirically tested in a randomized clinical trial in 1962, where 20/93 (21%) patients showed 
regression (Johnston & Novales, 1962). Because of the wide variability in response to heat killed 
bacterial vaccines, and as mentioned above the difficulties in replicating Coley’s techniques, 
replacement of Coley’s toxins with radiation therapy happened for cancer treatment starting in the 
1900s (McCarthy, 2006). Post revival of tumor immunology as a viable therapeutic option, there 
are several clinical trials today evaluating heat killed bacterial vaccines as potential adjuvants for 
cancer therapy (Karbach et al., 2012).  
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1.4.2. Early tumor immunology and pre-checkpoint era 
As mentioned in earlier sections, many fundamental discoveries made in the last century with 
respect to histocompatibility and the adaptive immune system were discovered because of 
studies in tumor rejection in mice (see section 1.1.1 on Tyzzer, Groer and Snell). Paul Ehrlich, 
known for his Nobel Prize winning contributions to the discovery of antibody, and one of the first 
adopters of chemotherapy, was also one of the first proponents of the concept that tumors could 
be recognized by the immune system (Himmelweit, 1958; Moticka, 2016b). Because of large 
gaps in knowledge with respect to tumorigenesis, as well as on autoimmunity, Ehrlich did not link 
antitumor immunity as being autoimmune in origin. Instead, Ehrlich proposed the concept of 
“horror autotoxicus”, where immune response against self could not possibly happen because of 
the disastrous consequences to the organism’s integrity (Moticka, 2016b). Later in 1900s, this 
would be proven otherwise because of the seminal work on tumor and graft transplantation 
undertaken by George Snell, Peter Medawar and Frank Burnett (sections 1.1.1-1.2.2).  
 Parallel to the work conducted by early transplantation immunologists, the finding by Paul 
Uhlenhuth that tissue specific proteins can induce the formation of highly unique and specific 
antibodies in various animals indicated that tumors could also develop unique tumor-specific 
antigens (Moticka, 2016d). In 1965, Gold and Freedman showed that extracted human colon 
cancer cells when injected into mice produced antibodies that reacted with colon and 
gastrointestinal malignant tissue, proving first experimental evidence of tumor-specific antigens 
(Gold, 1965; Gold & Freedman, 1965). With the advent of monoclonal antibody production by 
Georges Kohler and Cesar Milstein in 1965, cancer biology and immunology was given access to 
unprecedented view of cellular proteins in various model systems for research (Moticka, 2016d). 
Monoclonal antibody production allowed immunologists in particular to define the many different 
subsets of the immune system via their cell surface cluster of differentiation (CD) markers (Who 
Nomenclature Subcommittee, 1984).  
 In the mid-1970s, Steve Rosenberg and colleagues at the National Cancer Institute, USA 
pioneered the tumor immunology field with several seminal studies (Moticka, 2016d). First, they 
showed that interleukin 2 (IL-2) treated mouse splenocytes in in vitro cultures were cytotoxic to 
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mouse tumors when adoptively readministered (Yron, Wood, Spiess, & Rosenberg, 1980). 
Subsequently, the group demonstrated partial regression (21/55, ~38%) of tumors using 
autologous IL-2 primed T-cells from the peripheral blood of several metastatic melanoma cancer 
patients in what would be the first in human adoptively transferred T-cell human clinical trials (S. 
A. Rosenberg et al., 1985). The Rosenberg group was also the first to demonstrate in mouse 
models that tumor infiltrating lymphocytes (TILs) were 50-100 times more cytotoxic against 
autologous tumors, which would later be revealed to be a tumor-specific CTL-memory response 
(S. Rosenberg, Spiess, & Lafreniere, 1986). In the 1970s, with the discovery of viral mediated 
tumors in the form of the human papillomavirus (HPV) (zur Hausen, Gissmann, Steiner, Dippold, 
& Dreger, 1975), Epstein Barr Virus (EBV), and Hepatitis B virus (HBV) (Buynak, 1976), indicated 
further that the adaptive immune system could be used against treating tumors.   
1.4.3. Advances in tumor biology 
During 1900s, there were also fundamental breakthroughs made in understanding tumor biology 
and tumorigenesis as a phenomenon. For instance, Peter Nowell and David Hungerford 
discovered the Philadelphia chromosome, a major chromosomal abnormality with translocation 
between chromosomes 9 and 22 in more than 95% of patients with chronic myeloid leukemia 
(CML) (Koretzky, 2007). PC Nowell would also later propose the seminal hypothesis on the clonal 
origins of tumorigenesis via acquired somatic mutations (Nowell, 1976). Subsequently, 
oncogenes (e.g. Her2) (Nowell, 1976; Slamon et al., 1989), tumor suppressor genes TP53 (Oren 
& Levine, 1983), and the retinoblastoma gene (Rb) (Cavenee et al., 1983) were discovered. All 
these seminal studies on the nature, the biology and the mutational spectrum of cancer would 
later be synthesized by Robert Weinberg and Douglas Hanahan into the seminal work of the 
hallmarks of cancer (D. Hanahan & Weinberg, 2000). However, between 1990-2010, the tumor 
immunology field would make several fundamental contributions and milestones to the field of 
both cancer biology and immunology that Weinberg and Hanahan would include Tumor immune 
evasion and Tumor promoting inflammation as two emerging hallmarks in their revised version of 
the hallmarks of cancer (Douglas Hanahan & Weinberg, 2011). 
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1.4.4. Tumor immune editing 
In the 1980s, the incidence of acquired immunodeficiency (AIDS) cases caused by the human 
immunodeficiency virus (HIV) rose to epidemic proportions in the US LGBT community 
predominantly due to their manifestation as Kaposi’s Sarcoma (KS), a viral mediated cancer 
(Haverkos & Curran, 1982). A major outcome out of the research on HIV-AIDS is the finding that 
the virus caused massive systemic immune suppression in the infected individuals, which in turn 
caused the patients to succumb to opportunistic infections such as KS (Haverkos & Curran, 
1982). However, HIV-induced KS also highlighted the dominant role of the human immune 
system to seek and destroy any cancer that could have been formed otherwise. It also implicated 
that there could be immune evasion mechanisms that are actively employed by viruses and 
cancers that allow them to persist, and in the subsequent decade these would become the 
subject of intense investigations.  
 Frank Burnett in 1957 proposed that tumors might be constantly forming and regressing 
in an individual because of an immunologic reaction to tumor specific antigens (M. Burnet, 1957; 
Dunn, Bruce, Ikeda, Old, & Schreiber, 2002). However, because of several failures to adequately 
test the hypothesis and in lack of an in depth understanding of the adaptive immune system, it 
would take more than 30 years before several groups revisited the immune surveillance 
hypothesis. For instance, nude mice lacking a functional immune system were prone to form 
more tumors when injected with a chemically transformed mouse carcinoma (Engel et al., 1996). 
The discovery that interferon-γ (IFNγ) produced endogenously or when administered to mice 
resulted in tumor regression in mice undergoing transplantable tumors suggested a T-cell 
mediated control of many tumors (Dighe, Richards, Old, & Schreiber, 1994). Similar results were 
obtained with C57BL/6 mice lacking perforin, effector molecules secreted by CTLs to initiate 
target cell lysis (van den Broek, 1996), as well as recombination activating gene (RAG-1, RAG2)  
deficient mice which have profound immunodeficiency (Shinkai et al., 1992). The human 
relevance of these studies was clearly observable in immunosuppressed HIV-1+ AIDS patients 
(Haverkos & Curran, 1982), and transplant patients, with both groups being susceptible to higher 
incidence of many different cancers (Gatti & Good, 1971; Penn & Staezl, 1972). Synthesizing all 
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these results, Robert Schreiber and colleagues proposed “cancer immunoediting”; the idea that in 
immunocompetent individuals, tumor evolution is sculpted by the host immune response, giving 
rise to tumors that are heavily resistant to immune targeting (Dunn et al., 2002). 
 Cancer immunoediting involves three major phases; 1) Elimination 2) Equilibrium and 3) 
Escape (Dunn et al., 2002). In the early elimination phase, tumors are immunogenic and are 
susceptible to host adaptive immune response. The coordinated innate and adaptive response is 
in part due to tumor intrinsic genomic instability and other hallmarks of the tumor (Dunn et al., 
2002). In this phase, the tumors also express tumor-specific/associated antigens, or tumor- 
specific neoepitopes that are derived from the antigen presentation of non-synonymous mutations 
on HLA class I molecules. Tumors in this phase can also be susceptible to CD4+ T-cells if they 
 
Figure 1-4. The Cancer Immunoediting process. Elimination (left panel) process occurs due to 
normal immune surveillance where in tumor infiltrating immune cells eliminate immunogenic 
clones. Effector molecules (e.g. Perforin, IFNγ) are secreted by immune cells. Resistant clones 
(pre-existing or arising de novo, in magenta) survive and exist in a dynamic equilibrium phase 
with the immune cells, and strength of immune response decreases. In Escape phase (right 
panel), occurs with clonal expansion of the resistant clones (select examples of mechanisms are 
shown). Figure was adapted with modifications from Dunn et al., 2002. 
  22 
 
are antigenically processed and presented by APCs, NK cells if they lack antigen presentation, 
and other various different types of immune-mediated cell death (Dunn et al., 2002). Thus, the 
elimination phase is a direct consequence of the immune surveillance hypothesis proposed by 
Burnett and others (Figure 1.4, left panel). In the equilibrium phase, a darwinian selection of 
immune-resistant clones allows the temporal and spatial survival of the tumor (Figure 1.4, middle 
panel). Because there is a loss of the immunogenic clones from the tumor due to immune 
elimination, and a subsequent loss of tumor infiltrating immune cells, there is a dynamic 
equilibrium that persists over several years between the immune system in the tumor (Dunn et 
al., 2002). In this phase, it is likely that the resistant clone was pre-existing, or arose de novo due 
to the immune selection pressure (Figure 1.4, middle panel). In the escape phase, variant clones 
are now resistant and insensitive to immune detection and elimination. This process can involve 
for instance de novo or pre-existing variant clone upregulation of the programmed death ligand 1 
(PD-L1) in response to IFNγ secreted by TILs (Tumeh et al., 2014), or loss of the entire 
antigen/epitope that resulted in the CTL-mediated tumor cell death of the dominant immunogenic 
clone (Matsushita et al., 2012; Tran et al., 2016). Other mechanisms of immune escape and 
resistance have been described elsewhere (Schreiber, Old, & Smyth, 2011), and are currently the 
subject of intense investigation (Pardoll, 2012b; Schreiber et al., 2011). The resistant clones can 
thus largely avoid immune detection and escape, metastasize, and colonize the body. The cancer 
immunoediting hypothesis was seminal in that it gave an evolutionary framework to understand 
cancer immune response, based on clonal origins of tumorigenesis suggested by PC Nowell 
(section 1.4.3). Today, cancer immunoediting is widely applied to conceptualize and test immune 
based therapies. In Chapter 4, I apply this framework to investigate the mechanisms of immune 
resistance employed in response to the HPV-infection in head and neck cancers. 
1.4.5 The checkpoint era 
The logical extension from studies on tumor immunity, tolerance, and immunodeficiency observed 
in chronic viruses such as HIV-1, was the idea that there should be immune regulatory molecules 
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that rein in the efficacy of T-cell mediated immune response.  Such biochemical pathways could 
in be theory leveraged by self-reactive T-cells to avoid causing immunopathology, a major cause 
for many of the disease symptoms observed in autoimmune conditions.  
 The first such discovered molecule was cytotoxic T-lymphocyte–associated antigen 4 
(CTLA-4) in 1987 by Brunet et al (Brunet et al., 1987). CTLA-4 is expressed on 90% of human 
CD4+ T-cells and in about 50% of human CD8+ T-cells (Peggs, Quezada, Korman, & Allison, 
2006). Because of CTLA-4’s homology to CD28 (a co-stimulatory molecule expressed on T-cells 
required for adequate T-cell stimulation) (Linsley, 1991), CTLA-4’s apparently redundant function 
was under subject of investigation (Pardoll, 2012). However, Jim Allison, Jeffrey Bluestone and 
colleagues performed in vitro antibody cross linking experiments that suggested that CTLA-4 
might be a negative regulator of T-cell stimulation (Krummel & Allison, 1995; Walunas et al., 
1994). CTLA-4-deficient mice (CTLA-4
-/-
) developed by Arlene Sharpe’s group, and independently 
by Tak Mak and colleagues ultimately confirmed these findings by demonstrating that CTLA-4
-/-
 
mice displayed massive inflammatory conditions, characterized by severe lymphadenopathy and 
lymphoproliferation in all organs (Tivol et al., 1995; Waterhouse et al., 1995). Subsequently, 
CTLA4 antibodies that can partially block CTLA-4 functions in vivo developed by Allison and 
colleagues showed that substantial tumor rejection can be achieved in mice models (Leach, 
Krummel, & Allison, 1996; Sutmuller et al., 2001). The results highlighted the effect and extent of 
T-cells that are present in the periphery which could be leveraged to treat tumors (Pardoll, 2012).  
Functionally, CTLA-4 has been thought to inhibit T-cell function in two ways : 1) by 
recruiting alternative phosphatases to the TCR attenuating the strength of T-cell activation (Lee et 
al., 1998); 2) by directly competing for co-stimulatory molecules (CD80, CD86, due to its 
homology to CD28) on APCs making them unavailable for CD28-ligation (Qureshi et al., 2011). 
Biochemical and molecular functions of CTLA-4 is still a subject of active investigation. CTLA-4 
excited, and revived tumor immunology field spurring investigative humanized antibodies against 
CTLA-4 that were clinically developed by Medarex in collaboration with Jim Allison (later acquired 
by Bristol-Myers Squibb) (Pardoll, 2012). The first humanized immune checkpoint blockade 
antibody Ipilimumab (against CTLA-4) was approved by the FDA for the treatment of recurrent 
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metastatic melanoma in 2011 (Table 1-1) after a decade of clinical trials (Phan et al., 2003; 
Robert et al., 2011). In terms of response, Ipilimumab, although only effective in ~20% patients, 
causes long term complete regression of all metastatic lesions, with some stage III/IV melanoma 
patients surviving longer than 10 years (Pardoll, 2012).  
 The second major immune checkpoint molecules to be discovered were programmed 
death protein 1 (PD-1) and its ligand PD-L1. PD-1 was first discovered as a molecule that was 
thought to regulate programmed cell death in T-cells (Ishida, Agata, Shibahara, & Honjo, 1992). 
Although PD-1 knockout mice PD-1
-/-
 did not develop fulminant lymphadenopathy as CTLA-4
-/-
  
mice, PD-1
-/-
  mice upon aging would eventually develop strain specific and organ specific 
autoimmune reactions manifesting largely as Lupus like syndromes (Nishimura et al., 2001; 
Nishimura, Nose, Hiai, Minato, & Honjo, 1999). These results suggested a more fine-tuned 
regulatory function to PD-1 expressing T-cells. Subsequently, the ligands for PD-1 expressed on 
many dendritic cells, PD-L1 was discovered by Lieping Chen and colleagues (H. Dong, Zhu, 
Tamada, & Chen, 1999). Gordon Freeman and colleagues would then demonstrate that PD-
1/PD-L1 interaction delivered inhibitory signals to responding T-cells (Freeman et al., 2000).  
In contrast to the CTLA-4 pathway, PD-1/PD-L1 acted on the effector phase of T-cell 
stimulation, and was shown in several elegant studies by Rafi Ahmed and colleagues that in 
chronic virus systems, antigen persistence would result in the phenomenon of T-cell exhaustion 
(Barber et al., 2006; Day et al., 2006). T-cell exhaustion was characterized by the gradual loss of 
effector functions in antigen-specific CD8+ (and also CD4+) T-cells, with a distinct molecular 
signature resulting in impaired control of chronic virus infections in human and mice (Wherry et 
al., 2007; Zajac et al., 1998). Blockade of PD-1 restored (at least partially) functional exhaustion 
in CTLs and can resume T-cell mediated elimination of infections (Barber et al., 2006). Chen and 
colleagues would then demonstrate that PD-L1 expressing tumors evade immune response in 
mice models by causing T-cell apoptosis, establishing the link between PD-1 pathway and tumor 
immunity (Haidong Dong et al., 2002).  As with CTLA-4, investigations into blocking the PD-1 
checkpoint pathway was subsequently begun, resulting in several clinical trials again beginning 
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with melanoma (Brahmer et al., 2010; Topalian et al., 2012). Today, PD-1 antibodies Nivolumab 
and Pembrolizumab are among the most successful immune checkpoint blockade antibodies 
 
Table 1-1. Selection of FDA approved cancer immune therapies 
Name                                Target                              Type of Cancer                             Year 
Rituximab CD20 Non-Hodgkin lymphoma 1997 
Trastuzumab HER2 Breast Cancer 1998 
Ibritumomab CD20 Non-Hodgkin lymphoma 2002 
Cetuximab EGF Receptor Colorectal Cancer 2004 
Bevacizumab VEGF Colorectal Cancer 2004 
Panitumumab EGF Receptor Colorectal Cancer 2004 
Ofatumumab CD20 Chronic lymphocytic leukemia 2009 
Ipilimumab CTLA-4 Metastatic melanoma 2011 
Brentuximab CD30 Hodgkin lymphoma 2011 
Pertuzumab HER2 Breast Cancer 2012 
Obinutuzumab CD20 Chronic lymphocytic leukemia 2013 
Ramucirumab VEGF receptor 2 Gastric cancer 2014 
Blinatumomab CD19 and CD3 ALL, Melanoma 2014 
Dinutuximab GD2 Neuroblastoma 2015 
*Pembrolizumab,    
Nivolumab  
 
PD1 Melanoma 
NSCLC** 
Gastric Cancer**, HNSCC** 
Renal, Bladder Cancers  
MMR deficient, MSI positive CC    
Hodgkin lymphoma 
2014 
2016 
2017 
2017 
2017 
2017 
Tisagenlecleucel CAR T-cell therapy ALL  2017 
 
HER2, human epidermal growth factor receptor; EGF, epidermal growth factor; VEGF, vascular 
endothelial growth factor; CTLA-4, cytotoxic T lymphocyte antigen 4; PD1, programmed cell 
death protein 1; GD2,; Non-small cell lung cancer, NSCLC;  ALL,  Acute Lymphocytic Leukemia; 
MMR, Mismatch repair; MSI, Microsatellite instability. *Includes combined approvals for both 
Pembrolizumab and Nivolumab; ** Approved for recurrent metastatic cancers at present.  
Data current as of October 2017. Adapted from (Moticka, 2016d). 
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pursued in cancer immunotherapy with successful FDA approval for more than six cancers (Table 
1-1). PD-L1 and other checkpoint molecules are also being pursued for several ongoing clinical 
trials, as are other immune therapeutic modalities such as CAR T-cell, adoptive T-cell therapies. 
The dramatic, persistent, long-term response to CTLA-4 and PD-1 blockade antibodies in the 
treatment of select human cancers is partly attributed to the memory compartment of T-cell 
immunity, where recurring immunogenic lesions displaying antigens can be readily recognized 
and kept under control by a secondary immune response (Pardoll, 2012). However, the evolving 
fitness landscape of a tumor under cancer immunoediting hypothesis (section 1.4.4.) posits that 
some cancers will have resistant clones that can successfully thwart this immune assault. Thus, 
although checkpoint blockade immunotherapies are effective, objective long term clinical 
responses only occur in a subset of patients (~20% in CTLA-4 for melanoma, between 30%-40% 
for PD-1 blockade in melanoma and other cancers) (Pardoll, 2012a, 2012b).  Thus, it is highly 
likely that neoantigen and immune landscape of a tumor evolves as a result of specific tumor 
biology in addition to the immune heterogeneity observed in individuals (Schumacher & 
Schreiber, 2015). These observations argue for developing tumor-specific and perhaps patient-
specific immunotherapy regimens based on the tumor microenvironment and antigenic landscape 
of each tumor. The emphasis of current cancer immunotherapies has thus been to: 
● Understand response to checkpoint blockade immunotherapies to dissect mechanisms of 
immune dysfunction 
● Improve immunogenicity of weakly immunogenic tumors. This involves exploring the 
antigenic landscape of various tumors to identify epitope/neoepitope vulnerabilities.  
● Understand the limits of tolerance and self-reactivity in context of T-cells. 
● Understand the tumor microenvironment in context of the local factors influencing and 
editing the tumor immune response.  
In Chapter 4, I explore the landscape of antigenic epitopes and immune dysfunction in tumor 
microenvironment in the setting of HPV-associated head and neck cancers to develop better 
immune therapies.  
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1.5 Key thesis contributions 
This dissertation answers several fundamental questions in T-cell immunology, tumor 
immunology, and HPV-immunology, as well as develops novel techniques for applications in 
translational immunology. The key findings and contributions are listed as follows:  
1. The discovery that immunogenic MHC class I epitopes are characterized by a higher 
frequency of relatively hydrophobic amino acids at specific TCR-contact residues 
compared to non-immunogenic self-peptides, leading to a general biochemical parameter 
for T-cell self/nonself discrimination (Section 1.3) by CTLs (Chapter 2). 
2. The demonstration that amino acid biochemical properties in particular hydrophobicity, 
can be used to enhance the efficiency of prediction of immunogenicity of CTL-epitopes 
from any given antigen, and can correlate with epitope immunodominance hierarchies 
(Chapter 2). 
3. The discovery that human papillomavirus 16 (HPV16) antigen E2 elicits broad T-cell and 
B-cell reactivity in HPV+ HNSCC patients and is expressed in a subset of HPV+ HNSCC 
patients, making HPV16-E2 is a potential immunotherapeutic target for HPV-associated 
malignancies. (Chapter 4). 
4. The first comprehensive experimental definition of the landscape of HPV16 CTL-epitopes 
from E2, E6 and E7 across 12 different globally frequent HLA class I alleles from HNSCC 
patients (Chapter 4).  
5. The discovery that low immunogenicity of HPV16-E7 may be tied to the relatively higher 
levels of dysfunctional E7-specific CTLs compared to E2, E6-CTLs observed in HPV+ 
HNSCC patients (Chapter 4).  
6. The computational and experimental demonstration that the immunoregulatory enzyme 
indoleamine 2,3-dioxygenase (IDO-1) represents an HPV-specific immune evasion 
mechanism and is highly expressed in HPV-related malignancies (Chapter 4). 
7. The first mechanistic and experimental demonstration that IDO-1 inhibition can 
individually as well synergistically in combination with PD-1 blockade enhance the 
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cytotoxic potential of HPV-specific CTLs on HPV+ HNSCC cells, representing a new 
potential immunotherapeutic modality for HPV+HNSCCs (Chapter 4). 
8. The development of a novel single cell T-cell assay that can be employed to identify 
immunogenic T-cell antigens from whole pathogenome cDNA libraries (Chapter 5).  
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TCR CONTACT RESIDUE HYDROPHOBICITY IS A HALLMARK OF IMMUNOGENIC  
CD8+ T CELL EPITOPES 
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Abstract 
Despite the availability of major histocompatibility complex (MHC)-binding peptide prediction 
algorithms, the development of T-cell vaccines against pathogen and tumor antigens remains 
challenged by inefficient identification of immunogenic epitopes. CD8+ T cells must distinguish 
immunogenic epitopes from non-immunogenic self-peptides to respond effectively against an 
antigen without endangering the viability of the host. Because this discrimination is fundamental 
to our understanding of immune recognition and critical for rational vaccine design, we 
interrogated the biochemical properties of 9,888 MHC class I peptides. We identified a strong 
bias toward hydrophobic amino acids at T-cell receptor contact residues within immunogenic 
epitopes of MHC allomorphs, which permitted us to develop and train a hydrophobicity-based 
artificial neural network (ANN-Hydro) to predict immunogenic epitopes. The immunogenicity 
model was validated in a blinded in vivo overlapping epitope discovery study of 364 peptides from 
three HIV-1 Gag protein variants. Applying the ANN-Hydro model on existing peptide-MHC 
algorithms consistently reduced the number of candidate peptides across multiple antigens and 
may provide a correlate with immunodominance. Hydrophobicity of TCR contact residues is a 
hallmark of immunogenic epitopes and marks a step toward eliminating the need for empirical 
epitope testing for vaccine development. 
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2.1 Significance Statement 
The design of effective T-cell vaccines against pathogens and tumor antigens is challenged by 
the highly inefficient identification of the subset of peptides from a given antigen that effectively 
stimulate an immune response. Here we report that the relative hydrophobicity of T-cell receptor 
contact residues is markedly enriched in immunogenic major histocompatibility complex class I 
epitopes in both human and murine MHCs, and in both self and pathogen-derived immunogenic 
epitopes. Incorporating hydrophobicity into T-cell epitope prediction models increases the 
efficiency of epitope identification, which will manifest in the time and cost of T-cell vaccine 
development. Amino acid hydrophobicity may represent a biochemical basis by which T cells 
discriminate immunogenic epitopes within the background of self peptides. 
2.2 Introduction 
The interaction of CD8+ T cells with peptide-MHC complexes (pMHCs) is a key event in the 
development of cell-mediated immunity (Grakoui, 1999). MHC class I (MHC-I) molecules typically 
present 8-11 aa peptides derived predominantly from proteasomal degradation of intracellular 
proteins, either self-peptides or infection-derived antigens (Blum, Wearsch, & Cresswell, 2013). T 
cell receptors (TCRs) from CD8+ T cells bind antigenic pMHC molecules, triggering a 
downstream signaling cascade that leads to T cell activation, differentiation, and ultimately to 
cytolysis of target cells presenting the same epitope (Hennecke & Wiley, 2001). Vaccines and 
immunotherapies for the treatment of infection and cancer seek to incorporate cytotoxic T cell 
(CTL) epitopes, but defining such epitopes remains a costly and arduous process (Purcell, 
McCluskey, & Rossjohn, 2007). Understanding the molecular basis of TCR-pMHC recognition will 
aid discovery of immunogenic epitopes in infectious and autoimmune disease. 
During thymic development, CD8+ T cells undergo both positive and negative selection 
to acquire the ability to discriminate antigenic peptides from self-peptides (Hogquist et al., 1994). 
Costimulatory signals can enhance this discrimination (Medzhitov & Janeway, 2002), but a 
primary event that triggers CD8+ T cell activation is the non-covalent pMHC-TCR interaction. 
Proteasomal cleavage patterns and binding affinities of peptides to different MHCs have been 
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extensively studied (Falk, Rötzschke, Stevanović, Jung, & Rammensee, 1991; Kubo et al., 1994; 
Rammensee et al., 1999). In contrast, the biochemical basis of immunogenic epitopes is less 
well-defined (van der Merwe & Dushek, 2010). T cell epitope discovery is complicated by the 
codominance and polymorphism of MHC alleles, diversity of antigens (both infectious and self-
antigens), limited mass spectrometry-based confirmation of MHC-bound peptides, and a scarcity 
of experimentally confirmed immunogenic epitopes within the infectious and self-proteome 
(Purcell et al., 2007). As a result, T cell epitope prediction algorithms have focused on aa binding 
affinity for specific MHC-motifs and the proteins proteasomal cleavage pattern to identify 
candidate T cell epitopes (Honeyman, Brusic, Stone, & Harrison, 1998; Moutaftsi et al., 2006; 
Nielsen et al., 2007; Tenzer et al., 2005). Although computational tools have improved over the 
past decade, they have not been trained to predict immunogenicity. The major limitation when 
using such prediction algorithms is the presence of a significant number of binders from a given 
antigen that will never lead to an immune response (Newell et al., 2013). Thus, immunogenic CTL 
epitopes fulfill additional criteria that go beyond antigen processing and MHC-binding. 
Here, we sought to identify the biochemical criteria that define immunogenicity within 
the subset of MHC-I binding peptides. Using a curated repository of MHC-I epitopes from the 
Immune Epitope Database (IEDB) (Vita et al., 2009), we evaluated the biochemical properties of 
aas that discriminate between immunogenic epitopes and non-immunogenic self-peptides. We 
found a strong bias towards hydrophobicity in aa residues of immunogenic CTL epitopes that is 
highly selective for exposed TCR contact residues. Using these criteria, we trained an artificial 
neural network (ANN) model to identify immunogenic CTL epitopes from a data set and 
empirically assessed our prediction model for 3 human immunodeficiency virus 1 (HIV-1) Gag 
protein variants in a murine model of immunogenicity. We demonstrate the utility of this ANN 
model, which has the potential to significantly enhance the efficiency of T cell epitope discovery. 
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2.3 Results 
2.3.1. Amino Acid Use Differs Between Immunogenic and non-immunogenic Peptides 
CTLs recognize immunogenic epitopes from a background of poorly immunogenic self-peptides. 
To understand the biochemical basis of differences between these two classes of peptides, we 
retrieved all known MHC class I-binding peptides reported as T cell reactive (hereafter 
immunogenic) and self-peptides from MHC-ligand elution experiments with no known 
immunogenicity (hereafter non-immunogenic) from IEDB. Any eluted peptide that was 
immunogenic (either pathogen derived or self-antigen derived) was excluded to generate two 
mutually exclusive datasets that avoid any potential bias. Out of the 34,586 total retrieved 
peptides from IEDB, 5,035 8-11mer non-redundant peptides were reported to be immunogenic 
and 4,853 were non-redundant non-immunogenic and were used for further analysis. Frequency 
distributions of aas in 8-11mer immunogenic and non-immunogenic peptides showed significant 
variability in aa composition (Fig. 2-1-A). 
To identify overrepresentation of certain aa's in immunogenic epitopes, we computed a 
probability ratio for each aa. We then performed a correlation analysis between the probability 
ratio of each aa and three major biochemical properties using independent numeric scales: 
hydrophobicity (Kyte-Doolittle) (Kyte & Doolittle, 1982), polarity (Grantham) (Grantham, 1974), 
and side chain bulkiness (Zimmerman) (Zimmerman, Eliezer, & Simha, 1968) (Table A-1). We 
found a strong, statistically significant correlation between probability ratios and hydrophobicity 
values (Spearman ρ = 0.71, P = 4.24×10−4; (Fig. 2-2 A). Similarly, we also found a negative 
correlation between probability ratios and polarity of aas (Spearman ρ = −0.77, P = 6.97×10−5; 
(Fig. 2-2 B)), with highly polar aas being underrepresented in immunogenic epitopes. No 
significant correlation was observed with aa side chain bulkiness (Fig. 2-2 C). Most of the 
overrepresented and strongly bulky aas were also strongly hydrophobic. Cysteine, a non-polar 
hydrophobic aa was an outlier in the immunogenic dataset. Two potential sources of bias in our 
analyses were the variation in peptide length of MHC-I peptides and the dominance of human 
leukocyte antigen (HLA) A2 epitopes within existing databases. We analyzed on the 9mer 
epitopes (Fig. 2-1 B) and HLA class I restricted peptides excluding HLA-A2 peptides (Fig. 2-1 C).  
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Figure 2-1. Bias in amino acid usage between immunogenic and non-immunogenic MHC-I 
peptides. (A) Comparison of frequency distributions of amino acids between immunogenic and 
non-immunogenic datasets. (B) Probability ratio (P(x I immunogenic)/P(x I non-immunogenic)) of 
each amino acid as a function of its hydrophobicity, analyzed on just 9mer MHC-I peptides. (C) 
Probability ratio (P(x I immunogenic)/P(x I non-immunogenic)) of each amino acid as a function of 
its hydrophobicity, analyzed on 9mer HLA-I peptides excluding HLA-A2 restricted peptides.  
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Figure 2-2. Probability ratio of each amino acid as a function of its corresponding 
biochemical property. Each probability of each amino acid was computed from the frequency 
distribution of immunogenic epitopes and non-immunogenic peptides. Biochemical properties 
analyzed were (A) hydrophobicity, (B) polarity, and (C) side-chain bulkiness. A probability ratio >1 
indicates overrepresentation of the amino acid in the immunogenic dataset. The overrepresented 
outlier cysteine (C) was omitted for scale.  Spearman correlations coefficients (ρ) are shown. 
 
 
2.3.1. Hydrophobicity Bias in Selective TCR Contact Residues 
We first compared the mean hydrophobicity of each residue between immunogenic and non-
immunogenic peptides using the Kyte-Doolittle numeric hydrophobicity scale. Immunogenic 9mer 
epitopes were significantly more hydrophobic than non-immunogenic 9mer peptides at each 
residue (P < 1.6×10
−5
; (Fig. 2-4 A) and (Table A-2)). We observed similar results in 10mer 
peptides (P < 2×10
−7
 at every residue; (Fig. 2-3 A)), and within HLA-A2 excluded 9mer and 
10mer subsets (Figs. 2-3 B and C). Because the immunogenic dataset is biased to pathogen-
derived immunogenic epitopes, we performed similar analyses between immunogenic self-
epitopes and non-immunogenic self-peptides (P < 1×10
−4
 at all residues, except P5 and P6; (Fig. 
2-3 D)). We further compared immunogenic HLA-A2 restricted 9mer epitopes derived from 
pathogens with those derived from self-antigens and observed no significant difference in 
hydrophobicity (P > 0.05 at each aa residue except P6, P = 0.04; (Fig. 2-3 G)) revealing that T 
cells that escape thymic deletion recognize self-peptides with hydrophobicity profile that is 
virtually the same as that of pathogen-derived epitopes. Lastly, to evaluate if there is potential  
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Figure 2-3. Immunogenic pathogen-derived and self-epitope hydrophobicity. Each peptide 
sequence was transformed into numeric sequence based on hydrophobicity and the mean 
hydrophobicity at each position was computed. (A) Immunogenic and non-immunogenic MHC-I 
10mers; all residues P < 2x10
-7
. (B) HLA-I immunogenic and non-immunogenic 9mers excluding 
HLA-A2 epitopes. (C) Human HLA-I immunogenic and non-immunogenic 10mers excluding HLA-
A2 epitopes. (D) Immunogenic and non-immunogenic MHC-I 9mer self-peptides. (E) MHC-I 
9mers peptides discovered using whole organism as immunogen as opposed to peptide-
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immunization experiments (non-immunogenic dataset – same as Fig. 2A) (F) Human HLA-A2 
restricted immunogenic and non-immunogenic 10mers with arrows indicating anchor residues 
and stars for P < 0.005. (G) Human HLA-A2 restricted immunogenic pathogen-derived and 
immunogenic self 9mer epitopes. P-values for each figure were obtained using Wilcoxon rank-
sum test and are shown in Table A-2. 
 
bias created by using peptide immunization experiments, we did the same analysis using 
immunogenic epitopes identified using whole “Organism” as the immunogen (P < 0.01 at all 
residues except P1, P5 (Fig. 2-3 E)). Thus, our results demonstrate a preference for 
hydrophobicity in immunogenic epitopes across antigenic sources (self and pathogen) and MHC 
molecules (HLA-A2 and non-HLA-A2). 
The locations of anchor residues and TCR contacts have been mapped for many MHC 
peptides (Rudolph, Stanfield, & Wilson, 2006). If the observed bias toward non-polar hydrophobic 
aa’s within immunogenic epitopes affects TCR affinity, we predicted that it would be selective for 
TCR contact residues. We analyzed the mean hydrophobicity along the peptide for the highest 
represented MHC epitopes within the database: HLA-A2 (Fig. 2-4 B), and murine MHC H-2D
b
 
and H-2K
b
 (Fig. 2-4 C and D). HLA-A2 restricted 9mer peptides are anchored at residues P2 and 
P9, with P6 as an auxiliary anchor. We observed no statistical difference in hydrophobicity 
between the anchor residues of immunogenic and non-immunogenic peptides (P2, P = 0.9; P9, P 
= 0.08; (Fig. 2-4 B)). The observed difference in hydrophobicity was at specific TCR contact 
residues P4, P7 and P8 (P4, P = 6.3×10−12; P7, P = 5×10−13; P8, P < 2.2×10−16). In contrast, 
the auxiliary anchor P6 was more hydrophobic in non-immunogenic peptides (P = 3.1×10−7). 
Similar results were found for HLA-A2 restricted 10mer peptides (Fig. 2-3 F).  
To determine if the difference in hydrophobicity was species-specific, we evaluated the 
subset of known mouse MHC H-2Kb restricted 8mer peptides. Again, we observed a marked 
increase in relative hydrophobicity for the TCR contact residues P6 and P7 of immunogenic 
epitopes (P6, P = 7 × 10−5; P7, P = 1.1 × 10−6) but no difference in anchor residues (P5, P = 
0.67; P8, P = 0.15; (Fig. 2-4 C)). As observed with HLA-A2, the auxiliary anchor residue P3 was 
more hydrophobic in non-immunogenic peptides (P = 0.005). Finally, we analyzed mouse MHC 
H-2Db restricted 9mer peptides and observed that P7 and P8 TCR contact residues were more  
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Figure 2-4. Hydrophobicity comparison at each residue position between immunogenic 
and non-immunogenic MHC-I peptides. Mean hydrophobicity at each position was calculated. 
(A) All immunogenic and non-immunogenic MHC-I 9-mers; every residue had P < 1.6 X 105. (B) 
HLA-A2 restricted immunogenic and non-immunogenic 9-mers. (C) Murine MHC H-2Db restricted 
immunogenic and non-immunogenic 9-mers. (D) Murine MHC H-2Kb restricted immunogenic and 
non-immunogenic 8-mers. Down-arrows in B-D indicate anchor residues based on specific MHC 
motifs. ∗P < 0.008 in that residue position. P values are listed in Table A-2. 
 
 
hydrophobic in immunogenic epitopes (P7, P = 1.1×10−4; P8, P = 0.001; (Fig. 2-4 D)), with no 
difference in anchor residue P9 (P = 0.127). One exception was the anchor residue P5, which 
was more hydrophobic in immunogenic epitopes (P = 4.9×10−10). This discrepancy might be due 
to the presence of other potential anchors at P5 (apart from Asn) within immunogenic dataset. 
Hence we demonstrate that the observed bias towards relative hydrophobic aas in immunogenic 
epitopes is selective for TCR contact residues. 
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2.3.3. Differential Hydrophobicity can Predict Immunogenic CTL Epitopes 
While MHC-binding is necessary for antigen presentation, it is not sufficient to stimulate an 
immune response. We predicted that hydrophobicity could be incorporated into existing binding 
algorithms to improve prediction of CTL epitopes. To test this hypothesis, we used the IEDB-
consensus binding prediction tool to generate peptide predictions for HLA-A2 restricted peptides 
(9, 10mers) for two viral proteins: polyprotein from dengue virus type 1 (DENV1) and tegument 
protein pp65 from cytomegalovirus (CMV). Using mean hydrophobicity of aas in TCR contact 
residues (all residues except anchors: P2, P6, and P9 or P10), each predicted peptide was re-
ranked with decreasing TCR contact hydrophobicity values (Fig. 2-5). The rate at which 
experimentally defined HLA-A2 restricted CTL epitopes (Table A-3) were identified was increased 
using hydrophobicity-based predictions compared to IEDB-consensus binding predictions (Fig. 2-
5 A and B). As a negative control, we performed re-ranking of top predictions from the 2 proteins 
using mean hydrophobicity of just anchor residues (Fig. 2-5 C-D). The rate of prediction of HLA-
A2 restricted CTL epitopes was similar to IEDB-consensus binding predictions, confirming that 
relative hydrophobicity impacts immunogenicity and not HLA-binding. These results suggest that 
using TCR contact hydrophobicity could improve prediction of immunogenic epitopes.  
 
2.3.4. Hydrophobicity-based ANN Prediction Model 
The relative contribution of each aa residue to immunogenicity varies between MHC allomorph 
and is motif-dependent (Fig. 2-4) and (Table A-2). Furthermore, the immunogenicity of a peptide 
might result from nonlinear interactions between different TCR contact residues. Artificial neural 
networks (ANN) are designed to handle such nonlinearity (Bishop, 2006; Honeyman et al., 1998). 
Therefore, we developed and trained an ANN-based prediction model of immunogenicity using aa 
hydrophobicity (ANN-Hydro) with the goal of improving existing CTL epitope prediction algorithms 
and were used as the trainings sets for the two ANN-Hydro models (Fig. 2-6). An initial 
assessment of the trained ANN-Hydro model for HLA-A2 assigned a good probability of 
immunogenicity to 54/64 (> 80%) experimentally defined HLA-A2 restricted epitopes from 3 
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recent studies (Assarsson et al., 2008; Newell et al., 2013; Weiskopf et al., 2011) (P < 0.001, 
compared to the distribution of probabilities of immunogenicity of 64 randomly generated 9mer 
 
Figure 2-5. Differential Hydrophobicity can predict Immunogenic CTL Epitopes. Efficiency 
of predicting experimentally defined HLA-A0201 restricted immunogenic epitopes using mean 
hydrophobicity of TCR contact residues (straight lines) compared to IEDB consensus binding tool 
(IEDB-Bind) are shown (dashed lines). Tegument protein pp65 from cytomegalovirus (CMV) and 
polyprotein from dengue virus type 1 were used for predictions. (A-B) Predicted peptides from the 
IEDB-Bind were re-ranked using mean hydrophobicity of TCR contact residues. (C-D) Predicted 
peptides from the IEDB-Bind were re-ranked using mean hydrophobicity of anchor residues. 
  
 
  40 
peptides) (Table A-4). We then developed an epitope discovery strategy incorporating the ANN-
Hydro model to predict a previous set of experimentally validated H-2D
b
 and HLA-A2 epitopes 
from 5 pathogen and 5 tumor antigens (Table A-4). The IEDB-consensus MHC-binding prediction 
algorithm was used to obtain a list of predicted peptides for each antigen, which were each 
assigned a normalized binding score (SB). Since T cell epitopes are a subset of predicted 
peptides that bind to MHC molecules, normalized scores (SI) based on probabilities of 
immunogenicity obtained by ANN-Hydro were assigned to each peptide (Fig. 2-6). We then 
defined a total score (S) as S = SB . SI for the rate of identifying CTL epitopes from the list of 
predicted H-2D
b
 and HLA-A2 peptides from each antigen. The total score is therefore dependent 
on contribution of both scores, reflecting two critical aspects: binding and immunogenicity (Fig. 2-
6). Our strategy of re-ranking by prioritization of high-binding and high-immunogenic peptides 
over other predicted peptides ((Fig. 2-6), Materials and Methods), scored 42 out of the 43 H-2D
b
 
and HLA-A2 9mer epitopes within the top 20 ranked peptides (Table A-4). Each peptide 
sequence in the H-2D
b
 and HLA-A2 datasets was transformed into a corresponding numeric 
sequence based on the hydrophobicity value of aas prediction algorithms, ranked the same 
epitopes up to rank 133 (Table A-4). Therefore, the ANN-Hydro model can be used in conjunction 
with IEDB-consensus to improve the efficiency of prediction of CTL epitopes. 
 
2.3.5. Prediction Validation by in Vivo Discovery of HIV-1 Gag Epitopes 
To comprehensively evaluate the predictive capacity of our approach for CTL epitope discovery 
and to correlate immunodominance, we interrogated 3 HIV-1 Gag variant proteins: Consensus B 
 (ConsB), 96ZM651.8 (ZM96), and 97/CN54 (CN54) (Fig. 3.4). With no prior knowledge of Gag-
specific CTL epitopes, our model was used to generate a list of ranked H-2D
b
 restricted peptides, 
of which the top 20 predictions for each interrogated Gag sequence are shown (Table B.8). To 
validate our predicted epitopes in vivo, B6 mice were immunized independently against each of 
the three different Gag variants and the peptide specificity of effector CD8+ T cell responses 
analyzed using overlapping peptide pools (Table A-5). Deconvolution and truncation experiments 
allowed us to define a unique dominant H-2D
b
-restricted epitope within each Gag protein (SI9 for 
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ConsB, QL11 for CN54, RT9 for ZM96), as well as shared subdominant epitopes: Db-restricted 
RT9, AI9, YI9 and Kb-restricted VL8 (Fig. 2-7). Comparison of empirically defined epitopes to 
predictions made using ANN-Hydro revealed that H-2D
b
 restricted 9mer CTL epitopes for HIV-1 
  
Figure 2-6. Workflow for CTL epitope prediction using the ANN-Hydro model and the MHC-
binding prediction tool IEDB-consensus. For training and application of the ANN-Hydro model for 
immunogenicity scores, each peptide sequence in the HLA-A2 and H-2Db dataset was 
transformed into a corresponding numeric sequence based on the hydrophobicity value of amino 
acids. To obtain a list of candidates for MHC-bound peptides from a given antigen, IEDB-
consensus binding algorithm was used and a normalized binding score (SB) was assigned. The 
trained immunogenicity ANN model was applied on the same list of peptides independently to 
assign immunogenicity scores (SI). After the subset of top binding peptides was selected, 
peptides from each region ranging from high-binding highly-immunogenic peptides to modest-
binding low-immunogenic peptides (quadrants 1 through 4 in inset) were re-ranked based on total 
score S = SB . SI. An example of epitope prediction is shown in the plot for experimentally defined 
H-2D
b
 restricted CTL epitopes from LCMV-GP.  
 
 CN54 Gag and ZM96 Gag correlated with ANN-Hydro model epitope sequences predicted within 
the top 15 ranked peptides; and for ConsB Gag within the top 11 ranked peptides (Table A-5). In 
striking contrast, prediction of the identified Gag epitopes by individual prediction algorithms was 
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more varied, with predictions up to rank number 46, depending on the binding or processing 
algorithm used. Although the IEDB consensus binding and NetMHCpan algorithms predicted the 
identified Gag epitopes within the top 6 ranked peptides, the performance of these algorithms 
(unlike the ANN-Hydro model) was highly variant with the antigen selected (variance ranges 
from66.72 to 220.27; (Table A-5). In sum, the ANN-Hydro model predicted 52 out of 53 
experimentally validated H-2D
b
 and HLA-A2 9mer epitopes from 13 different antigens within the  
  
Figure 2-7. Summary of identified epitopes.  Responses to the RT9, VL8, AI9, and YI9 
epitopes are observed for all three Gag protein variant peptides. Overlapping sequences of 
individual peptides are shown. The QL11 epitope was only immunogenic for the CN54 Gag 
protein, but not ConsB or ZM96 Gag proteins, likely due to the A to E substitution at position 2. 
The SI9 epitope was only immunogenic in the ConsB Gag protein, as both CN54 and ZM96 had 
major deletions and substitutions in this sequence. MHC restriction was confirmed using MHC 
class I tetramer staining, and Gag amino acid positions are in reference to the HXB2 strain. 
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Figure 2-8. ANN-Hydro model prediction validation by in vivo discovery of HIV-1 Gag 
epitopes. Predictions for H-2D
b
 epitopes were made for three HIV-1 Gag proteins using the 
ANN-Hydro model, and then a blinded epitope discovery study was performed in vivo. (A–C) B6 
mice were immunized with AdHu5 vaccines expressing the ConsB, CN54, or ZM96 Gag, and 
CD8+ T-cell responses determined by intracellular IFN-γ or IFN-γ ELISPOT after ex vivo 
stimulation with peptide pools of 15-mer peptides (overlapping by 11 mer) spanning the entire 
Gag sequence (ConsB or CN54, A and B) or with a complete set of overlapping 20-mer peptides 
spanning ZM96 (C). (D–H) Positive responses to pools were deconvoluted by stimulation with 
individual 15-mer peptides from the positive pools (ConsB or CN54, D and E). Minimal epitopes 
were identified by stimulation with truncated peptides and are shown (F–H). 
 
top 20 ranked peptides (Fig. 2-9), corresponding to a 98% success rate in identifying 
immunogenic epitopes. Moreover, this predictive improvement was reflected in lower variability of 
epitope identification, a variance of 37.72 using ANN-Hydro as opposed to 66.72 by IEDB alone 
(P < 0.05, F-test). 
 
2.3.6. Prediction of Immunodominant Epitopes 
The probabilities of immunogenicity assigned by ANN-Hydro were interrogated with respect to 
epitope immunodominance using three antigens with a clear vertical epitope hierarchy, as 
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identified by ex vivo experimental data (Oukka et al., 1996; van der Most et al., 1998) and this 
study). The epitope hierarchy defined experimentally in LCMV-GP, Flu-NP, and ZM96 Gag 
showed robust correlation with the probabilities of immunogenicity assigned by ANN-Hydro (r > 
0.94,P < 0.05; (Fig. 2-9 B-D)). In contrast, predicted MHC-binding assigned by IEDB-consensus 
showed no correlation with epitope immunodominance in LCMV-GP and ZM96-Gag (Fig. 2-9 E 
and G). Epitope immunodominance in Flu-NP correlated with both predicted ANN-Hydros 
probability and predicted MHC-binding (Fig. 2-9 C and F). As a further correlate, seven of 13 
epitopes predicted in lower rankings by ANN-Hydro along with IEDB-consensus were modest 
immunogens derived from LCMV-GP, LCMV-NP, ZM96, CN54, and Consensus Gag (Table A-6). 
Therefore, efficient pMHC-TCR affinity may contribute towards epitope immunodominance. By 
using ANN Hydro, epitope predictions were consistently less variable, and improved the 
prediction of immunodominant CTL epitopes. 
2.4 Discussion 
At present, there is no consensus on the molecular mechanisms by which CD8+ T cells 
discriminate immunogenic antigens within the background of poorly immunogenic self peptides. 
Understanding this discrimination has implications in rational vaccine design and the identification 
of antigenic targets of malignant and autoimmune diseases. While several theories have been 
proposed to explain the concept of self/non-self discrimination (Pradeu & Carosella, 2006), the 
present study is the first attempt to provide a biochemical explanation for this fundamental 
phenomenon. We show that relative aa hydrophobicity within immunogenic epitopes reveal an 
antigenic pattern that could be recognized by TCRs. We leveraged these findings to design an 
immunogenicity model, trained and validated using experimentally defined epitopes. ANN-Hydro 
consistently reduced variable standard prediction outputs across multiple antigens, demonstrating 
an important step forward in reducing the empirical element of T cell epitope prediction.  
The majority of antigens within the immunogenic dataset used in this study are derived 
from intracellular pathogens, such as viruses, which have been shown to favor a lower G+C 
genomic content, reflected in their aa usage (Calis, Sanchez-Perez, & Keşmir, 2010). Strongly  
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Figure 2-9. Incorporating ANN-Hydro in the IEDB-binding tool improves epitope prediction. 
(A) Ranked epitopes for 26 H-2D
b
 CTL epitopes from eight well-described antigens and for 27 
HLA-A2 CTL epitopes from five tumor antigens (Melan-A, Wt-1, gp100, TRAG-3, and p53), each 
column is a different prediction algorithm with epitopes and their corresponding predicted ranks 
shown. (B–D) Epitope immunodominance as a function of probability of immunogenicity for 
LCMV-GP, Flu-NP, and Gag-ZM96. (E–G) Epitope immunodominance as a function of predicted 
MHC binding (IEDB consensus) for LCMV-GP, Flu-NP, and Gag-ZM96. Immunodominance was 
determined from percentage-specific lysis of target cells ex vivo. (B and E) 9-mer versions of 
SGV11 and CSA10 were used. (C and F) Percent survival of peptide-primed mice on lethal 
challenge of virus (D and G) IFN-γ spots per million cells on ex vivo peptide stimulation post 
vaccination with antigen (this study). 
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hydrophobic aas (e.g. L, I, V, F, M) are characterized by low G+C codons while hydrophilic aas  
are not (Khrustalev & Barkovsky, 2011). This suggests the possibility that pathogens, in general, 
have a higher usage of hydrophobic aas that could be exploited for TCR recognition. A second 
possibility is that antigen presentation inherently favors hydrophobic regions within a protein. A 
recent study demonstrated that exposing hydrophobic domains significantly enhances the rate of 
proteasomal degradation and MHC presentation (Huang, Kuhls, & Eisenlohr, 2011). Moreover, 
immunogenic CTL epitopes are also positionally biased towards the center of their source 
antigens (Huang et al., 2011; Kim, Yewdell, Sette, & Peters, 2013), consistent with the fact that 
cytosolic proteins with a central hydrophobic core are the major substrates of proteasomal 
degradation. Thus, protein hydrophobicity can enhance both antigen presentation and 
immunogenicity, perhaps an evolutionary adaptation of hydrophobicity driven by damage-
associated molecular patterns (Seong & Matzinger, 2004).  
TCRs are estimated to recognize on average about 5 non-anchor residues of a presented 
peptide because of the angle of peptide contact (Burroughs, de Boer, & Keşmir, 2004; Hennecke 
& Wiley, 2001). For 3 pMHC allomorphs analyzed by hydrophobicity in this study, only 4-5 
positions on the peptide were significantly different between immunogenic and non-immunogenic 
peptides (Fig. 2-4), similar to published pMHC-TCR structures (Rudolph et al., 2006). This 
hydrophobicity difference is relative, not absolute. Certain aa positions in the peptide may be 
hydrophilic (e.g. P4 in HLA-A2 9mers, (Fig.2-4 B)). However, even in such inherently hydrophilic 
residues in the peptide, immunogenic epitopes are less hydrophilic (more hydrophobic). Covering 
exposed hydrophobic residues on the peptide by a TCR may be a thermodynamically favorable 
process, facilitating the pMHC-TCR interaction as noted in retrospect, by a recent study 
(Birnbaum et al., 2014). TCR-engagement of pMHC complexes may be enhanced by water-
exclusion from the immunological synapse or by increased Kon rates of the TCR-pMHC complex 
by relatively hydrophobic aas. 
In the absence of a good understanding of the biochemical composition of peptide 
ligands that result in T cell activation, current strategies for epitope discovery either rely on the 
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unbiased synthesis of a large number of overlapping peptides, or use MHC-binding/antigen 
processing algorithms to select candidate peptides. While the former is an expensive and 
laborious process, the latter results in a large number of false positive peptides that are not 
immunogenic. Advances in the development of combinatorial technologies have allowed the rapid 
identification and characterization of antigen-specific T cells (Newell & Davis, 2014). However, 
even such novel technologies rely on binding predictions to create candidate peptides lists that 
require extensive empirical validation. For instance, 77 candidate good-binders for HLA-A2 from 
the rotavirus proteome were chosen for recombinant pMHC tetramer production based on their 
MHC-binding capability, but only 6 (four being 9mer epitopes) were confirmed to be immunogenic 
epitopes (Newell et al., 2013). Therefore, T cell antigen discovery studies need strategies that 
improve the efficiency of epitope prediction.  
ANN-Hydro assigned high probabilities of immunogenicity to 80% of the HLA-A2 9mer 
epitopes described in the three proteome wide studies. Of note, three of the four rotavirus 9mer 
epitopes from the data set scored a probability of immunogenicity greater than 0.8 (Table A-4). In 
the HIV-1 Gag study, over 364 overlapping peptides were tested in vivo from the Gag variants 
(length: 500aa) for epitope discovery. Using the ANN-Hydro model combined with SB scores 
narrows the validation discovery process down to 11-15 peptides per Gag protein to be tested. 
Similarly, applying ANN-Hydro also improved predictions of immunogenic H-2Db and HLA-A2 
epitopes from 10 independent antigens compared to individual prediction algorithms. Thus, 
models such as ANN-Hydro adds an extra dimension (immunogenicity) to MHC-binding for CTL 
epitope prediction and could be used to significantly reduce the variability associated with 
standard prediction algorithms, and the time and cost of experimental validation (Fig. 2-9), (Table 
A-6). With the advent of tumor exome sequencing in immune therapy settings, we anticipate that 
immunogenicity models such as ANN-Hydro will be critical in identifying immunogenic neo-
antigens for tumor immune therapies (Snyder et al., 2014; Yadav et al., 2014). 
The ANN-Hydro model differs from existing MHC-binding/antigen-processing prediction 
algorithms in two respects: First, the ANN-Hydro was trained on a relative hydrophobicity scale, 
which facilitates the model to discover complex numeric relationships between different aa 
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residues. Second, the dataset used for training was immunogenic epitopes and non-immunogenic 
self-peptides, which do not differ in binding motifs but only in immunogenicity. While some high-
binding epitopes (e.g. SI9 from ConsB) are readily predicted by all algorithms, other epitopes 
(e.g. the immunodominant dominant RT9 from ZM96, LL9 from LCMV-GP) are predicted at 
variable rankings by different algorithms (Table A-6). In comparison, ANN-Hydro rescued these 
epitopes by virtue of their probability of immunogenicity. Although ANN-Hydro marks a step 
forward in efficiently predicting 9mer epitopes, it is currently limited in terms of predicting longer or 
shorter epitopes, exemplified by the 11mer epitope (QL11) deduced by epitope mapping from the 
CN54 Gag protein. To improve longer or shorter epitope predictions, larger representative 
datasets are required for training. Nonetheless, the model predicted a 9mer version of this 
epitope ranked at 35 and 44, which is consistent with presentation of nested length peptides 
(Riemer et al., 2010). A second limitation of the current model is its applicability to predict 
epitopes for other HLA class I alleles. In theory, the ANN-Hydro model could be applied to predict 
CTL epitopes for any MHC class I allele, but large representative datasets are required for 
training the model for representative MHC allomorphs. We anticipate that advances in mass 
spectrometry-based MHC peptide discovery will result in more extensive training databases for 
predicting longer and shorter epitopes from a broader selection of HLA class I molecules (Riemer 
et al., 2010; Tan, Croft, Dudek, Williamson, & Purcell, 2011). 
While immunogenicity models have been developed by others for prediction of CTL 
epitopes (Calis et al., 2013; Harndahl et al., 2012), they considered only the impact of pMHC 
stability and positional significance along the peptide for immunogenicity. In contrast, a crucial 
feature of our approach is the use of ligand-eluted non-immunogenic self-peptides as the 
comparator set. Because binding and antigen processing are required for all epitopes, we built 
upon existing algorithms for immunogenic pMHC predictions. “Layering” the immunogenicity 
model on top of existing prediction algorithms enabled us to predict epitopes with increased 
effectiveness than standalone predictions. Importantly, the empirical evaluation of our 
immunogenicity model and epitope prediction approach without a priori knowledge of the 
immunodominant HIV-1 Gag epitopes in vivo gives strong support for these results. In summary, 
  49 
integrating aa hydrophobicity into pMHC prediction algorithms should significantly enhance the 
success of epitope discovery. The biological mechanism underlying TCR preferences for non-
polar hydrophobic residues remains to be evaluated.  
 
2.5 Materials and Methods 
For full details of methods and construction of data sets see Appendix A. 
 
2.5.1. Construction of Datasets 
All MHC-I peptides used in this study and design of the ANN-Hydro prediction model was 
retrieved from IEDB (Vita et al., 2010) (www.iedb.org, last accessed: 08/11/2013). Epitopes with a 
positive T cell response represent the immunogenic epitope group. The non-immunogenic self-
peptide group represent cell surface ligand eluted MHC-I self-peptides that have been 
antigenically processed and MHC-bound. Additional curation and exclusion criteria resulted in a 
final dataset with 5,035 8-11mer immunogenic epitopes and 4,853 8-11mer non-immunogenic 
peptides (See Appendix A for further details). 
 
2.5.2. Amino Acid Scales 
These were derived from Expasys ProtScale (http://web.expasy.org/protscale/) (Gasteiger et al., 
2005), specifically, Hydrophobicity scale (Kyte and Doolittle) (Kyte and Doolittle, 1982), Polarity 
(Grantham) (Grantham, 1974), and Bulkiness (Zimmerman) (Zimmerman et al., 1968). The 
scales are relative, e.g., negative to positive values in the hydrophobicity scale correspond to a 
relative hydrophobicity increase between aas (Table A-1). 
 
2.5.3. Position-based Hydrophobicity Analysis 
We transformed our datasets of immunogenic and non immunogenic peptides into numeric  
arrays using the R statistical software (RDevelopment, 2012). Separate numeric arrays were 
generated for immunogenic and non-immunogenic 8, 9 and 10mers. Mean hydrophobicity of 
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immunogenic and non-immunogenic peptides at each position was calculated and were 
compared residue-by-residue through Wilcoxon rank-sum tests to quantify statistical significance. 
 
2.5.4. Hydrophobicity-based ANN Prediction Model (ANN-Hydro) 
The R neuralnet package was used to design and train the two ANN-Hydro models on H-2Db and 
HLA-A2 restricted 9mer peptides known to be immunogenic (n=204 and n=374, respectively) or 
non-immunogenic (n=232 and n=201, respectively). Each peptide sequence in the respective H-
2Db and HLA-A2 datasets were transformed into a corresponding numeric sequence based on 
aa hydrophobicity using R statistical software. A three-layer fully connected feed-forward ANN 
was comprised by nine input neurons, one hidden layer with three neurons, and one output 
variable (Fig. 2-6). 
 
2.5.5. Application of ANN-Hydro 
For each H-2Db and HLA-A2 restricted epitope prediction, we used IEDB-consensus to generate 
a list of epitope predictions. Each peptide was assigned a normalized binding score (SB) and a 
subset of these predicted peptides was then selected by defining a SB threshold of 0.1 for antigen 
length >100 aas and a SB-threshold of 0.2 for antigen length ≤ 100 aas. Independently, 
probabilities of immunogenicity were obtained by applying ANN Hydro to this subset of binding 
predictions. Normalized scores (SI) were then assigned based on the probabilities of 
immunogenicity (Fig. B.3). Predicted peptides were re-ranked based on total score, S = SB . SI, 
ranging from lowest score to the highest score. The lower the total score of a predicted peptide, 
the higher its probability of being an immunogenic epitope. See Appendix A for details. 
 
2.5.6. Vaccines 
Recombinant Adenovirus type 5 (rAdHu5) vectors encoding codon optimized HIV-1 Gag from 
Cons B, strain 96ZM651.8 (ZM96) and strain 97CN54 (CN54) (Bachy et al., 2013) are described 
in Appendix A. 
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2.5.7. Immunization of Mice 
C57BL/6 mice were immunized with 109 virus particles. All animal studies were conducted in 
accordance with UK Home Office regulations and Kings College London ethics committee. 
 
2.5.8. Peptides 
15mer peptides spanning HIV-1 CN54 Gag and a 20mer set of peptides spanning HIV-1 ZM96 
were provided by the UK Centre for AIDS Reagents. 15mer peptides spanning HIV-1 Cons B Gag 
were provided by the NIH AIDS Reagent Reference Program. Truncated HIV-1 Gag peptides 
were purchased from Proimmune. 
 
2.5.9. T Cell Epitope Mapping 
Spleen cells were re-stimulated either with media alone or with peptides, either in pools or 
individually (each at 1M final concentration) and IFN- production was detected by intracellular 
cytokine staining or by ELISPOT assay as previously described (Bachy et al., 2013). Cons B and 
CN54 Gag epitopes were deconvoluted to individual 15mers from peptide pools, and truncated 
versions of the 15mer peptides were synthesized and tested. For ZM96 Gag, 49 individual 20mer 
peptides were tested. Reactive peptide sequences were confirmed against the corresponding 
15mer peptide to the reactive sequence and 9mer peptides were synthesized and tested. 
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CHAPTER 3 
T-CELL EPITOPE DISCOVERY FOR THERAPEUTIC CANCER VACCINES 
 
This chapter is published: 
Sri Krishna and Karen S. Anderson. Vaccine Design: Methods and Protocols: Volume 1: 
Vaccines for Human Diseases, 779-796. Springer New York. 2016. 
 
Abstract 
The success of recent immune checkpoint blockade trials in solid tumors has demonstrated the 
tremendous potential of immune-mediated treatment strategies for cancer therapy. These 
immune therapies activate preexisting cytotoxic CD8+ T cells (CTL) to selectively target and 
eradicate malignant cells. In vitro models suggest that these therapies may be more effective in 
combination with priming of CTL using cancer vaccines. CTL-mediated tumor targeting is 
achieved by its recognition of tumor antigenic epitopes presented on human leukocyte antigen 
(HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is therefore central to 
the design of therapeutic T-cell vaccines and immune monitoring of these complex 
immunotherapies. However, selecting and monitoring T-cell epitopes remains difficult due to the 
extensive polymorphism of HLA alleles and the presence of confounding non-immunogenic self-
peptides. To overcome these challenges, this chapter presents methodologies for the design of 
CTL-targeted vaccines using selection of target HLA alleles, novel integrated computational 
strategies to predict HLA-class I CTL epitopes, and epitope validation methods using short-term 
ex vivo T-cell stimulation. This strategy results in the improved efficiency for selecting antigenic 
epitopes for CTL-mediated vaccines and for immune monitoring of tumor antigens. 
3.1 Introduction 
Recent clinical trials of vaccines, checkpoint blockade, and immunotherapy have demonstrated 
the potential efficacy of harnessing cytotoxic T cells for treatment of many cancers (H.-J. Kim & 
Cantor, 2014; Mellman, Coukos, & Dranoff, 2011; Trimble & Frazer, 2009). Unlike multimodality 
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therapy with surgery, radiation, and chemotherapy, immune therapies against tumor-specific or 
tumor-associated antigens hold great promise for targeted tumor eradication with relatively 
minimal side effects. Prophylactic subunit vaccines, such as the hepatitis B vaccine (HBV) and 
the human papillomavirus (HPV) vaccines, stimulate protective antibody responses and have 
been highly successful with >90 % efficacy (Chang et al., 1997; Giuliano et al., 2011; Mast et al., 
2005). However, eradicating preexisting pathogenic infections and malignancies is difficult to 
achieve by antibody-mediated immunity alone. For instance, the prophylactic HPV VLP vaccine 
has limited efficacy for the therapeutic treatment of existing lesions (Trimble & Frazer, 2009). 
Solid tumors, in particular, have a limited number of selective cell surface targets, a striking 
genomic heterogeneity, and rapid evolution of antigenic escape. Therefore, vaccines that induce 
T-cell-mediated immunity against established malignancies for therapeutic intervention are 
needed (H.-J. Kim & Cantor, 2014; Mellman et al., 2011; Trimble & Frazer, 2009).  
 The primary goal of immune therapies for tumor eradication has been the induction of 
cytotoxic CD8+ T cells (CTLs). CTLs are activated by their recognition of 8–11 amino acid 
peptides derived from proteasomal degradation of either pathogen-derived or self-antigens in 
association with human leukocyte antigen (HLA) class I molecules (Blum, Wearsch, & Cresswell, 
2013; Grakoui et al., 1999). The downstream signaling cascade triggered by the binding of T-cell 
receptors (TCRs) to epitope specific peptide-HLA complex causes antigen-specific effector CTL 
proliferation and the cytolysis of target cells presenting the epitope (Hennecke & Wiley, 2001). 
The αβTCR-peptide-HLA interaction is thus a critical event in CTL-mediated immunity and is 
fundamental for rational vaccine design. These CTL epitopes can be incorporated as a 
component of the therapeutic vaccine, or they can be useful for immune monitoring post-therapy 
(Trimble & Frazer, 2009).  Identifying immunogenic CTL epitopes remains a major challenge in 
vaccinology. Three major hurdles impede efficient discovery of CTL epitopes: (1) target antigen 
selection for vaccine design, (2) the codominance and polymorphism of HLA alleles which vary in 
populations by ethnicity and geographic location, and (3) the identification of the minimal peptidic 
sequence that can stimulate antigen-specific effector T-cell responses (Purcell, McCluskey, & 
Rossjohn, 2007). Identifying antigenic peptides reduces the cost of vaccine manufacture and 
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limits exposure to competing non-immunogenic peptides within the vaccine formulation (Purcell et 
al., 2007). Comprehensive T-cell epitope mapping across different HLA alleles is important to 
identify relevant epitopes that are antigenically processed and presented on the tumor tissue 
(Riemer et al., 2010).  
 Antigens for tumor immunotherapy may be derived from mutated, splice-variant, or 
structurally altered antigens (tumor specific antigens), overexpressed wild-type antigens (tumor-
associated antigens), as well as other neo-antigens against which central or peripheral T-cell 
tolerance has not been established (Ernst & Anderson, 2015; Mellman et al., 2011). Ideal 
antigens are those that are strongly expressed in tumor tissue and required for tumor 
pathogenesis. Examples of tumor-specific antigens are the HPV16 viral oncogenes E6 and E7 
which are integrated into the host genome in cervical carcinomas and have sustained expression 
during tumor progression. E6 and E7 are excellent candidates for CTL-mediated recognition of 
malignant cells harboring these “non - self” antigens (Trimble & Frazer, 2009). Several groups 
have targeted E6/E7 in therapeutic vaccines (Ma, Xu, Hung, & Wu, 2010), but comprehensive 
CTL epitope and HLA-restriction mapping of the HPV immunome are still limited (Riemer et al., 
2010; Yadav et al., 2014). With recent advances in tumor exome and RNAseq analysis, target 
antigens are increasingly being discovered using bioinformatics analysis of the tumor genome 
(Rajasagi et al., 2014), exome (Pulido et al., 2012; H.-G. Rammensee & Singh-Jasuja, 2013; 
Segal et al., 2008; Yadav et al., 2014), or post-hoc analysis of patients in response to immune 
therapies . Advances in proteomic tools such as mass spectrometry (MS) are now more routinely 
used to identify the tumor peptidome for antigen discovery (Rizvi et al., 2015; Snyder et al., 
2014). Advances in proteomic tools such as mass spectrometry (MS) are now more routinely 
used to identify the tumor peptidome for antigen discovery (Fortier et al., 2008; Riemer et al., 
2010; Yadav et al., 2014).  
The second limitation of CTL epitope discovery is the codominance and polymorphism of 
HLA alleles (Lund et al., 2004; Purcell et al., 2007). Bioinformatic and sequence analyses have 
demonstrated that most HLA-class I alleles can be classified into one of the 9–12 common 
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supertypes of HLA alleles, providing a population coverage of over 90 % within the HLA 
supertypes (Lund et al., 2004; Sette & Sidney, 1999). HLA alleles and their supertypes can 
be obtained using bioinformatic analyses from the global HLA database 
(http://www.ebi.ac.uk/ipd/imgt/hla/). For targeting HLA alleles from each supertype with maximal 
population coverage for tumor antigen discovery, we have chosen ten common HLA alleles 
corresponding to a 60 % of the HLA-A locus and a >35 % HLA-B locus-specific population 
coverage (HLA-A alleles: A*0101, A*0201, A*0301, A*1101, A*2402; HLA-B alleles: B*0702, 
B*0801, B*2705, B*3501, B*5701). Using these HLA supertypes, the selected alleles represent 
the most common representatives of HLA supertypes for a CTL vaccine targeting over 90% of the 
global population coverage, according to Lund et al. (Lund et al., 2004).  
There are several methods to define antigenic epitopes for T-cell immunotherapy (Fig. 3-
1). Conventional discovery of CTL epitopes has relied on in vitro or in vivo testing of overlapping 
peptides spanning the entire target antigen length, followed by peptide deconvolution and serial 
truncation to identify the minimal immunogenic epitope(s). Alternatively, the protein sequence can 
be scanned for potential HLA-binding motifs based on known amino acid preferences of different 
HLAs for peptide binding (Vonderheide, Anderson, et al., 2001). Potential peptides can be tested 
for HLA-binding affinity on cell lines with defective antigen processing such as T2 (Riemer et al., 
2010; Vonderheide, Anderson, et al., 2001). Recently, computational tools developed over the 
past decade have become increasingly reliable for predicting HLA-peptide affinity (Honeyman, 
Brusic, Stone, & Harrison, 1998; Moutaftsi et al., 2006; Tenzer et al., 2005). These computational 
prediction tools leverage large experimentally derived datasets on peptide-HLA binding for 
training Markov models or neural networks and have now been expanded to additionally include 
antigen-processing elements such as proteasomal cleavage patterns (Honeyman et al., 1998; 
Moutaftsi et al., 2006; Tenzer et al., 2005). Additionally, we and others have developed 
computational models which predict HLA-binding peptide immunogenicity (Calis et al., 2013; 
Chowell et al., 2015). These immunogenicity models can be used in conjunction with existing 
prediction algorithms to further improve efficiency of CTL epitope predictions (Chowell et al., 
2015). Additional algorithms for HLA-class II peptide predictions reviewed in Nielsen, & 
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Figure 3-1.  Techniques to identify T-cell epitopes. Note that computationally predicted 
peptides need validation by one or more experimental techniques. 
 
 
Lundegaard, 2010 can be used concurrently with class I predictions to improve T-cell vaccine 
targets for tumor antigens.  
 Predicted CTL epitopes are conventionally tested for HLA binding using recombinant 
HLA proteins or cellular assays, T-cell stimulation with Elispot assays (Vonderheide, Schultze, et 
al., 2001), antigen processing using mass spectrometry (Fortier et al., 2008; Hirano, 2006), or 
HLA multimers to determine the frequencies of antigen-specific T cells in the peripheral blood 
(Fig. 3-1). Despite these major advances in computational immunology, there is huge variability 
that exists between the different prediction algorithms and results in a significant number of non-
immunogenic false-positive epitopes from a given antigen. Here, we will focus on a reverse 
immunology CTL epitope discovery strategy that improves the efficiency of epitope prediction and 
experimental validation by short-term ex vivo T-cell cultures (Newell et al., 2013; Newell & Davis, 
2014). Despite these major advances in computational immunology, there is huge variability that 
exists between the different prediction algorithms (Lin, Ray, Tongchusak, Reinherz, & Brusic, 
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2008) and results in a significant number of non-immunogenic false-positive epitopes from a 
given antigen (Newell et al., 2013). Here, we will focus on a reverse immunology CTL epitope 
discovery strategy that improves the efficiency of epitope prediction and experimental validation 
by short-term ex vivo T-cell cultures. 
 
3.2 Comparative CTL epitope prediction strategy 
CTL epitope identification strategies for tumor and pathogen derived antigens are predominantly 
limited to the well-represented HLA-A2 allele. There is a need to define CTL epitopes for other 
non-A2 major HLA supertypes in order to develop globally relevant immune therapies. A number 
of open-access prediction algorithms are available for peptide-MHC binding and antigen 
processing (Honeyman et al., 1998; Nielsen et al., 2007). However, a recent study showed that 
there is huge variability associated with the use of these prediction algorithms depending on the 
HLA type and antigen chosen (Lin et al., 2008). To counter this variation in performance and 
scores, we employ a strategy that makes use of commonly used algorithms (three HLA-binding 
tools and two antigen processing). This strategy of pooling multiple epitope prediction algorithms 
increases the likelihood of obtaining a true positive epitope. Potential HLA binders for the desired 
antigen are predicted for the five HLA-A alleles (A*0101, A*0201, A*0301, A*1101, A*2402) and 
five HLA-B alleles (B*0702, B*0801, B*2705, B*3501, B*5701). Five prediction algorithms are 
used to predict candidate peptides per antigen per HLA. Three of these algorithms (IEDB-
consensus (Moutaftsi et al., 2006), NetMHCpan (Nielsen et al., 2007), and Syfpeithi (H. 
Rammensee, Bachmann, Emmerich, Bachor, & Stevanović, 1999)) predict HLA binding, while the 
other two algorithms (IEDB recommended (Tenzer et al., 2005) and SMMPMBEC (Y. Kim, 
Sidney, Pinilla, Sette, & Peters, 2009)) predicted candidate peptides based on antigen 
processing. A common pool of top-ranked peptides from each algorithm is re-ranked using a 
normalization score from three binding algorithms, and the top candidate peptides are selected. 
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3.3 Pooled Epitope Screen-1 
Of the potential peptidome from a target antigen, only those peptides that can stimulate CD8+ T-
cell response in tumor samples will be useful targets for immunotherapy. Both epitope targets and 
HLA restriction of tumor-reactive T cells are largely unknown for both cancers and pathogens. 
Long overlapping peptides from target antigens have been widely used in T-cell assays, but serial 
truncation of positive peptides is still required for epitope identification. This is a labor-intensive 
and expensive process, limited by the number of samples and more difficult for large antigens 
(Purcell et al., 2007). The low frequencies of precursor tumor antigen-specific CTLs can be 
amplified by expansion of antigen-specific CTLs ex vivo in a 10-day stimulation protocol using 
autologous peripheral blood mononuclear cells (PBMCs) as antigen presenting cells (Fig. 2) 
(Hida et al., 2002; Parikh et al., 2014). Because of emerging evidence of the role of PD-1/PD-L1 
checkpoint blockade to activate a potent antitumor immunity in HPV-associated as well as other 
tumors (Binder et al., 2013; Lyford-Pike et al., 2013), anti-PD-1 antibody is used on day 1 of our 
culture protocol to inhibit antigen-specific T-cell suppression. Since candidate peptides are 
predicted for several HLAs, they are pooled into separate 8–10 peptide pools. Peptide pools are 
designed to limit intra-pool binding competition by different peptides to the same HLA. Activation 
of antigen-specific CTLs is identified by standard interferon gamma (IFNγ) enzyme-linked 
immunospot (Elispot) assay. The mean spot-forming units (SFUs) from each peptide pool are 
assessed in triplicate. The mean SFU of any peptide pool greater than twice the mean SFU of 
negative control (PBS-DMSO or irrelevant peptide pool) with statistical significance (P < 0.05 by 
two-sample T-test) is considered as a positive response. 
 
3.4 Peptide Pool Deconvolution Screen-2 
Once peptide pool(s) that has a positive signal from several patient PBMCs is identified by the  
primary screen culture protocol, the minimal peptide(s) responsible for CTL stimulation is 
identified by deconvoluting the peptide pool (Fig.  3-2). The same ex vivo short-term culture 
protocol (including anti-PD-1) is repeated now with individual peptides from the positive peptide 
pool from the initial screen (screen-2). The reactive parent peptide pools from screen-1 are 
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included as a biological replicate. Concurrently, the positive responder’s HLA-class I type is 
identified either by HLA-specific monoclonal antibodies using flow cytometry (low-resolution HLA 
typing) or by commercial HLA-typing (high-resolution) services such as the type HLA 
(ProImmune, Oxford, UK). Low-resolution HLA typing by flow cytometry is performed on PBMCs 
set aside during screen-1 during any of the 2–3 days following day-1 stimulation. High resolution 
commercial HLA typing requires genomic DNA (2μg total) isolated from the PBMCs and sent out 
to commercial services. Because it requires more material, it is usually done on the last day of the 
Elispot screen. Cells are collected from the Elispot plate and washed once, and genomic DNA is 
isolated. 
  
Figure 3-2. Ex vivo short term cultures, epitope deconvolution, and HLA-restriction 
identification. 
 
 
If there are limitations on sample availability, only those peptides that correspond to the 
patient’s HLA-class I types are tested. In such cases, a small number (~1 million cells) of donor 
PBMCs is set aside during screen-1, and HLA typing is performed (low and/or high resolution). 
Once screen-1 is complete, only those candidate peptides from a pool that are predicted to bind 
the donor’s HLA type are tested in the subsequent screen-2. This minimizes the amount of 
sample and the number of peptides to be tested. However, this approach will not successfully 
identify cross- reactive promiscuous HLA binders, which can be lost when focusing on donor-
HLA-specific candidate peptides. 
 
 
  60 
3.5 Materials 
 
3.5.1. Comparative CTL Epitope Prediction Strategy 
1. Antigenic protein sequence. Usually obtained from literature or from National Center for  
Biotechnology (NCBI) RefSeq database (Pruitt et al., 2014) and UniProt servers (UniProt 
Consortium, 2015).  
2. Immune epitope database (IEDB) MHC-peptide binding algorithms: NetMHCpan, IEDB 
consensus binding prediction tool, both accessible at http://tools.immuneepitope.org/main/tcell/. 
3. SYFPEITHI algorithm: http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm. 
4. IEDB antigen-processing: IEDB-consensus antigen-processing tool, SMMPMBEC antigen-
processing algorithms http://tools.immuneepitope.org/main/tcell/ 
5. Microsoft Excel 
6. R statistical software. 
 
3.5.2.   Assessing peptide immunogenicity by short term ex vivo cultures (Screen-1) 
1. 1x tissue-culture grade phosphate buffered saline (PBS) (Cellgro, Mediatech, VA, USA). 
2. Dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA). 
3. Acetic acid (Amresco, Solon, OH, USA). 
4. T-cell culture media: To RPMI-1640 (ATCC, Manassas, VA, USA), add 100 U(μg)/mL 
penicillin-streptomycin (Gibco, Grand Island, NY, USA), 10 mM HEPES (Gibco, Grand Island, 
NY, USA), 2 mM l-glutamine (Gibco, Grand Island, NY, USA), and 10 % human serum (Gemcell, 
USA). Filter through 0.22μm Corning sterile filter, IL-2, IL-7. Store at 4℃.  
6. Recombinant human IL-2 (R&D Systems, MN, USA): Reconstitute at 100μg/mL (=1,640,000 
U/mL) in 100mM sterile acetic acid. Add 100 μL acetic acid into 16.6 mL water to make 100 mM 
acetic acid; filter through 0.22μm Corning sterile filter. Store at -80°C. Working solution is 2000 
U/mL in sterile PBS. Final concentration in culture is 20 U/mL and can be stored at 4°C. 
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6. Recombinant human IL-7 System Systems, MN, USA): Reconstitute at 50μg/mL in sterile PBS. 
Keep at −80℃. Working solution at 1μg/mL in sterile 1x PBS, stored at 4℃ until use. Final 
concentration in culture at 10ng/mL and can be stored at 4℃.  
7. Peptide pools (ProImmune, Oxford, UK, other commercial sources are also available): Peptide 
purity >70%. Reconstitute all stock peptides at 20mg/mL in DMSO or according to manufacturer 
specifications (for certain peptides) and store at −20°C. To create a working peptide pool, add 
each peptide corresponding to 1 mg/mL final concentration and make up the rest of the volume in 
sterile 1x PBS to 1mL. Make smaller 100μL aliquots and store at –20°C. Working peptide pool 
tube can be stored at 4°C for about 2 months. Final concentration in culture is 10μg/mL.  
8. CEF-peptide pool (ProImmune, UK): Reconstitute at 20mg/mL in DMSO. Follow 
manufacturer’s instructions and make a 1 mg/mL stock using sterile 1x PBS. Store in −20°C and 
an aliquot in 4°C. Final concentration in culture is 1μg/mL. 
9. Phytohemagglutinin M form (PHA-M), for positive stimulation (Gibco, NY, USA). 
10. DMSO in 1x sterile PBS can be used as a negative control. 
11. Anti-PD-1 antibody: Antihuman CD279 (PD-1) purified, clone eBioJ105 (eBioscience, CA, 
USA). Store at 4°C. Stock 0.5mg/mL. Working concentration is 1μg/mL. Store at 4°C. 
12. Levy counting chamber (Hausser Scientific, USA). 
13. Centrifuge (Beckman Coulter, Pasadena, CA, USA). 
14. Antihuman IFNγ monoclonal antibody, 1-D1K (1 mg/ mL) (Mabtech, OH, USA). Store at 4℃. 
15. Biotinylated antihuman IFNγ monoclonal antibody, 7-B6-1 biotin (1 mg/mL) (Mabtech, OH, 
USA). Store at 4°C.  
16. BCIP/NBT Color Development Substrate (Promega, Madison, WI, USA). Store at −20℃. 17. 
Ethanol (Avantor Performance Materials, Center Valley, PA, USA).  
18. Fetal bovine serum (FBS). Store at −20℃ after heat inactivation for 20 min at 56℃. 
19. Tris (Sigma, St. Louis, MO, USA). Store at room temperature. 
20. Magnesium chloride (MgCl2) (Sigma, St. Louis, MO, USA). Store at room temperature. 
21. Sodium chloride (NaCl) (Sigma, St. Louis, MO, USA). Store at room temperature. 
22. Multiscreen filter plate, 2EM004M9 or MSIPS4W10 (Millipore, Billerica, MA, USA). 
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23. AID or other ELISPOT reader (Autoimmun Diagnostika, Strassberg, Germany). 
24. 1x PBS 0.5 % FBS buffer for ELISPOT washes (0.5 % FBS wash solution).  
 
3.5.3. HLA-Typing and Positive Peptide Pool Deconvolution (Screen-2) 
1. Materials 1 through 23 from Subheading 2.2.  
2. Individual peptides from the immunogenic peptide pool identified through screen-1. 
Reconstitute all stock peptides at 20 mg/mL in DMSO or according to manufacturer specifications 
(for certain peptides) and store at −20℃. To create a working peptide solution, make a 1mg/mL 
final concentration and make up the rest of the volume in sterile 1x PBS to 1mL. Make smaller 
100μL aliquots and store at 20℃. Working peptide tubes can be stored at 4℃ for about 2 months. 
Final concentration in culture is 10μg/mL.  
3. Fluorescently conjugated monoclonal antibodies (mAbs) for 10 HLA alleles e.g., HLA-A2 mAb 
clone BB7.2-PE conjugated; from BD Pharmingen, San Jose, CA, USA). 
4. Fluorescently conjugated isotype controls (e.g., mouse IgG2a-PE for HLA-A2 staining, BD 
Pharmingen, San Jose, CA, USA). 
5. Attune or a similar flow cytometer (Life Technologies, Grand Island, NY, USA). 
6. Staining buffer. 1x PBS (Cellgro, VA, USA) with 1% bovine serum albumin (BSA, Sigma, USA). 
7. DNAzol Reagent (Life Technologies, NY, USA) for genomic DNA isolation. 
8. Sodium hydroxide monobasic (Sigma, St. Louis, MO, USA) used with DNAzol. 
9. 100 % ethanol (Avantor Performance Materials, Center Valley, PA). 
10. Nuclease-free water (Hyclone, Thermo Fisher Scientific, Waltham, MA, USA). 
11. Nanodrop 2000 C (Thermo Fisher Scientific, Waltham, MA, USA). 
 
3.6 Methods 
3.6.1. Comparative CTL Epitope Prediction Strategy 
1. Access IEDB prediction server: (http://tools.immuneepitope.org/main/tcell/). 
2. Select “Peptide binding to MHC class I molecules” link. 
3. Enter the antigen protein sequence in FASTA format. 
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4. Select “Consensus” or “NetMHCpan” as the prediction method. 
5. Select “human” as the MHC source species. 
6. Select the desired “HLA allele” (each of HLA-A’s and HLA-B’s listed in Subheading 1.3). 
7. Select “all lengths” as the predicted peptide length. 
8. Choose “Percentile rank” for IEDB-consensus and “Predicted IC50” for NetMHCpan as the 
output type to sort the peptides. 
9. Choose “XHTML table” as the output format. 
10. Download the results as an excel file. 
11. Select “Proteasomal cleavage/TAP transport/MHC class I combined predictor” IEDB server. 
12. Enter the antigen protein sequence in FASTA format. 
13. Select “IEDB recommended” or “SMMPMBEC” as the prediction method. 
14. Repeat steps 5–7 for the different HLA alleles. 
15. Sort the peptide list by “Total score” for both the algorithms (should be in a decreasing order). 
16. Repeat steps 9 and 10. 
17. Access SYFPEITHI: http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm. 
18. Select the “MHC type” for each of the HLA alleles. 
19. Choose “All mers” for peptide length. 
20. Paste the antigen protein sequence in non-FASTA format. Click Run. 
21. Save the output by copying all the predicted peptides into MS Excel and removing blank 
spaces between different lengths. 
22. From each prediction algorithm’s output per HLA, select the top two-thirds (66 %) of all 
predicted peptides (i.e., for 100 predicted peptides, select the top 66). Do this for each prediction 
algorithm’s output in MS Excel or database program. 
23. By using a local script on R, create a separate list of peptides common between the five 
prediction algorithms. 
24. Using the output scores as described above normalize the common pool of predicted 
peptides as follows: (a) For algorithms displaying results ranging from low score to high score 
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(IEDB-consensus binding and NetMHCpan), )/()( minmaxmin   ii , where i  
represents the normalized score of the peptide; i , the assigned output score by the prediction 
algorithm; min , the minimum score assigned in prediction output; and max , the maximum score 
assigned in the entire prediction output. 
25. Calculate the average binding score SB from the three normalized binding scores. 
26. Using the “sort” function in MS Excel, sort the SB score list ranging from the lowest to the 
highest. Lower the SB score, higher its probability of being a candidate peptide. 
27. Select the top candidate peptides including promiscuous binders (usually up to 5 or 10, 
depending on feasibility) and order synthetic peptides for immunogenicity assessment. Greater 
than 70% purity is sufficient for T-cell assays. 
28. Once synthesized peptides are received, reconstitute the peptides according to 
manufacturer’s instructions. 
29. Create the peptide pools by having between 1 and 3 binders per HLA allele within each pool. 
This limits intra-pool binding competition by different peptides for the same HLA. Store the 
peptide pools at 4℃. 
 
3.6.2.   Peptide pool immunogenicity assessment by short-term ex vivo cultures 
1. Obtain a frozen PBMC cryovial from liquid nitrogen and rapidly thaw in 37℃ water bath. 
2. Pipette the cells drop by drop into a 15 mL tube with pre-warmed T-cell culture media. 
3. Centrifuge at 300g for 5 minutes, remove supernatant for wash. 
4. Resuspend cells gently in T-cell culture media. Count cells using a hemacytometer. Set aside 
500,000 PBMCs for low-resolution HLA typing (Subheading 3.3). 
5. Prepare cell suspension at 1 x 10
6
 cells/mL. Seed cells in a round bottom 96-well plate, 200 
μL/well (=200,000 cells/well). 
6. On day 1, stimulate with 20U/mL IL-2, 10ng/mL IL-7 (1μg/mL Anti PD-1), and 10μg/mL peptide 
pool or CEF-peptide pool. Use 1 % PHA-M for positive control stimulation (2μL/well). 
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7. On day 5, remove 100μL media from each well and add 100μL/well fresh T-cell culture media. 
Add IL-2 for final concentration at 20 U/mL and peptide pool at concentration 10μg/well. 
8. On day 7, pre-wet an ELISPOT plate with 35% ethanol at room temperature, 35μL/well. 
9. Wash with sterile water for five times, 200μL/well. 
10. Coat with capture antibody 1-D1K, 100μL/well. Dilute capture antibody in 1x PBS at final 
concentration 5μg/mL. 
11. Seal the plate and incubate at 4℃ overnight. 
12. On day 8, wash with RPMI 1640 (serum free is fine) for five times, 200μL /well. 
13. Add T-cell culture media, 200μL/well. Keep at room temperature in the hood for 30 minutes. 
14. On day 8, remove 100μL media from each well and add 100μL/well fresh T-cell culture media. 
Add IL-2 for final concentration at 20U/mL, and peptide pool at concentration 
10 μg/well. Add IL-2 for final concentration at 20U/mL. 
15. Add cells from each of the wells (200μL/well) from the culture plate into a corresponding well 
on the ELISPOT plate, triplicate for assays. Stimulate with antigenic peptide at final concentration 
10μg/mL (2μg/200 μL). The same quantity of CEF-peptide pool as peptide controls. Use 1 % 
PHA-M (2μL/well) for positive control. 
16. Cover with plate lid and incubate in CO2 incubator for 48 hours (days 8–10). 
17. On day 10, wash with sterile 1x PBS for three times, 200μL/well. Save cells for genomic DNA 
isolation (high-resolution HLA typing, Subheading 3.3). 
18. Wash with 0.5% FBS wash solution three times, 200μL/well with intervals between washes. 
19. Add detection antibody 7-B6-1 Biotin, 100μL/well. Dilute detection antibody in 0.5% FBS 
wash solution at final concentration 1μg/mL. 
20. Seal the plate and incubate at room temperature for 2 hours in the dark. (Leave the sealed 
plate in the hood if preferred.) 
21. Wash with 1x PBS for three times, 150μL/well. 
22. Wash with 0.5 % FBS wash solution for three times, 150μL/well, 5 minutes interval washes. 
23. Add streptavidin-ALP, 100μL/well. Dilute streptavidin-ALP in 0.5 % FBS wash solution at final 
concentration 1:1000. 
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24. Incubate at room temperature (preferably dark) for 1 hour. 
25. Wash with 1x PBS for three times, 150μL/well. 
26. Wash with 0.5 % FBS wash solution for three times150μL/well. 
27. Add BCIP/NBT mixed solution, 100μL well. 
28. Watch for spot development. 
29. Stop reaction by rinsing with cool tap water. 
30. Dry the plate in the dark at room temperature overnight (leave the lid partially open). 
31. Read the ELISPOT plate after 24–48 h on the AID ELISPOT reader. 
32. Calculate mean Spot Forming Units for each peptide pool. 
 
3.6.3.    HLA-typing and positive peptide pool Deconvolution (Screen-2) 
1. Low-resolution HLA typing is performed using the 500,000 cells set aside on day 1 of screen-1. 
2. Pool cells in media into a single tube and wash once with staining buffer (500g, 3 min). 
3. Divide the washed PBMCs into appropriate number of HLAs and isotype controls to be tested, 
in 100μL staining buffer per tube. 
4. Add appropriate mAbs and isotype controls to be analyzed. 
5. Incubate on ice in the dark for 30 min. 
6. Wash twice with staining buffer. Resuspend in a final volume of 200–300μL 1x PBS for flow 
cytometry analysis. 
7. Run isotype controls, gate on live lymphocyte population, and collect 10,000 events/gate. 
8. Run the individual samples stained with HLA-mAbs and analyze. 
9. Genomic DNA (gDNA) extraction for high-resolution commercial HLA typing is performed on 
the last day (day 10) of screen-1; when incubating, PBMCs are washed from the Elispot plate. 
10. Collect cells from the Elispot plate (contains media) in a reservoir. 
11. Wash the Elispot plate with 1x PBS and collect remaining cells in the reservoir. 
12. Pool cells from reservoir into a 15 mL conical tube. 
13. Centrifuge the cells, 500g 3 minutes. Remove supernatant. 
14. Wash the pellet once with 5 mL 1x sterile PBS, centrifuge and remove the supernatant. 
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15. Add 500 μL DNAzol directly to the pellet. 
16. Follow manufacturer’s protocols and isolate gDNA. 
17. Determine the concentration of gDNA using nanodrop. 2μg gDNA is shipped to the company 
for high-resolution HLA typing. 
18. Once screen-1 (Subheading 3.2) is completed, perform data analysis to identify the peptide 
pool with statistically significant higher mean SFUs compared to the negative control  
19. Repeat the ex vivo short-term culture protocol (steps 1 through 32) using individual peptides 
from the reactive peptide pool from screen-1. 
20. At the end of the short-term culture, analyze mean SFU from individual peptides as described 
before and correlate with donor-HLA type to identify reactive CTL epitope and its HLA restriction. 
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CHAPTER 4 
IMMUNOGENIC AND DYSFUNCTIONAL CD8+ T-CELLS IN HPV+HEAD AND NECK CANCER 
 
Abstract 
Human papillomavirus subtype 16 (HPV16) is the primary cause of an increasing number of head 
and neck squamous cell carcinomas (HNSCCs), providing strong rationale for T-cell immune 
therapies against HPV+ HNSCC. Here, we sought to assess immunogenicity of HPV16-specific 
CD8+ T-cells (CTLs), and to understand HPV-specific mechanisms of T-cell dysfunction. We 
experimentally identified 16 strong and 29 moderately immunogenic CTL-epitopes from HPV16 
E2, E6 and E7 antigens restricted by 12 common HLA class I alleles. Relative to E6 and E7, E2-
specific CTL-reactivity is higher in HPV+ HNSCC patients than in healthy controls (>3-fold, P = 
0.012). Upon antigen re-exposure, E7/E2-CTL-dysfunction phenotype was observed in more 
patients than E6-CTL-dysfunction, indicating inter-antigenic heterogeneity of HPV-CTL-
exhaustion. Immunogenomic analyses of 119 HNSCC transcriptomes revealed high T-cell 
infiltration and dysfunction in HPV+ HNSCCs, and correlation of HPV-antigen expression with T-
cell exhaustion gene signatures. We found that Indoleamine 2,3-dioxygenase (IDO-1), is strongly 
expressed in HPV+ HNSCCs compared to HPV- HNSCCs (P = 0.001), and correlates with E7-
expression in vitro (R
2
 = 0.84, P = 0.033). Combination treatment with PD-1 blockade and IDO-1 
inhibition overcomes profound CTL-dysfunction, enhancing HPV+ HNSCC sensitivity to CTL-
cytotoxicity in vitro (up to 10-fold in E7-CTLs, P = 0.011). Our findings implicate mechanisms of T-
cell escape in HPV+ HNSCC, wherein high tumoral HPV-antigen load results in high expression 
of immune dysfunction genes on tumor cells (e.g. IDO-1), and dysfunction of HPV-specific CTLs 
(e.g. E7,E2-CTLs). The HPV16 CTL-epitopes identified in this study, in synergy with combination 
blockade of HPV+ HNSCC-specific checkpoints may be useful for targeted immunotherapy.        
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4.1 Significance 
Strategies enhancing immune based targeting of tumor cells have come to the forefront of cancer 
treatments. A subset of head and neck cancers (HNSCCs), caused by human papillomavirus 16 
(HPV16), is an ideal candidate for T-cell cancer immunotherapies. Here, we identified 
immunogenic CD8+ T-cell (CTL) epitopes from 3 HPV16-antigens, and studied T-cell dysfunction 
mechanisms in HPV+HNSCC. We detected several novel CTL-epitopes from HPV16-genes E2, 
E6 and E7 across multiple HLA-alleles in peripheral blood CTLs of HPV+ HNSCC patients. We 
identified that tumoral viral load largely drives T-cell infiltration and subsequent CTL-exhaustion 
observed in HPV+HNSCC. Our study underscores the importance of host immune control of 
HPV, and identifies combination PD-1/IDO-1 inhibition as a novel strategy to enhance CTL-
targeting of HPV+HNSCC.  
4.2 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide 
with close to 600,000 cases diagnosed annually (Torre et al., 2015). A subset of HNSCCs are 
caused by the human papillomavirus (HPV), (HPV+ HNSCCs) (Marur, D’Souza, Westra, & 
Forastiere, 2010; Parfenov et al., 2014a), which are molecularly and clinically distinct from non-
HPV associated HNSCCs (HPV- HNSCCs)(The Cancer Genome Atlas Network, 2015). In the 
United States, 70-80% of HPV+ HNSCCs are caused by the oncogenic HPV type 16 (HPV16) 
(Chaturvedi et al., 2013; Dahlstrom, Anderson, & Sturgis, 2017; Giordano & Macaluso, 2016). 
Incidence of HPV+ HNSCC increased 225% from 1984-2004 and has now surpassed the 
incidence of cervical cancer (Maura L. Gillison et al., 2012; Jemal et al., 2013). Although HPV 
vaccines effectively prevent HPV-related cancers, the impact of vaccination on HNSCC incidence 
may not occur until 2060, likely due in part to slow vaccine uptake, and the decades between 
infection and clinical HPV+ HNSCC diagnosis (M. L. Gillison, Chaturvedi, Anderson, & Fakhry, 
2015; Williams et al., 2017). As a result, over 600,000 cases are predicted in the interim, 
providing a strong rationale for the development of novel therapeutic strategies against HPV+ 
HNSCC. 
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The recent development of clinically effective tumor immunotherapies, such as 
checkpoint blockade (CKB) using PD-1/PD-L1 inhibitors (Herbst et al., 2014; Pardoll, 2012; 
Robert et al., 2015), has led to FDA approval of nivolumab and pembrolizumab for HNSCC 
(Chow et al., 2016; Ferris et al., 2016). It is now established that the clinical response to CKB is 
correlated with tumor neo-epitope load. Tumor-specific neo-epitopes have been directly targeted 
using therapeutic vaccines and/or adoptive T-cell therapy (ACT), and have been shown to 
enhance cytotoxic T-cell targeting of multiple solid tumors (Ott et al., 2017; Schumacher & 
Schreiber, 2015; Tran et al., 2016). Thus, there is a renewed interest in defining the human 
leukocyte antigen (HLA) restricted antigenic repertoire of tumor infiltrating lymphocytes (TILs) to 
develop targeted therapeutic vaccines (Kenter et al., 2009), to identify T-cell receptors (TCR) for 
ACT (Schumacher & Schreiber, 2015), and to monitor clinical responses to complex cancer 
immunotherapies (Rizvi et al., 2015; Rosenblatt et al., 2016). 
HPV-associated cancers express multiple viral neo-antigens. HPV integration into host 
genome in cervical cancer results in derepression of the oncogenic drivers E6 and E7 
(Woodman, Collins, & Young, 2007). Immune therapies targeting E6 and E7 have thus been 
developed, including peptides, DNA, and ACT therapies (Draper et al., 2015; Kenter et al., 2009; 
Trimble et al., 2015). However, in comparison to cervical cancer, HPV+ HNSCCs have both lower 
rates of genome integration, and less interruption of the viral transcriptional regulatory gene E2 
(Akagi et al., 2014; Parfenov et al., 2014b; Rusan, Li, & Hammerman, 2015). Thus, subsets of 
HPV+ HNSCCs also express E2 in addition to E6 and E7 (Parfenov et al., 2014b; Zhang et al., 
2016). 
We and others have previously shown that high titers of serum antibodies against 
HPV16-E2, E6 and E7 are detectable in most HPV+ HNSCC patients, indicating immunogenicity 
and persistence of these antigens (Anderson et al., 2015; D’Souza et al., 2007). We thus 
hypothesized that patients with HPV+ HNSCC would have pre-existing HPV-specific CTLs, and 
that HPV-antigen expression levels would influence CTL-dysregulation in tumor 
microenvironment. We identified the T-cell antigenic landscape of globally frequent HLA class I 
alleles from HPV16 E2, E6 and E7. By phenotyping HPV-specific CTLs from HPV+ HNSCC 
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patients, and analyzing the immune transcriptomes of 119 HNSCCs, we demonstrate intratumoral 
and peripheral CTL-dysfunction in HPV+ HNSCC. We show that this CTL-dysfunction can be 
reversed using targeted HPV-specific T-cell expansion, and synergistic inhibition of IDO-1 and 
PD-1. These results have implications for the development of effective T-cell therapies for HPV+ 
HNSCC.  
4.3 Results 
4.3.1. Frequency and specificity of HPV16 E2, E6 and E7-specific CTLs in HPV+ HNSCC 
We performed a systematic analysis of potential CTL-epitopes from HPV16 E2, E6 and E7 
antigens restricted by 15 globally frequent HLA class I alleles representative of major HLA 
supertypes (Lund et al., 2004) (Fig 4-1 A-D). We used a comprehensive CTL-epitope prediction 
strategy we previously developed by incorporating stringent selection criteria (Appendix B, 
Methods) to control for inter-algorithmic variations (Chowell et al., 2015; Krishna & Anderson, 
2016). Fifty-nine candidate peptides (24 from E2, 20 from E6 and 15 from E7) were selected 
covering 13 of the 15 common HLA class-I alleles as candidate HPV-CTL peptides based on 
predicted HLA-affinity and antigen processing percentile scores (Fig. 4-1 A, 4-1 E-F). Several 
previously described HLA-A*02:01-restricted HPV16 E6 and E7 epitopes were predicted with high 
scores (e.g. E6-KLP epitope, total percentile 94.6, Table B1) confirming our prediction strategy. 
Within the 59 candidate HPV16-peptides, E2 had the lowest number of previously defined CTL-
epitopes (3/24, 12%), while E6 and E7 had higher number of previously described CTL-epitopes 
(35% and 46% respectively). The number of predicted HPV16-peptides ranged from 15 peptides 
(A*02:01), to 0 peptides (B*40:01, B*44:02) among the selected HLA-alleles (Fig 4-1 A). To 
determine if lack of HLA-binding motifs in the 3 HPV-antigens can poise specific HLA-alleles as 
risk-factors for HPV+ HNSCCs, we calculated the odds-ratio of HLA-allele frequencies in HPV+ 
HNSCCs (N=77), compared to HPV- HNSCCs (N=64) (Appendix B). HLA B*40:01, which had no 
predicted HPV16-peptides for E2, E6 and E7 had an odds-ratio of 7.48 compared to HPV- 
HNSCCs (Fig. 1A-B, P = 0.059), and had poor-binding peptides for all HPV16-antigens (bottom 
20
th
 percentile compared to other HLAs, Appendix Fig. B1). HLA-alleles A*24:02, B*07:02, and 
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B*51:01 were also overrepresented (OR>=2) in HPV+ HNSCCs, although they were not 
statistically significant. Of note, HLA-B*07:02 (OR = 2, Fig. 4-1 B), has been previously reported 
to be associated with poor clinical outcome in cervical cancer and escape HPV-specific T-cell 
(HPV-CTL) recognition (Ellis et al., 1995). These results point to the importance of CTL-mediated 
control of HPV16 malignancies.  
Because HPV-CTLs in peripheral blood mononuclear cells (PBMCs) are not abundant 
(Badoual et al., 2013; Riemer et al., 2010), we used PBMCs stimulated for 10 days with 
candidate peptides and CKB antibodies αCTLA4 and αPD-1 to enhance HPV-CTL reactivity 
(Appendix B, Fig. B-2). We compared HPV-CTL frequency in PBMCs between HPV+ HNSCC 
patients (N=18) and healthy controls (N=14) by interferon gamma (IFNγ) Elispots using antigen 
specific peptide pools (Fig. 4-2 A-B, Appendix B Table B1) (Parikh et al., 2014a). The HLA 
frequency distribution of this cohort largely mirrored median HLA-frequency distribution in the 
USA (Fig. 4-1 D). IFNγ responses against HPV16-E2 were substantially more common (>3-fold 
higher) in HPV+ HNSCC PBMCs compared to healthy control PBMCs (Unpaired Welch’s T-Test, 
P=0.012, 4-2 A). Moderate to high E6-reactivity was observed in HPV+ HNSCC patients (1.5 fold 
higher in HPV+ HNSCCs), while E7-reactivity was generally low (Fig. 4-2 B-C). To determine if 
PBMC T-cell reactivity correlates with B-cell immunity, we measured IgG serologic responses to 
the E2, E6, and E7 antigens in the 18 patients. E2 and E7-specific serum IgG titers were higher 
relative to E6 (>2-fold, P < 0.05) in the patients (Fig. 4-2 C). The majority of patients who had IgG 
to E2, E6 and E7 also had a measurable CTL response (E2=72%, E6=60%, E7=70%, 
respectively, Fig. 4-2 D). There was strong concordance between seroreactivity and T-cell 
reactivity within same antigens (Chi-squared independence test, P = 0.03). These results indicate 
E2 and E6 antigens are more CTL-reactive than E7 in patients, and HPV-CTL response 
enhanced by CKB antibodies.  
 
4.3.2. Mapping immunodominant epitopes of HPV16 E2, E6 and E7 in HPV+ HNSCCs 
To identify novel CTL epitopes from E2, E6 and E7, we performed a second IFNγ Elispot analysis 
using individual predicted HPV16-peptides against patient-specific HLA-alleles (Fig. 4-3). 51 out 
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of 59 predicted peptides elicited a T-cell response in at least one patient, indicating a high degree 
of success (86%) of our prediction-validation strategy (Fig. 4-3, Table B1). Consistent with pooled 
 
 
 
Figure 4-1. HPV16 E2, E6 & E7 predicted epitope distribution and risk factor for HPV+ 
HNSCCs. (A) Distribution of 59 predicted HPV16-peptides by each HLA-allele ranked from 
highest to lowest. (B) Odds ratio of HLA-allele frequency in HPV+ HNSCC patients compared to 
HPV- HNSCC patients *P = 0.059 (C) Median USA HLA-allele frequencies obtained from Allele 
frequency net database. (D) HLA-frequency distributions of MSSM-cohort. Distribution of 59 
predicted HPV16-peptides binned according to (E) total binding percentile scores (F) total 
antigen-processing percentile scores.  
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antigen Elispot results (Fig. 4-2 A-B), we observed sub-dominant E7-specific CTL-reactivity 
relative to E2, E6 epitope-specific CTL-responses (Fig. 4-3). Sixteen epitopes had an average 
response frequency of >=100 mean spot forming units (SFUs)/10
6
 PBMCs and were classified as 
strongly immunogenic (representative e.g. Fig. 4-4, Table B1). Twenty nine CTL-epitopes had an 
average response frequency between 10-100 SFU/10
6
 PBMCs (moderately immunogenic), while 
6 epitopes had an average response frequency <10 SFU/10
6
 PBMCs (low immunogenic). The 
majority of moderate to highly immunogenic epitopes (77%) was novel, or had not been 
described with the observed HLA restriction (Figs 4-3, 4-4, Table B1). We also observed 16 
unique epitopes that elicited a cross-reactive response to other alleles within the same supertype 
supporting the strategy for HLA-supertype based epitope prediction (Table B1). Figure 4-4 D 
shows a representative example, where an HLA-A*11:01 restricted E2-peptide had strong 
predicted binding affinity and elicited strong CTL-reactivity to HLA-A*68:01 (A3 supertype). 
Within the E2 antigen, most CTL-epitopes (52%) were clustered within the trans-
activating DNA-binding domain, 23% in the hinge region, and 24% in the DNA-binding domain 
(Fig. 4-5 A). Within E6, immunodominant regions (70% of epitopes) encompassed AAs 37-109 
with 40% of epitopes arising in the first zinc finger domain (Fig. 4-5 B). Interestingly, the zinc 
finger domain of E7 also had 42% of the CTL-epitopes (Fig. 4-5 C). Thus, we have defined 
immunodominant regions and enhanced the landscape of E2, E6 and E7 CTL-epitopes for future 
studies. 
 
4.3.3. HPV-specific T-cells exhibit dysfunctional phenotype in HPV+ HNSCC patients 
While CTL dysfunction in chronic viral infections and cancers has been described (Barber et al., 
2006), few studies have focused on the extent of T-cell exhaustion in HPV+ HNSCC patients 
because of the difficulties in studying low-frequency HPV-CTLs (Badoual et al., 2013). We 
assessed HPV-CTL dysfunction in HPV+ HNSCC patients after ex vivo stimulation by autologous 
antigen-presenting cells (APCs) presenting cognate HPV16-antigen in the absence of CKB 
antibodies. Our rationale here was that activated HPV-specific PD1+ CTLs that are poised 
towards the exhaustion spectrum, will become further dysfunctional after APC-stimulation and 
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Figure 4-2. HPV16 E2, E6 & E7 T-cell and B-cell immunogenicity in HPV+ HNSCCs. (A) 
Summary of CTL-reactivity. Predicted HPV16-peptides were pooled according to antigen (Table 
S1) and tested for CTL-reactivity by IFNγ Elispot. P-values from Unpaired Welch’s T-test are 
shown. (B) Representative example of CTL-reactivity from one HPV+ HNSCC patient PBMC with 
SFUs after background subtraction (left panel) and images from each pool in triplicate (right 
panel). (C) Seroreactivity of HPV16-E2, E6, E7 antigens in HPV+ HNSCC MSSM patients 
screened for CTL-responses by Rapid-ELISA (SI Methods)  (D) Seroreactivity and CTL-reactivity 
concordance for each HPV-antigen in responding HPV+ HNSCC patients. Circles are 
proportional to number of responding HPV+ HNSCC patients for each antigen. % represent 
patient responses. 
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Figure 4-3. Landscape of CTL-epitopes from HPV16 E2, E6 and E7 in HPV+ HNSCCs. HPV+ 
Summary of Elispot epitope deconvolution screen showing all responding HPV+ HNSCC patients 
(each column) against tested HPV16-peptides (each row) in log scale. Within each antigen, 
peptides are ranked from most number of CTL responses (top) to the least (bottom).  
 
acquire additional inhibitory markers characteristic of profound dysfunction, such as CD39 and 
TIM-3 (Gupta et al., 2015; Wherry, John Wherry, & Kurachi, 2015). In 4 HLA-A*02:01+ patients 
with HPV-specific CTLs detectable by antigen-specific tetramers (Fig. 4-6), and one HLA-
A*68:01+ patient with CD137-positivity defining HPV-CTLs, we phenotyped total CD8+ and E2,  
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Figure 4-4. Identifying antigen specific epitopes from HPV16 E2, E6 and E7 in HPV+ 
HNSCCs. Examples of individual responding patients after background subtraction. (A) HLA-
A*02:01+ patient; (B) HLA-A*02:01/B*07:02+ patient; (C) HLA-A*24:02/B*35:01+ patient. (D) 
HPV16-peptides predicted for the HLA-A3-supertype can stimulate a CTL response to 
representative allele (A*68:01). Inset shows binding affinities for predicted peptides for A*68:01, 
peptide labels shows HLA-allele the peptide was originally predicted. Positive responders are 
shown in bold.  *P < 0.1, **P < 0.01, Unpaired two-tailed Welch’s T-test.  
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Figure 4-5. Immunodominant regions of HPV16-E2, E6 and E7. All immunogenic CTL-
epitopes identified in this study mapped onto the 3 HPV16-antigens. Protein domain information 
was obtained from PAVE. Strength of immune response in the regions are indicated by the 
shaded boxes encompassing all peptides from the region, numbers indicate the number of unique 
HPV+HNSCC MSSM patient-specific responses.  
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Figure 4-6. HPV16-specific T-cells acquire dysfunctional phenotype upon ex vivo 
stimulation. (A) Representative flow cytometry plots from an HLA-A*02:01 HPV+ HNSCC patient 
CTLs stimulated with autologous APCs transfected with cognate antigen. Left: HPV16-Tetramer+ 
CD8+ T-cells one example for each HPV16-antigen; labels correspond to HPV16-epitope, % 
indicate tetramer+ events within CD8-gate; Right: CD8+PD1+CD39+ (in black) or 
CD8+Tetramer+PD1+CD39+ (DP
Ex
-phenotype, back gated in red). % - back gated 
CD8+Tetramer+DP
Ex
. (B) Pt.7002 HPV-CTL dysfunction, Top panel: CD8+ Tetramer+ events 
from the 3 HPV16-antigens (left), each point is an HPV16-epitope-tetramer. Fold change in total 
CD8+DP
Ex
 % after CTL-stimulation with HPV16-antigen transfected APCs, compared to mock 
transfected APCs (right). Bottom panel: % Total CD8+DP
Ex
 (left), % CD8+Tetramer+DP
Ex
 (right). 
P < 0.1, **P < 0.01, ***P < 0.001, Unpaired two-tailed Welch’s T-test.  
 
 
E6 and E7-specific CTLs exhibiting CD8+CD39+ PD-1+ or CD8+TIM-3+ PD-1+ phenotype (DP
Ex
-
phenotype) indicating substantial exhaustion. As shown in the representative example Pt.7002, 
two weeks after stimulation, E2-CTLs were higher in frequency than E6 and E7-CTLs (Fig. 4-6 A). 
Within the HPV16-antigens in Pt.7002, CTLs stimulated with E7-transfected APCs exhibited the 
highest levels of CD8+DP
Ex
 fold-change relative to mock-antigen transfected (2-4 fold,Fig. 4-6 B) 
followed by E2 (1-3 fold, Fig. 4-6 C) and E6 respectively. 
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Figure 4-7. Dysfunctional phenotype heterogeneity upon ex vivo stimulation. (A) Summary 
of dysfunction experiments in 4 other HPV+ HNSCC patients. Top: % Total CD8+DP
Ex
, Bottom: 
% CD8+Tetramer+DP
Ex
 for all except Pt. 7007 (% CD8+CD137+DP
Ex
). (B) Unsupervised 
hierarchical clustering of %DP
Ex
 from E2, E6 and E7 total CTLs (left) and HPV-specific CTLs 
(HPV-Tetramer+, CD137+, right) from patients analyzed in 3A-C. Each row is an epitope specific 
DP
Ex 
response per patient. *P < 0.1, **P < 0.01, ***P < 0.001, Unpaired two-tailed Welch’s T-test.  
 
 
In 3/5 HPV+ HNSCC patients, total CD8+ DP
Ex
 and HPV-specific CD8+DP
Ex
 cells were 
higher in CTLs stimulated with E7-antigen (between 2-10 fold) relative to E2/E6 antigen-
stimulated CTLs (Pts. 7002, 7007, 7012,  figs. 4-6 B, 4-7 A, Unpaired Welch's T-test, P < 0.1), 
independent of HLA-status (e.g. HLA-A*68:01+ Pt. 7007) (Fig. 4-7 A). In the other two patients, 
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E2-CD8+DP
Ex
 was higher than E7-CD8+DP
Ex
 (2-3 fold, Pts. 7035, 7050, Fig. 4-7 A, Unpaired 
Welch's T-test, P < 0.1), indicating heterogeneity in HPV-specific CTL-dysfunction in HPV+ 
HNSCC. Interestingly, compared to E2 and E7-CTLs, E6-CD8+DP
Ex
 remained relatively low in 
most patients, and there was an inverse relationship within patients between E7-CD8+DP
Ex
 and 
E2/E6-CD8+DP
Ex
 (Fig. 4-7 A). Unsupervised hierarchical clustering of DP
Ex
-frequencies of total 
CD8+ as well as HPV-specific CD8+ T-cells revealed this trend where high E2-CD8+DP
Ex
 and 
E6-CD8+DP
Ex
 co-occurred in patients who had relatively lower E7-CD8+DP
Ex
 and vice versa  
(Tukey’s multiple comparisons test, E2 vs. E7, P  = 0.014,  E6 vs. E7, P  = 0.084, E2 vs. E6, P = 
NS) (Fig. 4-7 B). These results indicate that in most HPV+ HNSCC patients, E7-CTL dysfunction 
is distinct and might be either temporally or mechanistically unrelated to E2/E6 CTL-dysfunction. 
 
4.3.4. HPV16-antigen load correlates with T-cell exhaustion  
To provide a broader analysis of immune dysfunction from the tumor side in HPV+ HNSCCs, we 
performed an immune signature analysis of publicly available HNSCC transcriptomes (TCGA, 
UM-cohorts N =119, 51 HPV+, 68 HPV-)(The Cancer Genome Atlas Network, 2015; Zhang et al., 
2016). We used previously-validated immune signatures representing tumor infiltrating immune 
cell subsets and performed single-sample gene set enrichment analysis (ssGSEA, Methods, 
Table B2 lists the gene signatures) to score the HPV+ and HPV- subsets (De Simone et al., 
2016; Mandal et al., 2016a; Şenbabaoğlu et al., 2016a). HPV+ HNSCC patients in general had 
higher immune infiltration scores compared to HPV- HNSCCs (Fig. 4-8), with 36/51 (70%) of 
HPV+ HNSCC samples represented in the T-cell-high gene cluster, and few HPV+ HNSCC 
samples (17%) with very low immune cell infiltration scores, confirming and expanding the 
findings in previous studies (Mandal et al., 2016a). To assess the impact of HPV gene expression 
on immune cell infiltration, we calculated the Spearman correlation coefficients among ssGSEA 
scores for the entire gene sets across all patients, including HPV16 genes and performed an 
unsupervised clustering on the correlation matrix (Fig. 4-9, Table B3).  
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Figure 4-8. T-cell infiltration and dysfunction signatures are enriched in HPV+HNSCCs. 
Unsupervised hierarchical clustering of validated normalized immune signatures (Table S3), in 
119 HNSCC transcriptomes (TCGA+UM cohorts) by ssGSEA (SI Methods). Each column 
represents one HNSCC patient tumor ssGSEA scores. Four clusters are revealed and their 
names are indicated in the bottom. Number and percentages of HPV+HNSCCs in each cluster 
are indicated. 
 
 
Interestingly, HPV-gene signatures also negatively correlated with neutrophils and other 
myeloid gene signatures, indicating that lymphocytes dominate the immune landscape of HPV+ 
HNSCCs (Fig. 4-9). We also observed a previously described exhaustion gene set correlating 
with HPV-gene sets in this module (Spearman ρ = 0.33, Fig. 4-9). Unsupervised hierarchical 
clustering on expression levels of constituent genes within the exhaustion gene set revealed 
three main groups with low (L), moderate (M), and high (H) expression of immune regulatory 
gene expression within HPV16+HNSCC patients  (Fig. 4-10 A). We then analyzed individual 
HPV16-gene expression in the HPV16+HNSCC tumors (N=40) stratified into Exhaustion-high 
(EX-H) and Exhaustion moderate/ low tumors (Fig. 4-10 B). EX-High HPV16+HNSCC tumors had 
higher gene expression of E1, E2, E4, E6 and L2 genes compared to the EX-ML subset (Fig. 4-
10 B, Unpaired Welch's T-test; E1, E2, P < 0.01; E4, E6, L2, P < 0.1). E7-expression was 
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Figure 4-9. T-cell exhaustion signatures correlate with HPV16-antigen expression. 119 
HNSCC transcriptomes (68 HPV- HNSCCs and 51 HPV+ HNSCCs), were analyzed for immune 
cell infiltration by ssGSEA (Appendix B, Methods). Clustered correlation matrix of immune 
signatures with HPV-gene sets (HPV - All 8 HPV genes, HPV.Early - E1, E2, E4, E5, HPV.Onco - 
E6, E7). All gene sets are listed in Appendix B Table B-2. Gene set correlations were clustered by 
hierarchical clustering creating distinct modules (Table B3). 
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Figure 4-10. HPV16-antigen load likely drives T-cell infiltration and dysfunction. (A) 
Unsupervised hierarchical clustering of 49 genes in the exhaustion gene set (De Simone et al., 
2016) in HPV+ HNSCC. Patient clusters: low exhaustion (L), moderate (M) and high exhaustion 
(H). (B) HPV gene levels (Log2-TPM+1) in 40 HPV16+HNSCCs from 4-8 A classified into 
exhaustion high (EX-H in main text, N=15) and exhaustion low+moderate subsets (EX-ML in 
main text, N=25). *P < 0.1, **P < 0.01, Unpaired two-tailed Welch’s T-test.  
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comparably high in both the subsets, while E5 known to downregulate MHC-class I expression 
(Campo et al., 2010), remained low in the EX-H subset (Fig. 4-10 B). These computational 
analyses along with previous experiments (Fig. 4-7) suggest that HPV-specific CTLs have T-cell  
exhaustion at tumor sites, driven by intra-tumoral HPV-antigen expression. 
 
4.3.5. IDO-1 represents a novel HPV+ HNSCC specific immune target 
We analyzed differential expression of constituent genes within the exhaustion gene set 
between HPV+ HNSCCs and HPV- HNSCCs (Fig. 4-11). We observed several well-known T-cell 
regulatory genes such as LAG-3, GAL-9, CEACAM-1 and CTLA-4 overexpressed in HPV+ 
HNSCCs compared to HPV- HNSCCs, consistent with high T-cell infiltration and dysfunction as 
observed in our results (Figs. 4-8, 4-9), and other studies (Mandal et al., 2016a). Interestingly, we 
also observed exhaustion genes NRP1, CD39 and CD73 that were selectively upregulated in 
HPV- HNSCCs compared to HPV+ HNSCCs (Fig. 4-11), indicating distinct types of T-cell 
dysfunction between the two HNSCC subtypes. Indoleamine 2,3-dioxygenase (IDO-1), an L-
Tryptophan catabolizing enzyme was one of the highest differentially expressed gene (based on 
To validate the immune signature analysis indicating that HPV-antigen expression can impact 
immune regulatory gene expression such as IDO-1 (Fig. 4-12 A), we performed immunoblotting 
for IDO-1 expression in a panel of HPV16+ cancer cell lines (2 cervical, 4 HPV+ HNSCC). These 
showed variability in HPV16-E7 protein expression (Fig. 4-12 B). IDO-1 expression followed a 
striking correlation with E7-protein expression in the same cell lines (R
2
 = 0.84, P = 0.033, Fig. 
5B). Transfection of the 3-HPV16-antigens into a non-HPV cell line (HEK-293-T) did not alter 
IDO-1 protein expression (Appendix B-3A). A cross-cancer (N = 30 types, 45708 total tumors) 
gene expression analysis from cBioPortal (Cerami et al., 2012), revealed that IDO-1 is also highly 
expressed in the HPV-malignancy cervical cancer (Fig. 4-12 C). These results suggest that tumor 
IDO-1 expression is linked to immune selection pressure from TILs rather than a direct 
molecular/biochemical consequence of the HPV-life cycle. Of note, PD-L1 protein expression on 
the same cell lines did not correlate with E7-antigen expression (Spearman ρ = 0.17, P = NS, 
Appendix B-3B).  
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Figure 4-11. Differential expression of exhaustion genes in HPV+ vs. HPV- HNSCCs. Box 
plots representing Log2 TPM from HPV+, HPV- HNSCC patients showing median from 
exhaustion gene set (Table B2), whiskers indicate 10-90th percentile. P<0.1, **P<0.01 ranked P-
value) from exhaustion set in HPV+ HNSCCs compared to HPV- HNSCCs (Fig. 4-12A; Mann-
Whitney test, P = 0.0012).  
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Figure 4-12. IDO-1 expression is an HPV-specific immune regulatory gene. (A) Box plots 
representing  Log2 TPM from HPV+, HPV- HNSCC patients showing median from exhaustion 
gene set (Table S3), whiskers indicate 10-90th percentile. Each data point represents one 
patient. P < 0.1, **P < 0.01 by Mann-Whitney test. (B) Correlation of IDO-1 protein levels to 
HPV16-E7 antigen expression in 6 HPV16 cell lines (2 cervical cancer, 4 HPV16+ HNSCC). Top 
pane: Immunoblot, Bottom panel: correlation of IDO-1 and E7 protein levels normalized to 
GAPDH (R
2
 = 0.84, P = 0.033).(C) Log2 mRNA TPM levels were obtained from cBioportal, for 30 
different types of cancers from 45708 total tumors from TCGA. Each blue data point represents 
expression from one patient tumor for respective cancer, red representing a mutation or other 
alteration and grey represents unsequenced tumors. 
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4.3.6. IDO-1 inhibition enhances T-cell targeting of HPV+ HNSCCs 
IDO-1 inhibitors are being evaluated in pre-clinical and clinical settings to enhance tumor 
immunity (Gangadhar et al., 2015; Sheridan, 2015). We therefore explored the possibility of 
exploiting IDO-1 inhibition to overcome HPV-CTL dysfunction, especially using E7-CTLs. We 
fluorescently labelled the HLA-A*02:01+ HPV+ HNSCC cell line UM-SCC-104 (SCC-104), which 
has high IDO-1, E7 and PD-L1 expression (Fig. 4-12 B, Appendix B-3B). SCC-104 cells were 
previously reported to have a distinct hierarchy of HPV16-antigen expression where E7 > E6 > E2 
(Olthof et al., 2015).  We assessed HPV-CTL mediated cytotoxicity on SCC-104 cells, after co-
incubation with ex vivo expanded HPV-CTLs from an HLA-A*02:01+ HPV+ HNSCC patient in the 
presence of either anti-PD-1 antibody (ɑPD-1+DMSO) or IDO-1 inhibitor Epacadostat (Ig+IDO-1i), 
or both (ɑPD-1+IDO-1i). Within E7-CTLs (Fig. 4-13 A, 4-13 B right side), single-agent treatment 
with either ɑPD-1 or IDO-1i individually resulted in a 3-5 fold increase in sensitivity of SCC-104 to 
E7-CTL mediated cytotoxicity compared to mock (Ig+DMSO) treatment (Fig. 4-13 A-B, ɑPD-1 vs. 
mock, P = 0.024, IDO-1i vs. mock, P = 0.064). In contrast, combination blockade with both ɑPD-
1+IDO-1i resulted in a 10-fold increase in tumor cytotoxicity compared to mock treatment (4-13 A-
B, P = 0.011), and a 2-3 fold increase in tumor cytotoxicity compared to the single-agent 
treatments 4-13 A-B, P = 0.04 compared to IDO-1i, P = 0.013 compared to ɑPD-1). Similar 
results were obtained with ɑPD-1+IDO-1i combination therapy on E2 and E6 CTL cytotoxicity 
although to a lesser extent (3-fold increase for E2, and 5-fold increase for E6 compared to mock 
treatment, P <  0.01, Fig. 4-13 B) likely reflecting the lower expression of these antigens in SCC-
104 cell line (Olthof et al., 2015). These results demonstrate that IDO-1 is a novel HPV+ HNSCC 
specific checkpoint correlating with HPV-antigen expression, and combination inhibition of PD-1 
and IDO-1 can sensitize HPV+ HNSCCs to HPV-CTL mediated cytotoxicity.  
4.4 Discussion 
HPV-driven malignancies remain an ideal model system for cancer immunotherapy, due to 1) a 
long lead time from infection to malignancy, 2) emerging immune and viral biomarkers for early 
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detection, 3) the persistent tissue expression of viral oncogenes and 4) epidemiologic evidence of 
the central role of T-cell control of viral persistence. However, the dynamics of viral persistence 
within immunocompetent individuals and the mechanisms of tumor immune escape remain 
 
Figure 4-13.  IDO-1 inhibition enhances T-cell targeting of HPV+ HNSCCs. Celltracker 
labeled SCC-104 cells were co-incubated with polyclonal E2, E6 and E7-specific T-cells at an 
effector/target ratio of 5:1 for 48 hours, and assessed for cell death (TRACK+ PI+ events) under 
ɑPD-1, IDO-1 single or dual-inhibition conditions. (A) Representative flow cytometry plot from E7-
specific T-cell mediated cytotoxicity on SCC-104 cells. % indicates celltracker labeled dead SCC-
104 cells. (B) Summary of SCC-104 cytotoxicity (3 biological replicates) by E2, E6 and E7-CTLs 
under treatments indicated. *P < 0.1, **P < 0.01, Unpaired two-tailed Welch’s T-test.  
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largely unknown, in particular for HPV+ HNSCC. The emerging epidemic of HPV+ HNSCC and 
lack of screening modalities represents a major clinical challenge and opportunity for targeted T-
cell immunotherapy. 
In this study, we have expanded the spectrum of HPV+ HNSCC-specific immune 
therapeutic targets at the CTL-epitope level and at the target tumor cell-modulatory level. We 
chose E2, E6 and E7-antigens, as they induce strong B-cell immunity, have been detected in pre-
invasive and/or invasive cervical cancer, and we confirmed viral antigen expression in HPV16+ 
HNSCC transcriptomes. Most studies that have attempted to define CTL-immunogenicity from 
HPV16 have primarily focused on a limited number of HLA-alleles (e.g. A*02:01) and peptides 
from E6 and E7 (Table B1), with limited data on immunogenic targets in in HPV+ HNSCC 
(Ressing et al., 1995; Riemer et al., 2010; Rudolf, Man, Melief, Sette, & Kast, 2001). The 15 HLA 
alleles chosen for this study are predicted to include 10/12 of HLA supertypes and over 95% of 
the global population (Lund et al., 2004; Riemer et al., 2010). Of the 15 HLA alleles, we failed to 
identify peptides for HLA-B*40:01 and HLA-B*4402. HLA B*40:01 is significantly overrepresented 
in the HPV+ HNSCC cohort compared with HPV- HNSCC (Fig. 4-1 B), but these data remain to 
be confirmed in larger datasets and association studies. Viral immune escape by altering HLA-
binding CTL epitopes has been documented in HIV-1 and HCV infections (Petrovic, Dempsey, 
Doherty, Kelleher, & Long, 2012; Price et al., 1997), but not as well for DNA viruses such as  
HPV, where the mutation rates are markedly lower. 
We identified several immunogenic CTL-epitopes from the 3 HPV16-antigens (Fig.4-3, 
Table B1). In our experiments, addition of PD-1 and CTLA-4 CKB antibodies aided our ability 
amplify and detect low-frequency HPV-CTL-response in both healthy and HPV+ PBMCs ex vivo 
(Figs.4-1-4.4, B1). Our results indicate that HPV16-E2 and E6 induce more CTL responses than 
HPV16-E7 (Figs. 4-1, 4-2). HPV16-E6 and E7 have been the dominant targets for T-cell based 
immune therapies against HPV thus far Draper et al., 2015; Kenter et al., 2009). In contrast E2-
specific CTL-reactivity has been unexplored as an immunotherapeutic target in HPV+ HNSCCs 
due to the assumption that E2-locus is interrupted by viral integration, similar to that observed in 
cervical cancer (Woodman et al., 2007). However, several recent whole genome studies in 
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HNSCCs have indicated that viral breakpoints in HPV+ HNSCCs are distributed throughout the 
genome, with preferential integration in the E1 region (Akagi et al., 2014; Parfenov et al., 2014b). 
E2 is also a larger antigen >3-times the size of E6, E7, possibly explaining the bigger spectrum of 
CTL-epitopes from the protein. These results, taken along with the high proportion of episomal full 
length HPV DNA in HNSCC lesions (Olthof et al., 2014), and our data demonstrating strong E2-
specific T-cell and B-cell reactivity (Figs. 4-1, 4-2) warrant further investigation of E2 as a T-cell 
therapeutic target in addition to E6 and E7 in HPV+ HNSCCs. 
Despite the addition of CKB antibodies in the ex vivo T-cell stimulation protocol, we 
detected low levels of E7-CTLs compared to E2 and E6-CTLs in this study. This can be due to 1) 
inaccurate prediction of CTL-epitopes, 2) inherently low immunogenicity of E7-antigen, 3) low 
antigen load in patients, or 4) higher levels of dysfunctional E7-specific CTLs. Our ability to 
accurately predict previously described epitopes from E7 and the successful identification of 
novel CTL-epitopes from E2 and E6 across various HLA-alleles (Fig. 4-3), argues against a sub-
optimal prediction strategy. The presence of high levels of serum titers against E7 in HPV+ 
HNSCC patients indicates that the antigen is presented and is immunogenic at least in context of 
B-cell immunity (Fig. 4-2C-D). Gene expression analysis of HPV+ HNSCC tissue and cell lines 
showed that E7-antigen load is high in patient tumors, consistent with several other studies 
(Olthof et al., 2014; Zhang et al., 2016). However, E7-CTLs tended to exhibit higher levels of 
PD1+CD39+ or PD1+TIM3+ DP
Ex
-phenotypes compared to E2 and E6-CTLs after ex vivo 
stimulation in 3/5 independent HPV+ HNSCC patients (Figs. 4-6, 4-7). In particular, E7-CTL 
dysfunction rarely occurred in concert with E2/E6 CTL dysfunction within the same patient (Fig. 4-
7). Since antigen persistence and subsequent magnitude of CTL-response are major factors in 
chronic viral T-cell exhaustion (Mueller & Ahmed, 2009), we speculate that in each of these 
patients, the variable HPV-dysfunctional CTLs might reflect temporal tumor HPV-load or tumor 
heterogeneity, although this remains to be elucidated. Future studies that compare and correlate 
tumor antigen load in vivo with the dynamics of E2, E6 and E7-CTL phenotypes in peripheral 
blood and tumor will be needed to verify in vitro CTL-dysfunction findings from our study. 
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While other studies have shown high levels of immune infiltration in HPV+ HNSCCs 
(Mandal et al., 2016a; Zhang et al., 2016), we show here that HPV-antigen load likely drives high 
CTL-infiltration and CTL-dysfunction (Fig. 4-9), arguing for better response to immune CKB 
therapies. Indeed, preliminary data from ongoing HNSCC clinical trials targeting the PD-1/PD-L1 
axis indicate more benefit for HPV+ HNSCCs compared to HPV- HNSCCs (Chow et al., 2016; 
Ferris et al., 2016). Our data thus provides mechanistic insights into this clinical response, 
wherein, high HPV-antigen load likely drives T-cell infiltration into HPV+ HNSCCs causing 
immune selection pressure for HPV-CTL dysfunction (in particular E7-CTLs), and that immune 
checkpoint blockade can at least partially reverse this effect in HPV+ HNSCCs (~32% ORR in 
(Chow et al., 2016)). 
In addition to the PD-1 checkpoint, we demonstrate both by computational and 
experimental in vitro assays that IDO-1 is highly expressed in HPV+ HNSCC and other HPV-
driven malignancies (Figs. 4-10, 4-12). In preclinical murine melanoma models, TILs increase 
tumor IDO-1 expression (Spranger et al., 2013) and IDO-1 inhibitors are showing promise in 
clinical trials in particular with PD-1/PD-L1 blockade (Sheridan, 2015). HPV+ HNSCCs 
expressing IDO-1 might similarly be driven by HPV-specific-CTL infiltration in response to high 
tumoral HPV antigen load (Fig. 4-12). In vitro, this resistance to CTL-targeting by HPV+ HNSCCs 
is apparent in the absence of PD-1/IDO-1 inhibition, where only ~5% of SCC-104 cells were 
sensitive to CTL-cytotoxicity regardless of the antigen-specificity of the HPV-CTLs (Fig. 4-13). In 
contrast, inhibition of IDO-1 alone or in combination with PD-1 blockade significantly enhances 
tumor cell cytotoxicity of E7-CTL (and, to a lesser extent, E2 and E6-CTL) derived from patients 
with HPV+ HNSCCs (Fig. 4-13). These data suggest that IDO-1/PD-1 blockade may have a 
significant effect to activate pre-existing HPV-specific CTL in the majority of HPV+ HNSCCs. 
Sixty years after the discovery of HPV and 10 years after FDA approval of the first HPV 
vaccine, HPV-associated malignancies remain a major public threat, with an estimated 14 million 
new HPV-infections occurring every year (Dunne et al., 2014).  The presence of highly-expressed 
viral antigens makes HPV+ HNSCCs a promising setting for targeted immunotherapies. We 
propose that vaccination or adoptive T-cell therapy to HPV16-specific CTL epitopes from E2, E6 
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and E7, and targeted immune modulation with a combination of PD-1 and IDO-1 inhibition 
warrant further evaluation in HPV+ HNSCC and other HPV-associated malignancies.  
4.5 Materials and Methods 
For full details of methods and construction of data sets see Appendix B. 
 
4.5.1. HPV16 candidate CTL-epitope prediction 
HPV16-candidate CTL epitopes were predicted using previously described prediction strategies 
developed by us (Chowell et al., 2015; Krishna & Anderson, 2016), except for the incorporation of 
immunogenicity scores. For the 15 HLA-class I alleles, 9-mer and 10-mer candidate epitopes 
derived from the HPV16 proteins E2, E6, and E7 were predicted from 5 independent prediction 
algorithms and normalized. Top 4-5 candidate peptides / HLA-allele were used for experiments. 
Further details are provided in Appendix B. For full list of peptides see Appendix Table B1. 
 
4.5.2. Epitope mapping from HPV+ HNSCC PBMCs 
PBMCs were obtained from stage III or stage IV HPV+ HNSCC patients (MSSM cohort). Patient 
characteristics are described in(Parikh et al., 2014b). All HPV16-peptides (> 80% purity) were 
synthesized by Proimmune, UK. HPV+ HNSCC PBMCs were thawed, rested with 1μg/mL of CKB 
antibodies anti-PD1 (eBosciences, USA) , anti-CTLA4 (eBosciences, USA) for 1 hour at 37 C. 
HPV16-peptides in pool or individually were added subsequently in biological triplicates, along 
with recombinant human IL-2 (20U/mL), human IL-7 (5ng/mL). On day 5, half the media was 
removed and replaced with fresh IL-2 and peptide pool. On day 8, half the media was removed 
and fresh media, IL-2 and peptide was added to the cells and replated into a 96-well multiscreen 
elispot plate for Elispot detection. Elispot detection is described in Appendix B. 
 
4.5.3. HPV-CTL stimulation for phenotyping 
HPV-specific T-cells were generated by stimulating autologous HPV+ HNSCC patient B-cell 
APCs (Appendix B). APCs were either peptide pulsed with HPV16-epitopes, or transfected with 
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whole HPV-antigen encoded in mammalian expression plasmid pCDNA3.2 (Invitrogen, CA, 
USA). APCs were washed and incubated with thawed whole HPV+ HNSCC PBMCs at a ratio of 
1:2 (200,000 APCs : 400,000 PBMCs) supplemented with 20U/mL recombinant human IL-2 (R&D 
Systems, MN, USA), 5ng/mL IL-7 (R&D Systems, MN, USA). On day 5, partial media exchange 
was performed. On day 10, expanded HPV-CTLs were restimulated with peptide-pulsed, 
transfected APCs similar to day 1. HPV-CTLs were used for cytolytic assays or 
immunophenotyped after day 20.  
 
4.5.4. Tetramer staining, HPV-CTL and HPV+cell line phenotyping 
HPV16-tetramers were obtained from NIH Tetramer Core Facility at Emory University. For 
tetramer staining, cells were re-suspended in 100μL staining buffer with 5% human serum and 
1mM Dasatanib (ThermoFisher Scientific, MA, USA), and each tetramer was added at 
concentration of 1:100 for 30 minutes at room temperature. Cells were washed twice and 
restained with anti-CD8-PC5, anti-CD4-FITC, anti-CD14-FITC and anti-CD19-FITC for exclusion 
gates, and either a combination of anti-PD1-BV605 and anti-CD39-BV-405 or anti-PD1-BV-605 
and anti-TIM3-BV-405 for 30 minutes on ice. HPV+ cell line PD-L1 staining was done for 30 
minutes on ice. Samples were then washed twice in 1x PBS, and analyzed by Attune flow 
cytometer (ThermoFisher Scientific, MA, USA). Tetramer and antibody details are provided in 
Appendix B. 
 
4.5.5. HPV-CTL cytotoxicity assays  
HLA-A*02:01+ HPV+ HNSCC+ SCC-104 cells were pre-labelled with 0.5μM CellTracker Green 
CMFDA (ThermoFisher Scientific, MA, USA) for 1 hour and washed. HPV-specific CTLs  were 
pooled by HPV-antigen, washed and resuspended in media supplemented with 20U/mL IL-2, with 
1μg/mL isotype IgG or anti-PD1 antibody, DMSO, and 1μM IDO-1 inhibitor Epacadostat (Selleck 
Chemicals, MA, USA) in various combinations as described. HPV-CTLs were added at ratio of 
5:1 to SCC-104 cells and incubated for 48 hours at 37 C, 5% CO2. Cocultured cells were 
harvested, neutralized with media supernatant from each well containing dead cells and 
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centrifuged for 850g, 10 minutes. Cell pellets were washed twice with sterile 1X PBS, 
resuspended with 1mL 1X PBS, and 2uL Propidium Iodide (ThermoFisher Scientific, MA, USA) 
and cell death was assessed by flow cytometry.  
 
4.5.6. RNASeq data alignment 
RNA-Seq reads for each sample were quality checked using FastQC (version 0.10.1, Babraham 
bioinformatics, Babraham Institute, Cambridge, UK) and aligned to the human genome build 38 
(GRCh38) primary assembly and HPV16 genome (GCF_000863945.1) simultaneously using 
STAR (version 2.5.2B). After alignment, variants were discovered following GATK Best Practices 
workflow for RNAseq. Raw RNAseq reads were pre-processed by adding read groups, indexing, 
marking duplicates and sorting, Split’N’Trim, reassigning mapping quality and base recalibration. 
 
4.5.7. ssGSEA analysis of HPV and immune gene signatures 
Log transformed transcripts per million (Log2 TPM+1) from each HNSCC sample, after 
subtraction of low expression genes was used for ssGSEA as previously described in 
Şenbabaoğlu et al (Şenbabaoğlu et al., 2016b). Pre-defined immune signatures (Appendix B 
Table B2), have been extensively validated in Şenbabaoğlu et al (Şenbabaoğlu et al., 2016b) and 
Mandal et al(Mandal et al., 2016b). ssGSEA scores were computed for each tumor sample using 
the R package GSVA, and Z-transformed across the cohort prior to analysis. To assess impact of 
HPV-gene expression on immune signatures, a correlation matrix was built using the R-library 
Corrplot with the Z-transformed ssGSEA scores and were displayed by hierarchical clustering of 
correlations (Appendix B Table B3). Individual gene expression analysis was performed by 
unsupervised hierarchical clustering methods and were used for heatmap analysis. 
 
4.5.8 Statistical Analysis 
Categorical variables, such as Elispot data, and Flow cytometric data were summarized as SFUs, 
and percentages. Continuous variables (RNAseq data) were presented with mean with standard 
error of mean (SEM). Unpaired T-test with Welch’s correction was used for all categorical variable 
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analyses, and for continuous variable analyses non-parametric Mann-Whitney’s test was used. 
For heatmaps of T-cell frequencies and ssGSEA RNASeq analyses, Z-transformation was 
performed to normalize the data across the cohorts. R statistical software V3.4.0 and Prism 
software (GraphPad Software) were used for data managements and statistical analyses. 
Significance levels were set at 0.1 (*), and P-values of 0.01 (**) or 0.001 (***) for all tests are 
indicated. 
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CHAPTER 5 
T-CELL ANTIGEN DISCOVERY BY SINGLE CELL CYTOKINE CAPTURE 
 
Abstract 
Peripheral CD8+ T-lymphocytes (CTL) are critical components of the human immune system 
performing constant immune surveillance and elimination of infected, malignant cells thereby 
protecting the host against a multitude of pathogenic infections. Despite major advances in 
technologies for T-cell epitope discovery, CTL antigen and epitope identification from large 
complex genomes remain a major challenge. Here, we develop a novel single cell assay using 
autologous CTLs and antigen presenting cells (APCs) to enable identification of immunogenic 
antigens from a cDNA library encoding whole genomes without the need for HLA-typing. The 
assay relies on the capture of interferon gamma secreted by effector CTLs on the surface of 
autologous APCs encoding an immunogenic antigen. We empirically show the this assay using 
peptide pulsed as well as transfected APCs as well as with a limit of detection of up to 10% of 
antigenic epitope pulsed APCs. We validated the IFNϒ APC capture assay by magnetic sorting of 
the IFNϒ + APCs followed by PCR amplification of an antigen cassette. We anticipate that this 
technology will enable the accurate identification of immunogenic antigens and epitopes relevant 
for T-cell vaccine and immunotherapy design.    
  
5.1 Introduction 
CD8+ T-cell (CTL) recognition of an antigenically processed intracellular epitope is critical for the 
adaptive immune based clearance of many pathogenic infections. CTLs use their T-cell receptor 
(TCR) to interact with linear immunogenic epitopes in complex with the human leukocyte antigen 
(HLA) class I molecules of infected cell surface (Grakoui et al., 1999). In the lymph node, 
professional antigen presenting cells (APCs) such as dendritic cells (Mildner & Jung, 2014), or 
activated B-cells (Coughlin, Vance, Grupp, & Vonderheide, 2004), can activate CTLs by 
integrating TCR-HLA-peptide complex (Signal 1) and costimulatory molecules CD80/86 (Signal 2) 
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to prime naive CTLs as well as boost memory CTLs (Pollizzi & Powell, 2014). This complex 
cellular interaction ultimately leads activated CTLs to seek infected, malignant cells expressing 
the same epitope, CTL-release of many proinflammatory cytokines such as interleukin-2 (IL-2), 
interferon gamma (IFNϒ), and finally release of effector molecules causing target cell lysis 
(Hennecke & Wiley, 2001). Thus, the identification of CTL-epitopes and antigens is a major effort 
in translational immunology which can aid in the design of effective T-cell vaccines, 
immunotherapies, and immune monitoring of many malignancies (Ott et al., 2017; Schumacher & 
Schreiber, 2015; Tran et al., 2016).  
The immense diversity of T-cell repertoire, the universe of pathogenic epitopes, and the 
polymorphism, codominance of HLA-alleles makes the identification of antigenic T-cell repertoire 
of any pathogen daunting. Several advances in genomics, proteomics and computational 
techniques have resulted in the development of novel approaches for identifying the HLA class I-
restricted antigenic repertoire of CTLs in the past decade. For instance, biochemical methods 
such as mass spectrometry (MS) can perform unbiased identification of the HLA-ligandome of 
any cell type (Kowalewski et al., 2015; Shao et al., 2017). However MS-identification while being 
sensitive, does not identify immunogenic epitopes that result in T-cell activation, and generally 
requires large amounts of sample. Fluorescent HLA-multimers in combination with 
multiparameter flow cytometry can be used identify immune reactive CTLs, and have recently 
been combined with genomics to identify immunogenic epitopes from complex libraries (Bentzen 
et al., 2016). However, such methodologies still require knowledge of the donor’s HLA-type, the 
predicted CTL-epitope, and its HLA-restriction. More recently, machine learning computational 
algorithms have been developed to predict HLA-binding candidate peptides from an antigen 
(Moutaftsi et al., 2006), and more recently, immunogenicity of HLA-binding CTL-epitopes 
(Chowell et al., 2015). However, computational predictions have an inherent error in their 
accuracy, and will need to be experimentally validated. Experimental techniques involve arduous 
low throughput immunological techniques such as Elispot, or flow cytometric evaluation (Miyahira 
et al., 1995; Zaritskaya, Shurin, Sayers, & Malyguine, 2010).  
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Our goal here was to develop a sensitive and inexpensive immunologic assay that 
overcomes many of the limitations inherent to experimental T-cell antigen discovery approaches. 
We hypothesized that directional secretion of cytokines by activated T-cells into the immunologic 
synapse can enable the detection of antigenic APCs from a cDNA library. Our assay employs two 
color flow cytometry combined with magnetic or fluorescence based identification with deep 
sequencing allowed us to correctly identify immunogenic antigen from a pool of control genes, 
with high sensitivity (upto ~10% antigen encoding APCs), specificity at low effector:target ratios 
(~1:1) without the need of knowledge of donor’s HLA type. 
 
5.2 Results 
5.2.1. Development of autologous APC system and APC capture assay 
Interaction between a T-cell and an APC presenting a cognate antigenic epitope causes 
polarization of the T-cell cytoskeleton resulting in the directional secretion of specific cytokines 
such as  IL-2 and IFNϒ preferentially into the immunologic synapse secreted directionally into the 
immunological synapse into the target cell (Huse, Lillemeier, Kuhns, Chen, & Davis, 2006; Xie, 
Tato, & Davis, 2012). The directional CTL cytokine secretion is temporally dependent on early 
time points after TCR-HLA-epitope interaction (Han et al., 2011; Sanderson et al., 2012; von 
Bergwelt-Baildon et al., 2002). We leverage this dynamic paracrine cytokine secretion by 
capturing IFNϒ secreted by CTLs on the immunologic synapse of APCs presenting cognate 
antigen via a commercially available bispecific IFNϒ catch antibody (Brosterhus et al., 1999; 
Campbell, 2003) (Fig. 5-1 B-C). We utilize CD40L activated B-cells (CD40L.APCs) expanded 
from T-cell depleted fraction, and purified CD8+ T-cells from subject blood mononuclear cells 
(PBMCs). CD40L.APCs have been previously shown to be a rapid source of autologous APCs, 
have abundant expression of the target CD45 protein for bispecific catch antibody, and are highly 
programmable by transfection methods (von Bergwelt-Baildon et al., 2002). As shown in Fig. 5-1 
A top panel, after two weeks of CD40L feeder cell stimulation, >90% of cells are CD19+ CD86+ 
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Figure 5-1. Development of CD40L-APC system and workflow of APC-cytokine capture 
assay. (A) Autologous CD40L.APCs can be expanded and matured (CD19+ CD86+ fraction) in 
two weeks (top panel); CD40L.APCs are efficient in inducing CTL-memory responses (FLUM1 
epitope from Influenza A virus) in control peptide compared to M1-epitope pulsed APCs (bottom 
panel) (B) IFNϒ captured by bispecific catch antibody on immunological synapse of APCs. (C) 
Workflow of the APC-capture assay followed next generation sequencing of antigen identification. 
 
 
expressing B-cells, indicating a pure mature APC fraction. CD40L.APCs are also very efficient in 
stimulating virus-specific CTLs as demonstrated in Fig. 5-1 A, where an HLA-A*02:01+ healthy 
donor had a 37-fold increase in FLUM1-epitope specific CTLs in two weeks compared to baseline 
frequencies (Fig. 5-1A, bottom panel). We developed a workflow based on this assay where 
mature CD40L.APCs are transfected with antigens derived from a cDNA library (encoding the 
whole pathogenome) and are then subject to APC-cytokine capture assay (Methods, Fig. 5-1C). 
APCs with the captured cell surface IFNϒ are subject to secondary antibody staining, followed by 
standard fluorescent or magnetic cell sorting assays. Following cell sorting, the target antigen-
  101 
expressing plasmid responsible for T-cell stimulation is isolated, amplified by universal primers, 
and identified by deep sequencing (Fig. 5-1 C). 
 
5.2.2. APC-capture assay methodology 
We first tested the feasibility of our APC-capture assay by peptide pulsing APCs overnight with 
pre-mixed virus specific peptide pools (CEF), labeled the APCs next day with the bispecific-IFNϒ 
antibody, and co-cultured them with purified CTLs for 4.5 hours at 37°C. A representative figure is 
shown in Fig. 5-2 A, where the CD8- fraction representing APCs have a significant increase (~ 5-
fold) in cell surface IFNϒ+ APCs compared to DMSO-pulsed APCs or APCs alone. We then 
tested the limits of the assay using peptide pulsed autologous CD40L.APCs at various CTL:APC 
ratios, and time points of APC maturity (Fig. 5-2). Although the assay worked well across all the 
conditions, we observed that an APC:CTL ratio of 2.5:1 was sufficient to distinguish CTL-targeted 
CEF-pulsed APCs from control-APCs, and increasing the number of CTLs led to slight increase in  
 
Figure 5-2. Experimental testing of APC-cytokine capture assay. (A) Representative example 
and gating strategy of APC-IFNϒ capture on peptide pulsed APCs E:T = 5:1. % indicate APC 
IFNϒ+ events within CD8- gate. (B) Quantification of APC-capture assay using different E:T 
(CTL:APC) ratios on day 10 of mature CD40L.APCs (top panel), and on day 20 of mature 
CD40L.APCs (bottom panel). CEF-Pep represents the pre-mixed immunogenic epitopes from 
CMV, EBV and FLU. Data represents mean of 3 biological replicates. *P < 0.05, **P < 0.01, 
Unpaired two-tailed Welch’s T-test.  
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background (5:1, Fig. 5-2 B top panel), and there was no benefit to increase CTL:APC ratio 
beyond 5:1 (Fig. 5-2 B bottom panel). We also observed a higher proportion of IFNϒ+ APCs 
when APCs were used by day 20, compared to less mature APCs from day 10 (>3-fold for 5:1 
E:T, 45% IFNϒ+ APCs compared to 15%), consistent with a highly pure CD19+ CD86+ faction 
observed in second week of CD40L.APC maturation (Fig. 5-1 A). We used an CTL:APC ratio of 
2:1, in week 3 of APC maturation for subsequent experiments.   
 
5.2.3. Specificity optimization of the APC-capture assay 
Because this workflow depends on capturing IFNϒ on single APCs encoding cognate antigen, we 
were concerned about “off-target” effects in which IFNϒ secreted by CTLs are captured on  
 
Figure 5-3. IFNϒ APC capture assay specificity optimization. (A) Representative flow 
cytometry plots from a donor with off-target effects showing no decrease in IFNϒ+ APCs with 
decreasing proportions of antigenic APCs. (B)  Representative flow cytometry plots from same 
donor with reduced off-target effects after optimization and dose-dependence (C) Quantification 
of biological triplicates in 5-3 B, with two different CTL:APC ratios.  
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bystander APCs without a cognate immunogen, leading to false positives. To test the specificity 
and sensitivity of this assay, we assessed CTL targeting of APCs with cognate antigen (CEF-
pulsed) mixed in varying proportions with control DMSO-pulsed “cold target” APCs. Our rationale 
here was that if there was off-target effects, bystander cold target APCs would also be labeled 
with IFNϒ regardless of the number of true antigen-specific APCs present in the pool. This 
assessment would allow us to estimate the specificity of the assay, especially for true target 
APCs present at low frequencies in the population.  
Our first attempts at this specificity experiments indicated that there were indeed off 
target effects, because IFNϒ+ APCs did not sufficiently decrease with decreasing proportion of 
CEF-pulsed APCs (Fig. 5-3 A). We further noted that the percentage of IFNϒ+ APCs in some 
cases far exceeded the total percent of immunogenic APCs (e.g. 25%, 10% CEF.APCs in Fig. 5-
3 A). However, because there was a general trend of decrease in overall IFNϒ+ APCs (100% 
CEF.APCs versus 10% CEF.APCs), we reasoned that IFNϒ secreted by CTLs diffused and 
labelled cold target APCs when the samples were mixed to transfer and perform antibody staining 
in the plate. To overcome these issues, we stopped CTL-IFNϒ secretion by incubating samples 
on ice for 30 minutes, followed by careful removal of any cytokine containing supernatant without 
mixing. These optimizations substantially decreased off-target issues, when the same donor 
showed substantially lower percentage of IFNϒ+ APCs even at 100% CEF.APCs (8.13% in Fig. 
5-3 B compared to 46.3% in Fig. 5-3 A). More importantly, there was a dose-dependent decrease 
of IFNϒ+ APCs following the trend of decreasing true antigenic APCs (Fig. 5-3 B-C), and was 
overall applicable to varying CTL:APC ratios (Fig. 5-3 C). These results indicated that the 
optimized APC capture assay was able to specifically label antigenic APCs, and had a sensitive 
detection limit of up to 10% target APCs (Fig. 5-3B). 
 
5.2.4. APC-capture assay and antigen recovery using transfected APCs 
We then tested the applicability of the assay to antigen transfected APCs in order to recover the 
target antigen responsible for CTL immunogenicity. We first assessed transfection efficiency by 
GFP expression 24 hours after transfection of APCs and observed that close to 60% of APCs 
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were positive (Fig. 5-4 A). We then repeated the cold targets experiment, where we mixed APCs 
transfected with either FLUM1 antigen (from Influenza A virus) or the control self-antigen GAPDH 
 
Figure 5-4. IFNϒ APC capture assay on transfected APCs. (A) Transfection efficiency of 
APCs assessed with GFP 24 hours post nucleofection (B) Representative flow cytometry plots 
from same donor with transfected cold targets showing dose dependent decrease in IFNϒ+ 
APCs (C) Quantification of biological triplicates in 5-4 B. 
 
 
in varying proportions and co-incubated with autologous CTLs (Fig. 5-4 B-C). Similar to the 
peptide pulse experiments, we observed a clear hierarchy of dose dependence from 9.5% mean 
IFNϒ+ APCs for 100% FLUM1.APcs down to 3% mean IFNϒ+ APCs with varying decreasing 
proportions in between (Fig. 5-4 C). We further noted that there was more consistency in 
hierarchy of dose dependence for antigenic IFNϒ+ APCs in transfected APCs compared to 
peptide pulsed APCs (Fig. 5-3). Similar results were obtained with other independent donors 
(data not shown). This might be due to a reduced antigen load in the APCs as opposed to 
saturating levels of epitopes loaded on HLA-I molecules when synthetic peptides are being used 
to load APCs. 
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Figure 5-5. Antigen recovery of IFNϒ+ APCs. (A) PCR amplification of the antigen cassette 
after MACS sorting of PE+ and PE- fractions (top panel); Gel intensity across lanes (horizontal 
profile) for GAPDH (middle panel), and FLUM1 antigen (bottom panel). (B)  Gel intensity of PCR 
cassette within the sample (vertical profile) indicating GAPDH and FLUM1 peaks. 
 
We then tested assessed the efficiency of antigen recovery from the transfected 
immunogenic APCs for applicability in the workflow described in Fig. 5-1 C. We labelled the 
pooled APCs and CTLs with IFNϒ-phycoerythrin (PE) conjugated secondary antibody, followed 
by magnetic associated cell sorting (MACS) with anti-PE conjugated magnetic beads (Methods). 
Following MACS isolation, cells were subject to plasmid extraction to recover the antigen, PCR 
amplified and run on an agarose gel to visualize the recovered antigen (Fig, 5-5). We compared 
the band intensities of the PCR-amplified cassette for both the IFNϒ+ fraction (PE+) and IFNϒ-
unbound flow through fraction (PE-) (Fig. 5-5). We observed a consistently higher FLUM1 band 
intensity in the PE+ fraction compared to the PE- fraction irrespective of the number of initial 
FLUM1.APCs (Fig. 5-5 A, bottom panel) indicating successful antigen recovery and that 
FLUM1.specific APCs are being enriched by the IFNϒ APC capture assay (Fig. 5-5 A-B). 
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Comparing the PE+ fractions alone, we observed a proportional decrease in FLUM1 bands with 
decreasing FLUM1-specific initial APCs (mirroring the flow cytometry results (Fig. 5-4). GAPDH 
bands on the other hand showed an increasing trend with decreasing FLUM1.APCs and were 
comparably represented in both the PE+ and PE- fractions in 100% GAPDH.APCs (Fig. 5-5, 
middle panel, last two samples). Lastly, within the sample, we observed higher intensity of the 
FLUM1 band relative to GAPDH band (Fig. 5-5 B) indicating specificity, although the specificity 
decreased with lower proportion of antigenic FLUM1.APCs (25%). These results indicated that 
while antigen specificity was significant by flow cytometry methods, magnetic sorting might be 
also selecting for non-antigenic targets via non-specific binding to cells (see Discussion).  
5.3 Discussion 
There is considerable interest in identifying the antigenic repertoire of CD8+ T-cells in a given 
individual. Knowledge of such antigens are critical to the development of novel T-cell based 
vaccines against pathogens (Robinson & Amara, 2005), cancer immunotherapies targeting tumor 
specific antigens, neoantigens (Carreno et al., 2015; van Rooij et al., 2013; Verdegaal et al., 
2016), identifying the T-cell receptor repertoire specific for antigens (Glanville et al., 2017; 
Strønen et al., 2016), and immune monitoring of various malignancies (Jäger et al., 2000; Snyder 
et al., 2014). 
 In this study, we aimed to develop an immunologic assay that when combined with next 
generation sequencing could yield a high throughput overview of immunogenic antigens from a 
given pathogenome. To this end, we leveraged directional IFNϒ secretion by CTLs to develop an 
IFNϒ APC capture assay presenting cognate immunogenic T-cell activating antigen. We 
optimized and tested the limits of this assay first by peptide pulsed APCs, then through antigen 
transfected APCs via flow cytometry and MACS sorting.  
 Our preliminary results indicate that IFNϒ APC capture can be used to identify 
immunogenic antigens and peptides with specificity and sensitivity to up to 10% APCs presenting 
cognate antigen (Figs. 5-3, 5-4). These results support other studies which have shown that even 
low frequency antigens (upto one epitope-HLA complex per cell) can stimulate and activate pre-
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existing T-cells (Huang et al., 2013; Sykulev, Joo, Vturina, Tsomides, & Eisen, 1996). As such, 
this simple flow cytometry based assay is performed using low sample numbers (200,000 CTLs : 
100,000 APCs per well), using frozen CTLs within a day (4-5 hours incubation). Thus, without 
invoking sequencing techniques, one can envision that differential labeling of antigens can 
enhance the throughput of this flow cytometric assay.  
However, in large pathogenomes (e.g. CMV ~ 200 genes) methods beyond multi-
parameter flow cytometry are required for high throughput antigen discovery. Therefore, we 
tested IFNϒ APC capture in transfected APCs and showed that the assay is consistent in 
transfected APCs, with results largely similar to peptide-pulsed APCs. After controlling for IFNϒ 
diffusion and off target effects (Fig. 5-3 A-B), transfected APC experiments showed that there is a 
clear dose dependent decrease in IFNϒ+ FLUM1.APCs dependent on starting proportion of 
either FLUM1 or control APCs (Fig. 5-4) which is critical for a highly sensitive single-cell assay. 
Furthermore, we were successful in isolating the FLUM1 amplicon from IFNϒ+ APCs and we 
demonstrated enrichment of the antigen in samples with varying proportions of the antigenic 
APCs (Fig. 5-5). These experiments will enable us to employ the assay to identify T-cell 
immunogenic antigens from complex pooled antigen libraries in future studies.  
The current experiments have also revealed caveats in our methodology. Although, flow 
cytometry experiments revealed high sensitivity and specificity across multiple donors, at low 
frequency antigenic APCs there were discrepancies when flow cytometry results were compared 
to MACS based antigen recovery. For instance, at 25% FLUM1.APC frequency, there was a five 
fold higher percentage of IFNϒ+APCs compared to control APCs (0% FLUM1.APCs) by flow 
cytometry (Fig. 5-4 B). However, MACS isolation antigen recovery and PCR amplification of the 
exact same sample showed only a modest enrichment of FLUM1 band relative to the control 
GAPDH band (Fig. 5-5 B, bottom panel). Based on these results, I speculate that at low antigen 
APC frequencies MACS sorting can lead to non-specific isolation of bystander cells and might 
therefore not be ideal for this assay in complex libraries. We therefore propose either further 
optimization of MACS sorting methodology or employ fluorescent activated cell sorting (FACS) to 
isolate highly pure enriched populations of antigenic IFNϒ+APCs for future experiments. 
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5.4 Materials and Methods 
 
5.4.1. Donor PBMC processing and cell separation 
Peripheral blood was obtained from healthy donors at Arizona State University under IRB 
protocol #MOD00006783. All subject blood samples were obtained under informed consent in 
accordance with ASU’s human subject research policies. For some samples, trima leuko 
reduction chamber residuals from Blood Centers of the Pacific blood collection center, CA, USA. 
PBMCs were extracted from both these source samples using Sepmate PBMC isolation tubes 
(StemCell technologies, MA, USA) according to manufacturer’s instructions. Isolated PBMCs 
were counted and CD8+ T-cells were isolated using human CD8+ T-cell isolation kit (Miltenyi 
Bitoec, Germany) according to manufacturer’s instructions, and purified CTLs were frozen until 
use. CD8- fraction was further subject to CD4 fraction removal using CD4 microbeads (Miltenyi 
Biotec, Germany) and frozen. CD4- CD8- fractions were counted and either frozen or used to 
generate CD40L activated APCs. Purity of each fraction was assessed by flow cytometry prior to 
being frozen. 
 
5.4.2. Autologous APC generation 
Autologous APCs were generated by methods described in Chapter 5 (Appendix B5). Briefly, 
CD40L-activated B-cell APCs were generated from donor CD4- CD8- PBMC fractions by 
incubating them with irradiated (32Gy) K562-cell line expressing human CD40L (KCD40L) at a 
ratio of 4:1 (800,000 CD4- CD8- to 200,000 irradiated KCD40Ls) in each well. The cells were 
maintained in BCM consisting of IMDM (Gibco, USA), 10% heat inactivated human serum 
(Gemini Bio Products, CA, USA), Antibiotic-Antimycotic (Anti-Anti, Gibco, USA). BCM was 
supplemented with 10 ng/mL recombinant human IL-4 (R&D Systems, MN, USA), 2μg/mL 
Cyclosporin A (Sigma-Aldrich, CA, USA), 1X insulin transferrin supplement (ITES, Lonza, MD, 
USA). APCs were re-stimulated with fresh irradiated KCD40Ls on days 5 and 10, after washing 
with 1X PBS and expanding into a whole 24-well plate. After two weeks, APC purity was 
assessed by CD19+ CD86+ expressing cells by flow cytometry, and were generally used for  T-
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cell stimulation after >90% purity. APCs were either restimulated upto 4 weeks or frozen and re-
expanded as necessary. 
 
5.4.3. IFNϒ APC capture assay  
APCs were used on days as indicated for the APC capture assay. For peptide experiments, 
peptide pulsing of APCs were done under BCM 5% human serum, with recombinant IL-4 
overnight. Transfection of APCs were done using the Lonza 4D Nucleofector, primary P3 buffer, 
program EO117 (Lonza, MD, USA) and incubated in BCM-10% human serum, IL-4 without any 
Anti-Anti. Twenty four hours later APCs were washed resuspended in MACS staining buffer, 
counted, and 8uL of  IFN𝛄 catch reagent (IFN-γ Secretion Assay - Cell Enrichment and Detection 
Kit, Miltenyi Biotec, Germany) for 20 minutes on ice. Purified CTLs were thawed either the night 
before or on the day of the assay, and resuspended at desired E:T concentrations as indicated in 
the experiment in BCM-5% human serum. After catch reagent labelling, APCs were washed three 
times with BCM-5% human serum, resuspended in desired E:T ratios as necessary for the 
experiment, and co-cultured with pure CTLs in a 96 well U-bottomed plate (Costar, USA), total 
volume of 200μL. The plate was centrifuged at 400g, 1 minute, without brakes to promote 
conjugate formation, and incubated at 37C for 4-5 hours.  For the optimization experiments, after 
the incubation time, the plate was chilled for 30 minutes on ice to stop IFN𝛄 secretion, and 
supernatant media was carefully removed. For initial washing of the cells, cold MACS buffer was 
added drop by drop to minimize IFN𝛄 diffusion. The plate was centrifuged at 500g, 5 minutes, 
followed by careful removal of supernatant and same wash procedure was repeated. After 
centrifugation, secondary detection IFN𝛄-PE antibody(IFN-γ Secretion Assay - Cell Enrichment 
and Detection Kit, Miltenyi Biotec, Germany) in 2μL/100μL/well MACS buffer was added and 
incubated for 20 minutes on ice. For flow cytometry analysis, additional CD8 antibody anti-CD8-
PC5 (clone B9.11; Beckman Coulter 1:100) was added. After incubation the plates were washed 
twice with MACS buffer, resuspended in 1x sterile PBS and analyzed by Attune flow cytometer 
(ThermoFisher Scientific, MA, USA). For MACS sorting, after IFN𝛄-PE antibody staining, cells 
were pelleted and 10μL anti-PE microbeads were added to the pellet in 90μL MACS buffer for 15 
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minutes. Cells were then washed once, isolated using MACS MS columns (Miltenyi Biotec, 
Germany), and flow through and eluate were subject to Hirt plasmid extraction. 
 
5.4.4. Tetramer staining 
FluM1-tetramer (corresponding to the HLA-A*02:01-restricted epitope GILGFVFTL) was obtained 
from Proimmune, UK. For tetramer staining, cells were re-suspended in 100μL staining buffer 
with 5% human serum and 1mM Dasatanib (ThermoFisher Scientific, MA, USA), and each 
tetramer was added at concentration of 10uL for 30 minutes at room temperature. Cells were 
washed twice and restained with anti-CD8-PC5, anti-CD4-FITC, anti-CD14-FITC and anti-CD19-
FITC for exclusion gates for 30 minutes on ice. Samples were then washed twice in 1x PBS, and 
analyzed by flow cytometry. 
 
5.4.5. Antigen recovery by Hirt plasmid extraction 
MACS sorted PE+/PE- CD8- cells were first pelleted by centrifugation at 500xg for 10 minutes. 
The supernatant was carefully aspirated and the cells re-suspended gently in 250 uL of chilled 
Hirt Buffer #1 (50 mM Tris, 10mM EDTA, 50ug/mL RNase A). Following resuspension 250 uL of 
Lysis Buffer #2 (1.2% SDS in Water) was added to each sample and the tubes were slowly and 
fully inverted 3 times and incubated for 5 minutes at room temperature. Cell lysis was stopped via 
the addition of 350 uL of Hirt Precipitation Buffer #3 (3M CsCl, 1M Potassium Acetate, 0.67M 
Acetic Acid) to each sample. After incubation the samples were quickly loaded into a 
microcentrifuge chilled to 4 degrees C and centrifuged for 30 minutes at 17,300xg. The 
supernatant was loaded onto Qiagen QIAprep Spin Miniprep Columns by spinning the columns at 
17,300xg for 1 minute. The column was washed twice with 700 uL of Hirt Column Wash #4 (60% 
EtOH, 10mM Tris, 50uM EDTA, 80 mM Potassium Acetate) and the flow through was discarded. 
Plasmid DNA was eluted from the column in nuclease-Free Water to the membrane and heating 
the column at 70 degrees C for 1 minute, followed by spinning the warmed column at 17,300 xg 
for 1 minute. The eluted DNA concentration was quantified by Nanodrop. 
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5.4.6. PCR amplification and gel analysis 
For each reaction, 25ng of plasmid DNA added to a mastermix solution containing 10uL 
SapphireAmp PCR Mix, 1 uL of each primer at 10 uM, with water added up to 20 uL for the total 
reaction volume. After a 5 minute initial denaturation and activation of the hot-start polymerase at 
95°C, the samples were cycled 27 times. Each cycle consisted of a 30 second denaturation step 
at 95°C, a 50 second annealing step at 57C, and a 3 minute extension step at 72°C. Finally, after 
27 cycles, the samples were extended once more for 7 minutes at 72°C, followed by cooling to 4 
C for overnight storage. 2 uL of each PCR reaction was loaded onto a 2% agarose gel prestained 
with 1uL GelRed / 2mL 1X TAE and visualized. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE OUTLOOK 
 
CD8+ T-cells form a critical part of a complex network of cell subsets in the human immune 
system causing immune mediated the elimination of many pathologies and malignancies. Despite 
major advances in the understanding of the molecular mechanisms underlying T-cell 
immunobiology, the core driving features of T-cell immunogenicity and tumor-specific 
mechanisms that cause T-cell dysfunction remain largely unknown. This dissertation is an 
attempt to address these questions experimentally using classical and novel immunological 
techniques, and computationally using data mining, statistical and machine learning tools. 
 In Chapter 2, I studied the biochemical hallmarks underlying T-cell immunogenicity in 
context of self/nonself discrimination. We identified an over representation of relatively 
hydrophobic amino acids at specific TCR contact residues of immunogenic CD8+ T-cell epitopes. 
We leveraged these findings to develop a computational immunogenicity model which can 
consistently improve prediction of immunogenic CTL epitopes. We further validated these findings 
by in vivo experiments in a murine HIV-1 infection model (Chowell et al., 2015).  
Interestingly, strong support for our study came from a subsequent 2016 study by 
Stadinski et al. (Stadinski et al., 2016), describing importance of hydrophobic amino acids at 
positions 6 and 7 of TCR CDR3β in the development of self-reactive T cells. One implication of 
Stadinski et al’s findings is that hydrophobic amino acids in the CDR3β region may de facto be 
crucial for T cell activation via recognition of self or foreign antigen as alluded in their study. Since 
negative selection eliminates the majority of self-reactive TCRs, current thinking would anticipate 
that the biochemical composition of TCRs in the periphery would be skewed towards amino acids 
that are not strongly hydrophobic. Nonetheless, for a selected TCR to be able to recognize a 
foreign antigen it must bind to the epitope with very high affinity, which can be effectively 
accomplished if the epitope is also composed of hydrophobic amino acids residues. This 
interpretation is consistent with our findings from Chapter 2 (Chowell et al., 2015), where we 
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reported that the hydrophobic composition of MHC class I epitopes determine their 
immunogenicity. Notably, we found that the relative differential hydrophobicity of TCR-contact 
residues (positions 4 to 7) is a hallmark of immunogenic pathogen-derived and self-reactive 
epitopes, in both human and mouse MHC-allomorphs (Chapter 2). This would explain that, both 
non-self-antigen and self-antigen reactive TCRs with hydrophobic CDR3β residues are perhaps 
not completely eliminated due to lack of antigenic gene expression in the thymus or inefficiencies 
in negative selection, respectively (Yu et al., 2015). 
Together, our study and that of Stadinski et al, shed light on understanding of the 
biochemical basis of self and non-self discrimination by T cells. They further underscore the 
predictive value of incorporating amino acid biochemical properties in identifying immunogenic 
epitopes
 
and their corresponding TCRs. Several important unresolved questions remain with 
respect to the role of hydrophobic amino acid residues in promoting T-cell activation. For 
instance, is TCR-pMHC interfacial hydrophobicity a general rule that applies across different 
MHC class I and II alleles and epitope lengths? Do TCRs tread a threshold value of affinity 
between their CDR3β and self-pMHC hydrophobic contact residues to avoid negative selection? 
Lastly, is the T cell receptor a hydrophobicity-driven pattern recognition receptor (Seong & 
Matzinger, 2004)? If so, the evolutionary basis of TCR recognition of amino acid hydrophobicity 
will be interesting to explore. Future studies will address these fascinating questions.  
In Chapter 3, I developed an experimental and bioinformatic methodology for the 
amplification and detection of low frequency T-cells in a short term ex vivo stimulation protocol 
(Krishna & Anderson, 2016). In Chapter 4, I used this methodology to define several novel CTL 
epitopes from the HPV16 antigens E2, E6 and E7. Although previous studies have attempted to 
define HPV16 CTL-epitopes (Ressing et al., 1995b; Riemer et al., 2010d; Rudolf, Man, Melief, 
Sette, & Kast, 2001b), to my knowledge this is one of the first comprehensive epitope, 
immunodominant domain mapping studies from E2, E6 and E7. Knowledge of these epitopes and 
regions from the antigens can aid the design and development of HPV-specific immunotherapies. 
My results also indicate that, in addition to E6 and E7, HPV16-E2 is an immunogenic antigen with 
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broad T-cell and B-cell reactivity and is expressed in a subset of HPV+ HNSCCs. My findings of 
E2-immunogenicity, supported by other recent studies indicating lower rates of genome disruption 
at the E2-locus (Parfenov et al, PNAS, 2014), warrants further investigation of E2 in immune 
therapeutic modalities in addition to E6 and E7.  
In Chapter 4, I also studied the different modes of HPV-specific CTL dysfunction in HPV+ 
HNSCC. I compared and contrasted dysfunctional phenotypes of HPV16-specific E2, E6 and E7 
CD8+ T-cells after ex vivo stimulation in HPV+ HNSCC patients. Most patients had higher levels 
of E7 or E2-specific T-cell dysfunctional phenotypes, compared to E6-T-cells, indicating a 
predictable but heterogeneous mode of HPV-specific T-cell dysfunction in HPV+ HNSCC. HPV-T-
cell dysfunction in HNSCCs has not been described before, and my findings aids better 
understanding of HPV-immunobiology. I also found by transcriptomic analysis that high HPV-
antigen load is strongly correlated with, and likely drives, T-cell infiltration and subsequent T-cell 
dysfunction observed in these tumors. I further show computationally, and then experimentally, 
that the immune modulatory indoleamine 2,3-dioxygenase (IDO-1) expression correlates with 
HPV-antigen load and is highly expressed in HPV+ cancers. Inhibiting the IDO-1 pathway can 
synergize PD-1 blockade by enhancing cytotoxic potential of E2, E6 and E7-specific CTLs in 
vitro. This result is particularly significant considering ongoing clinical trials that are exploring PD-
1 blockade with IDO-1 inhibition as immune therapies against HNSCCs (Ferris et al, NEJM, 2016, 
Gangadhar et al, JITC, 2015). To my knowledge, this is the first description of a mechanistic 
explanation of HPV-specific CTL dysfunction and immunogenicity in HNSCC patients. Future 
studies that compare the dynamics and interplay of HPV-CTLs from tumor, periphery with tumor 
HPV load will be necessary to verify the HPV T-cell dysfunction findings from this study.  
In the last chapter (Chapter 5), I developed an in vitro immunologic assay that can enable 
the identification of CTL-immunogenic antigens by flow cytometry. The IFNϒ APC capture assay 
was antigen specific, was sensitive to upto 10% of antigen encoded APCs, and was highly 
reproducible in multiple donors. Furthermore, the IFNϒ APC capture assay is inexpensive, is 
performed within one day, and requires minimal sample (CTL:APC ratios of 2:1). I also 
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demonstrated efficient antigen recovery from antigen transfected IFNϒ+ APCs. However, the 
assay needs to be optimized for isolating and antigen recovery of low frequency by magnetic or 
fluorescence based sorting. This is especially important when antigenic APC frequencies are low 
for high throughput antigen identification. To this end, future experiments that assess and 
compare the efficiency of FACS and MACS sorting methods for antigen recovery after the IFNϒ 
APC capture assay. After optimization of antigen recovery, the assay will be employed to identify 
immunogenic antigens from three common human viruses CMV, EBV and Flu.  
Thus, this dissertation makes a step towards understanding fundamental CD8+ T-cell 
immunobiology in context of cancer and viral infections, and develops methodologies for the 
design of effective T-cell immunotherapies. As such, I believe this dissertation will be of interest 
and of relevance to the fields of tumor immunology, virology, vaccinology and immunogenomics. 
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APPENDIX A  
TCR CONTACT RESIDUE HYDROPHOBICITY IS A HALLMARK OF  
 IMMUNOGENIC CD8+ T CELL EPITOPES 
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A.1 Construction of datasets 
All MHC class I peptides used in this study for analyses and the design of ANN-Hydro prediction 
model were retrieved from IEDB (www.iedb.org, last accessed: 08/11/2014). The IEDB is the 
largest curated dataset of MHC-I peptides identified from different primary research studies from 
over 334 different source organisms. We set the “Immune recognition context” as T cell response 
and selected “MHC class I” as the criteria for data retrieval. In total, there were 28,444 T cell 
epitopes reported to be immunogenic by T cell assays, including self and pathogenic epitopes 
and 6,142 peptides were reported to be positive by ligand elution analysis (either mass 
spectrometry or HPLC). To avoid redundancy and overrepresentation bias, we excluded all 
duplicate peptides, so that each peptide is present only once in the dataset. Positive CTL 
epitopes represent the immunogenic epitope group. Ligand eluted MHC-I self-peptides are 
generally eluted from cell surface and therefore they have been antigenically processed and 
MHC-bound. A vast majority of eluted self-peptides are derived from endogenous proteins. To 
completely separate immunogenic and non-immunogenic datasets, any immunogenic eluted self-
peptide associated with autoimmunity or cancer was excluded. The remaining peptides were 
used as the non-immunogenic peptide dataset for our analyses. Additionally, we removed any 
pathogen derived non-self- eluted peptides from the eluted peptide dataset to generate mutually 
exclusive datasets. These unique peptides were annotated for antigen name, peptide starting 
position, peptide ending position, and MHC restriction, which were required for inclusion. 
Peptides with “undetermined class I alleles” were also excluded. These filtering criteria resulted in 
a final dataset of 5,035 8-11mer immunogenic and 4,853 8-11mer non-immunogenic peptides.  
A.2 Position-based hydrophobicity analysis 
We transformed our datasets of immunogenic and non-immunogenic peptides into numeric 
arrays using the R statistical software. Separate numeric arrays were generated for immunogenic 
and non-immunogenic 8, 9 and 10mers. Mean hydrophobicity of immunogenic and non-
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immunogenic peptides at each position was calculated and were compared residue-by-residue 
through Wilcoxon rank-sum tests to quantify statistical significance.  
A.3 Rate analysis of predicted peptides 
An efficient prediction algorithm identifies consistently all possible CTL epitopes from a given 
protein in the fewest number of “hits” consistently. For each test protein, we created a subset with 
unique CTL epitopes retrieved either from the IEDB database. Each predicted peptide starting 
from rank one was queried for an exact match in the dataset of CTL epitopes. When there was an 
exact match, a positive hit was recorded. Graphical representations comparing the rate of 
predictions by the IEDB-consensus binding prediction algorithm and hydrophobicity-based 
predictions were generated (Fig 2-5).  
A.4 Hydrophobicity-based ANN prediction model (ANN-Hydro) 
The R neuralnet package
 
was used to design and train the two ANN-Hydro models on H-2D
b
 and 
HLA-A2 restricted 9mer peptides known to be immunogenic (n=204 and n=374, respectively) or 
non-immunogenic (n=232 and n=201, respectively). Each peptide sequence in the respective H-
2D
b
 and HLA-A2 datasets were transformed into a corresponding numeric sequence based on 
the hydrophobicity value of amino acids. Training peptides were derived from IEDB and 
SYFPEITHI’s epitope database. A three-layer fully connected feed-forward ANN was comprised 
by nine input neurons, one hidden layer with three neurons, and one output variable (Fig 2-6). 
Our ANN-Hydro prediction model is given by the following mathematical framework:  
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Where w0  denotes the intercept of the output neuron and w0i  the intercept of the i
th
 hidden 
neuron. Additionally, wi  denotes the synaptic weight corresponding to the synapse starting at the 
i
th
 hidden neuron and leading to the output neuron. Wi = (w1i,w2i,...,w9i )  is the vector of all 
synaptic weights corresponding to the synapse leading to the i
th
 hidden neuron, and  
  140 
))(),...,(),(( 921 RhRhRhH   the vector of all inputs, which corresponds to the numeric 
hydrophobicity representation of a 9mer peptide, where h(Ri ) is the hydrophobicity value of the 
amino acid . Finally, the output variable )(Hy  denotes the probability of a peptide being 
immunogenic (p-ANN-Hydro). Since the starting values for the weights are drawn from the 
standard normal distribution, the outputs were averaged over 60 realizations.  The activation 
function f (v) was chosen to be the sigmoid function f (v)=1/ (1+e-v ), and the sum of squared 
errors was used for the error function. The learning procedure was the resilient back-propagation 
with learning rate set to 0.01; a threshold set to 0.01 was defined for the partial derivatives of the 
error function.  
A.4 Application of ANN-Hydro 
For each H-2D
b
 and HLA-A2 restricted epitope prediction, we used the MHC-binding prediction 
tool IEDB-consensus to generate a list of epitope predictions on which the immunogenicity model 
could be applied. We normalized prediction binding scores (percentile rank) using the expression  
)/()( minmaxmin   iBiS  where iBS represents the normalized score of a given peptide; 
i , the assigned output score by IEDB-consensus; min , the minimum score assigned in 
prediction output by IEDB; and max , the maximum score assigned in the entire prediction output 
by IEDB.  To remove poor binding peptides from the list, a subset of predicted peptides was 
selected by defining a SB -threshold of 0.2 for antigen length <= 100 aa’s and a SB -threshold of 
0.1 (10
th
 percentile of predicted binders) for antigen length >100 aa’s. Independently, probabilities 
of immunogenicity were obtained by applying the ANN-Hydro model to this subset of binding 
predictions. Normalized scores (SI) were then assigned based on these probabilities of 
immunogenicity. Within the spectrum of predicted binders, we prioritized epitope re-ranking based 
on both SB and SI scores with first priority given to high-immunogenicity high-binders (probability 
of immunogenicity >= 0.4 and SB <=0.05; region I in Fig. S3), followed by modest-immunogenicity 
high-binders (probability of immunogenicity < 0.4 and SB <=0.05; region II in Fig. S3), then high-
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immunogenicity modest-binders (probability of immunogenicity >= 0.4 and SB > 0.05; region III in 
Fig. S3), and modest-immunogenicity modest-binders (probability of immunogenicity < 0.4 and SB 
> 0.05; region IV in Fig. S3).  For the antigens with length <= 100 aa’s, the SB cutoff for the four 
regions was set to 0.1 and probability of immunogenicity threshold remained at 0.4. Predicted 
peptides in each section were re-ranked based on a total score defined as S = SBSI. Final ranked 
list was obtained by sequential appending of the re-ranked peptides from each region. The list of 
predicted peptides was ranked based on this total score ranging from lowest score to the highest 
score. The lower the total score of a predicted peptide, the higher its probability of being an 
immunogenic epitope. Workflow of the prediction strategy is shown in Fig. 2-6. 
A.5 Statistical analysis of predicted CTL epitopes 
We used the F-test to quantify statistical significance (P < 0.05) of the variation of predicted 
rankings of T cell epitopes across different antigens between ANN-Hydro together with IEDB-
consensus and IEDB-consensus alone. 
 
A.6 In vivo discovery of HIV-1 Gag epitopes 
Mice. C57BL/6 mice were obtained from Harlan Laboratories. All mice used were between 6 and 
8 weeks of age. All animal study protocols were conducted in accordance with guidelines 
approved by the Institutional Animal Care and Use Committee at Kings College London and in full 
compliance with UK Home Office regulations under a project license to L.S.K. 
  
Vaccine immunization. Codon optimized HIV-1 gag plasmid DNA ZM96 from strain 96ZM651.8 
(provided by B Hahn, through the Centre for AIDS Reagents [CFAR] UK) and codon optimized 
HIV-1 gag Consensus B plasmid DNA (provided by D Garber, Emory University, USA) were used 
to construct and propagate replication defective (E1, E3 deleted) recombinant Adenovirus type 5 
(rAdHu5) vectors as described previously for the HIV-1 gag strain 97CN54(4). Animals were 
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immunized with 10
9 
virus particles (vp) as determined by the DNA Pico-Green assay (Invitrogen) 
and administered either i.m. in the quadricep muscle (rAdHu5 Consensus B gag) or i.d. at the  
base of the tail (rAdHu5 ZM96 and rAdHu5 CN54). 
 
 Peptides. 15mer peptides with an 11 amino acid overlap spanning the HIV-1 CN54 Gag protein 
and a 20mer set of peptides with 10 amino acid overlap spanning HIV-1 ZM96 were provided by 
CFAR, a set of 15mers with an 11 amino acid overlap spanning the HIV-1 Consensus subtype B 
Gag protein were provided from the NIH AIDS Reagent and Reference Program. ‘Optimal’ 9mer 
or 11mer peptides from HIV-1 CN54 Gag, ZM96 Gag and HIV-1 Consensus B were purchased 
from Proimmune. 
 
 T cell epitope mapping by intracellular interferon gamma staining. Spleens were harvested 
14 days after immunization, homogenized to single-cell suspensions, and RBCs were lysed using 
ACK lysis buffer (Lonza). Splenocytes were then used for in vitro re-stimulation, where 10
6
 cells 
were incubated for 6 h at 37°C with anti-CD28 (2mg/ml; BD Pharmingen), either alone 
(unstimulated control) or with peptides, either in pools or individually (each at 1mg peptide/ml), 
derived from Consensus B Gag. Brefeldin A (10mg/ml, Sigma-Aldrich) was added for the last 5 h 
of culture. After washing, cells were stained with anti-CD8 (clone 37.51, BD Biosciences) for 20 
min, then fixed and permeabilized with the BD Cytofiix/Cytoperm Kit according to the 
manufacturers’ instructions, and then stained 30 min with anti-IFN-g (clone XMG1.2, 
eBiosciences), washed and analyzed by flow cytometry. Consensus B epitopes were 
deconvoluted to individual 15mers from peptide pools, where each peptide is present in two 
independent pools within the matrix and reactive peptides confirmed in the second round against 
the 15mer peptide. Finally, based on the sequence of the reactive 15mer peptide, truncated 
versions of the 15mer peptides were synthesized and tested. 
 
T cell epitope mapping by ELISPOT assay. 14 days after immunization, splenocytes prepared 
(as detailed above) were re-stimulated in vitro with media alone, or with peptides, either in pools 
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or individually (each at 1mM final concentration) derived from CN54 or ZM96 Gag on mouse anti-
INF-g antibody coated 96 well plates (U-Cytech) and incubated for 16 h at 37°C, 5% CO2. IFN-g 
production was revealed according to the manufacturer’s instructions and IFN-g spot forming 
cells (SFCs) enumerated using an immunospot image analyser (Bioreader 5000). In the first 
round, CN54 Gag epitopes were deconvoluted to individual 15mers from peptide pools, where 
each peptide is present in two independent pools within the matrix and reactive peptides 
confirmed in the second round against the 15mer peptide. Finally, based on the sequence of the 
reactive 15mer peptide, 9mer peptides were synthesized and tested. For ZM96 (due to the 
absence of a complete set of overlapping 15mer peptides), 49 individual 20mer peptides were 
tested. The reactive peptide sequences were confirmed against the corresponding 15mer peptide 
(data not shown) to the reactive sequence and then 9mer peptides synthesized and tested. 
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Table A-1. Amino acid property scales used for analyses. Hydrophobicity scale (Kyte-
Doolittle) (5), Polarity (Grantham) (6), and Bulkiness (Zimmerman). 
 
Amino acid Hydrophobicity Bulkiness Polarity 
Alanine (A) 1.8 11.5 8 
Cysteine (C) 2.5 13.46 5.5 
Aspartic acid (D) -3.5 11.68 13 
Glutamic acid (E) -3.5 13.57 12.3 
Phenylalanine (F) 2.8 19.8 5.2 
Glycine (G) -0.4 3.4 9 
Histidine (H) -3.2 13.69 10.4 
Isoleucine (I) 4.5 21.4 5.2 
Lysine (K) -3.9 15.71 11.3 
Leucine (L) 3.8 21.4 4.9 
Methionine (M) 1.9 16.25 5.7 
Asparagine (N) -3.5 12.82 11.6 
Proline (P) -1.6 17.43 8 
Glutamine (Q) -3.5 14.45 10.5 
Arginine(R) -4.5 14.28 10.5 
Serine (S) -0.8 9.47 9.2 
Threonine (T) -0.7 15.77 8.6 
Valine (V) 4.2 21.57 5.9 
Tryptophan (W) -0.9 21.67 5.4 
Tyrosine (Y) -1.3 18.03 6.2 
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Table A-2. Hydrophobicity comparison between immunogenic and non-immunogenic MHC 
class I peptides. P-values were calculated using Wilcoxon sum-ranked test using different 
datasets as described in main text. 
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Table A-3. HLA-A2 restricted CTL epitopes for dengue virus 1 polyprotein and 
cytomegalovirus pp65 used in the rate analysis of predicted epitopes as shown in (Fig.2-
5).  All epitopes were retrieved from IEDB Vita et al, 2010. 
 
 
Antigen Epitope 
Epitope 
length 
 CMV-
pp65 
 
NLVPMVATV 9 
MLNIPSINV 9 
VLGPISGHV 9 
RLLQTGIHV 9 
LMNGQQIFL 9 
ILARNLVPM 9 
SLILVSQYT 9 
SIYVYALPL 9 
VIGDQYVKV 9 
YLESFCEDV 9 
AMAGASTSA 9 
KYQEFFWDA 9 
GLSISGNLL 9 
RQYDPVAAL 9 
VAALFFFDI 9 
ALFFFDIDL 9 
KISHIMLDVA 10 
SDNEIHNPAV 10 
FTWPPWQAGI 10 
LLCPKSIPGL 10 
 
    
       
 
 
 
 
 
Antigen Epitope 
Epitope 
length 
Dengue-
Polyprotein 
VLMLVAHYA 9 
ILLMRTTWA 9 
MLLALIAVL 9 
TLYAVATTI 9 
QEGAMHTAL 9 
LPAIVREAI 9 
SRNSTHEMY 9 
AIVREAIKR 9 
YLPAIVREA 9 
TLLCLIPTV 9 
VLNPYMPSV 9 
LMMMLPATL 9 
VTYECPLLV 9 
MMMLPATLA 9 
IILEFFLMV 9 
KTDFGFYQV 9 
VQADMGCVV 9 
GLLFMILTV 9 
QLWAALLSL 9 
LLMRTTWAL 9 
CLMMMLPATL 10 
ELMRRGDLPV 10 
MLLILCVTQV 10 
FLMVLLIPEP 10 
TLMLLALIAV 10 
LMLLALIAVL 10 
IILEFFLMVL 10 
TLTAAVLLLV 10 
VLLLVTHYAI 10 
ITLLCLIPTV 10 
KVLNPYMPSV 10 
HQLWATLLSL 10 
YTPEGIIPTL 10 
SIILEFFLMV 10 
LSMGLITIAV 10 
NQLIYVILTI 10 
LMMMLPATLA 10 
TLMAMDLGEL 10 
FTMGVLCLAI 10 
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Table A-4: Probabilities assigned by the ANN-Hydro A2-model for HLA-A2 restricted 9mer 
CTL epitopes. Three recent epitope discovery studies Assarsson et al. (2008); Weiskopf et al. 
(2011); Newell et al. (2013) that were based on a proteome-wide screen of various viral antigens 
and self-epitopes were chosen for assessment of the predictive capacity of the ‘A2-model’. 
Neoepitopes were obtained from rotavirus Newell et al. (2013) dengue virus Weiskopf et al. 
(2011) and influenza A Assarsson et al. (2008) and other positive control epitopes from several 
antigens (pathogenic and self) were obtained from Newell et al. Newell et al. (2013). Any epitope 
that was present in the training set for ANN-Hydro was removed. A cutoff probability (p-ANN-
Hydro) of 0.4 was set for a positive “hit”. 
 
 
Source Epitope Antigen p-ANN-Hydro Reference 
Neo-epitopes 
Rotavirus 
SLISGMWLL Rota-VP2_4 0.89 
Newell et al. 
TLLANVTAV Rota-VP6_4 0.87 
FLDSEPHLL 
Rota-
NSP1_2 
0.84 
LLNYILKSV Rota-VP7_1 0.37 
Influenza-A 
(FluA) 
QIAILVTTV NA 0.90 
Assarsson et al. 
GLIYNRMGA M1 0.89 
GILGFVFTL Flu_1 0.80 
FVEALARSI PB1 0.58 
VMNILLQYL GAD 0.57 
FVANFSMEL PB1 0.54 
TTYQRTRAL NP 0.47 
GLADQLIHL HIV_7 0.47 
Dengue-Virus 2 
(DENV-2) 
GLLTVCYVL NS2B 0.88 
Weiskopf et al. 
RLITVNPIV E 0.88 
IMAVGMVSI NS2B 0.85 
IILEFFLIV NS4A 0.79 
ALSELPETL NS4A 0.61 
YLPAIVREA NS3 0.50 
KLAEAIFKL NS5 0.44 
AAAWYLWEV NS3 0.27 
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Table A-4 continued. 
 
Source Epitope Antigen 
p-ANN-
Hydro 
Reference 
Positive Control epitopes 
Human 
herpesvirus 5 
(CMV) 
ALFFFDIDL CMV_5 0.84 
Newell et 
al. 
LMNGQQIFL CMV_18 0.81 
RIFAELEGV CMV_22 0.81 
QMWQARLTV CMV_21 0.78 
NLVPMVATV CMV_1 0.75 
VLEETSVML CMV-IE1 0.72 
FLMEHTMPV CMV_8 0.61 
IIYTRNHEV CMV_13 0.54 
SLLSEFCRV CMV_23 0.52 
ILSPLTKGI CMV_15 0.46 
VLAELVKQI CMV_2 0.24 
Human 
herpesvirus 4 
(EBV) 
GLCTLVAML EBV_2 0.87 
Newell et 
al. 
YVLDHLIVV EBV_1 0.84 
YLQQNWWTL EBV_5 0.79 
CLGGLLTMV EBV_4 0.79 
YLLEMLWRL EBV_3 0.28 
Influenza-A (FluA) 
FLDIWTYNA Flu_4 0.85 
NMLSTVLGV Flu_14 0.78 
LLIDGTASL Flu_12 0.68 
FMYSDFHFI Flu_5 0.63 
MMMGMFNML Flu_13 0.48 
GMFNMLSTV Flu_7 0.29 
   
Human 
Immunodeficiency 
virus (HIV-1) 
NVWATHACV HIV_1 0.94 
Newell et 
al. 
 
TLNAWVKVV HIV_2 0.86 
KLTPLCVTL HIV_4 0.84 
SLYNTVATL HIV_5 0.61 
ALVEMGHHA HIV_8 0.44 
ILKEPVHGV HIV_9 0.38 
LTFGWCFKL HIV_6 0.36 
Mycobacterium 
tuberculosis 
GLPVEYLQV TB_1 0.85 
KLIANNTRV TB 0.79 
Plasmodium 
falciparum 
YLNKIQNSL CSP 0.79 
LCMV YLVSIFLHL LCMV 0.77 
Herpes simplex 
virus (HSV-1) 
SLPITVYYA HSV1/2 0.90 
RSV KMLKEMGEV RSV 0.29 
Self Antigens 
ALWMRLLPL pp-Insulin 0.83 
YMCSFLFNL EZH2 0.51 
YMDGTMSQV Tyrosinase 0.49 
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Table A-5. Schematic of ConsB (top) and CN54 (bottom) 15mer peptide pools. Peptides 
were combined at 1mM/each peptide such that each peptide occurs in only two pools numbered 
7872 –7994 for ConsB (top) or 7080.01-7080.121 for CN54 (indicated by 1–121, bottom).  Yellow 
highlight indicates positive response to peptide pool. Green highlight indicates positive response 
to individual 15mer peptide, and red indicates negative response to individual 15mer peptide. 
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Table A-6: Ranking comparison of all the predicted epitopes (Prevalidation and in vivo 
validation) used in this study. The predictions used are as follows: ANN-Hydro - ANN-
hydrophobicity prediction model combined with normalized binding scores from prediction 
algorithms, IEDB-Bind -IEDB consensus binding tool, NetMHC-Bind - NetMHCpan binding tool, 
SYFPEITHI - SYFPEITHI epitope prediction tool, IEDB-Prot-IEDB recommended processing 
prediction, ANN-Prot - IEDB processing predictions using ANN. p-ANN-Hydro – Probability of 
immunogenicity assigned by the corresponding ANN-Hydro immunogenicity model.  
 
Antigen Epitope 
IEDB.
bind 
Syfpei
thi 
NetMHC.
bind 
IEDB.
prot 
ANN
.prot 
IEDB*Si 
p-ANN-
Hydro 
LCMV_glyco FALISFLLL 1 10 1 3 1 1 0.62 
LCMV_glyco WLVTNGSYL 3 1 2 5 4 11 0.4 
LCMV_glyco LIDYNKAAL 45 12 39 68 77 32 0.8 
LCMV_glyco KAVYNFATC 8 9 10 39 53 5 0.77 
LCMV_glyco DEVINIVII 24 4 74 133 115 10 0.66 
LCMV_NP FQPQNGQFI 1 1 1 2 1 1 0.69 
LCMV_NP SEVSNVQRI 7 2 7 37 50 12 0.14 
Ad.v.T.antige
n 
VNIRNCCYI 1 1 1 1 1 13 0.31 
Ad.v.T.antige
n 
CSDGNCHLL 21 4 9 11 44 20 0.8 
Flu_NP ASNENMETM 1 1 1 1 2 1 0.87 
Flu_NP RLIQNSLTI 3 3 2 3 3 2 0.67 
Flu_NP GERQNATEI 18 2 36 100 103 8 0.42 
Flu_NP YRRVNGKWM 19 4 35 80 65 9 0.44 
FluA-
Neuraminidas
e 
FCGVNSDTV 3 2 4 11 3 13 0.35 
FluA-
Neuraminidas
e 
ITYKNSTWV 4 8 3 4 2 1 0.52 
FluA-
Neuraminidas
e 
YRYGNGVWI 5 7 11 29 7 4 0.45 
Consensus 
Gag 
SQVTNSATI 1 1 1 1 1 7 0.2 
Consensus 
Gag 
AMQMLKETI 4 9 6 4 2 9 0.19 
Consensus 
Gag 
YSPTSILDI 6 19 4 11 3 11 0.39 
Consensus 
Gag 
RSLYNTVAT 3 32 5 45 29 1 0.82 
ZM96 Gag AMQMLKDTI 1 4 4 3 2 13 0.17 
ZM96 Gag YSPVSILDI 5 12 3 9 1 3 0.43 
ZM96 Gag RSLYNTVAT 4 28 5 46 27 2 0.77 
97CN54 Gag AMQILKDTI 1 4 4 3 2 13 0.16 
97CN54 Gag YSPTSILDI 5 19 2 9 3 15 0.36 
97CN54 Gag RSLFNTVAT 2 35 3 40 23 2 0.76 
Melan-A ALMDKSLHV 1 3 1 1 1 1 0.65 
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Melan-A GILTVILGV 2 1 2 2 2 2 0.86 
Melan-A ILTVILGVL 7 5 5 4 5 8 0.9 
Melan-A AAGIGILTV 9 4 7 19 17 9 0.86 
Wt-1 SLGEQQYSV 1 3 3 3 3 1 0.79 
Wt-1 RMFPNAPYL 2 10 2 2 2 2 0.53 
Wt-1 ALLPAVPSL 3 1 1 1 1 3 0.44 
Wt-1 DLNALLPAV 6 2 8 16 27 4 0.9 
Wt-1 VLDFAPPGA 7 31 7 15 13 8 0.87 
Wt-1 KLGAAEASA 9 16 9 21 26 5 0.94 
Wt-1 NLGATLKGV 12 4 10 12 14 12 0.76 
Wt-1 CMTWNQMNL 13 27 11 7 9 13 0.69 
Wt-1 RVPGVAPTL 25 17 21 11 11 19 0.81 
gp100 RLMKQDFSV 1 21 1 2 2 1 0.83 
gp100 MLGTHTMEV 2 15 2 3 1 2 0.65 
gp100 KTWGQYWQV 5 62 3 4 3 5 0.5 
gp100 YLEPGPVTA 16 20 19 34 25 11 0.93 
TRAG-3 GLIQLVEGV 1 1 1 1 1 1 0.43 
TRAG-3 HACWPAFTV 9 10 6 9 20 9 0.82 
TRAG-3 SILLRDAGL 6 2 8 5 7 5 0.92 
TRAG-3 ILLRDAGLV 3 3 2 4 4 3 0.7 
TRAG-3 ALSKFPRQL 4 5 4 3 2 4 0.34 
p53 RMPEAAPPV 1 1 8 2 2 1 0.51 
p53 LLGRNSFEV 2 2 4 1 4 2 0.46 
p53 VVPCEPPEV 13 14 21 14 11 9 0.77 
p53 YQGSYGFRL 5 5 65 3 3 10 0.41 
p53 KTCPVQLWV 14 15 19 34 25 11 0.77 
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Table A-7: Ranked list of top 20 predicted peptides for each of the Gag variant using the 
ANN-Hydro combined with normalized binding scores from predictions. SB) - Binding 
score, p-ANN-Hydro - probability of immunogenicity obtained by applying ANN-Hydro model to 
each peptide, (S) - Total score. This list was ranked based on total score S ranging from lowest 
score to the highest score within each section (I through IV) classified based on p-ANN-Hydro 
and SB (see section Application of ANN-Hydro). 
 
Rank Epitope
Binding  
(S B )
p-ANN- 
Hydro
Total 
score (S)
1 RSLYNTVAT 0.006 0.82 0.001
2 ATPQDLNTM 0.033 0.77 0.008
3 QVSQNYPIV 0.049 0.83 0.008
4 RFAVNPGLL 0.025 0.66 0.008
5 RMYSPTSIL 0.039 0.72 0.011
6 KARVLAEAM 0.021 0.4 0.013
7 SQVTNSATI 0 0.2 0
8 SQVSQNYPI 0.004 0.12 0.004
9 AMQMLKETI 0.008 0.19 0.006
10 GWMTNNPPI 0.008 0.14 0.007
11 YSPTSILDI 0.02 0.39 0.012
12 RSLFGNDPS 0.023 0.27 0.017
13 ASVLSGGEL 0.022 0.07 0.02
14 KALGPAATL 0.036 0.36 0.023
15 AAMQMLKET 0.039 0.33 0.026
16 VQNANPDCK 0.053 0.84 0.009
17 SALSEGATP 0.054 0.84 0.009
18 LLVQNANPD 0.051 0.76 0.012
19 ASLRSLFGN 0.096 0.79 0.02
20 SLYNTVATL 0.061 0.64 0.022
ConsB Gag predictions
                 
Binding  
(S B )
p-ANN- 
Hydro
Total 
score 
0 0.64 0
0.001 0.78 0
0.004 0.43 0.002
0.016 0.77 0.004
0.032 0.83 0.005
0.028 0.75 0.007
0.04 0.8 0.008
0.048 0.83 0.008
0.046 0.81 0.009
0.027 0.67 0.009
0.016 0.42 0.009
0.042 0.61 0.017
0 0.18 0
0 0.08 0
0.026 0.36 0.017
0.026 0.18 0.021
0.039 0.34 0.026
0.033 0.18 0.027
0.033 0.1 0.03
0.092 0.92 0.007
19 AWMTSNPPI
20 WMTSNPPIP
17 IMKQLQPAL
18 VKNWMTDTL
15 KALGPGATL
16 KIVRMYSPV
13 AMQMLKDTI
14 KSLFGSDPL
11 KARVLAEAM
12 NFLQNRPEP
9 LLVQNANPD
10 RFALNPGLL
7 RMYSPVSIL
8 VQNANPDCK
5 KVSQNYPIV
6 ATPQDLNTM
3 YSPVSILDI
4 YMIKHLVWA
1 MSQTNSVNI
2 RSLYNTVAT
ZM96 Gag predictions
Rank Epitope
 
 
 
Rank
Total 
score 
1 0.0003
2 0.0004
3 0.005
4 0.005
5 0.006
6 0.008
7 0.008
8 0.008
9 0.01
10 0.01
11 0.015
12 0.018
13 0
14 0.008
15 0.01
16 0.015
17 0.018
18 0.025
19 0.027
20 0.006
VKNWMTDTL 0.033 0.2
WMTSNPPVP 0.077 0.92
KSLFGNDPS 0.025 0.28
IMKQLQSAL 0.037 0.33
YSPTSILDI 0.015 0.36
RALGPGASI 0.02 0.24
AMQILKDTI 0 0.16
KAKVLAEAM 0.012 0.35
NFLQNRPEP 0.042 0.65
SALQTGTEE 0.042 0.57
LLVQNANPD 0.046 0.78
RMYSPTSIL 0.034 0.7
RFALNPGLL 0.027 0.7
VQNANPDCK 0.048 0.82
ATPQDLNTM 0.028 0.78
SALSEGATP 0.049 0.84
YMLKHLVWA 0.018 0.72
KVSQNYPIV 0.032 0.83
MSQTNSAIL 0.002 0.85
RSLFNTVAT 0.002 0.76
CN54 Gag predictions
Epitope
Binding  
(SB)
p-ANN- 
Hydro
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APPENDIX B  
IMMUNOGENIC AND DYSFUNCTIONAL CD8+ T-CELLS IN HPV+HEAD AND NECK CANCER 
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B.1 HPV16 candidate CTL-epitope prediction 
HPV16-candidate CTL epitopes were predicted using previously described prediction strategies 
developed by us (Chowell et al., 2015a; Krishna & Anderson, 2016a), except for the incorporation 
of immunogenicity scores. Briefly,  we predicted HLA-class I restricted 9-mer and 10-mer 
candidate epitopes derived from the HPV16 proteins E2, E6, and E7 were predicted for the HLAs 
A*01:01, A*02:01, A*03:01, A*11:01, A*24:02, B*07:02, B*08:01, B*15:01, B*27:05, B*35:01, 
B*40:01, B*40:02, B*44:02 B*51:01, and B*57:01. The protein reference sequences for each of 
HPV16 proteins were obtained from Papillomavirus Episteme (PAVE) and were then entered into 
5 different prediction algorithms; 3 MHC-binding : IEDB-consensus binding (Moutaftsi et al., 
2006a), NetMHCpan binding (Hoof et al., 2009), Syfpeithi (Rammensee et al., 1999a) and 2 
antigen-processing algorithms: IEDB-consensus processing, ANN processing (Rammensee et 
al., 1999b). The individual scores from each of the prediction algorithms were then normalized 
within the pool of predicted peptides after removal of poor-binders as described in (Chowell et al., 
2015b; Krishna & Anderson, 2016b), and the mean normalized binding scores were used to re-
rank the candidate peptides. Top 4-5 candidate peptides satisfying binding percentile scores 
>80% were chosen per antigen per HLA-allele for experimental testing. Predicted candidate 
HPV16-peptides, individual normalized and total binding percentile scores are listed in Table B1.  
B.2 Ex vivo stimulation and epitope mapping of HPV+HNSCC PBMCs 
PBMCs were obtained from stage III or stage IV HPV+HNSCC patients (MSSM cohort) as 
described previously (Parikh et al., 2014a). All human PBMCs were obtained using informed 
consent under clinical protocol HSM 10-00585. Patient characteristics are listed in (Parikh et al., 
2014b). PBMCs were stimulated as previously described (Krishna & Anderson, 2016a). Briefly, 
HPV16-peptide pools shown in Fig.4-1 (and listed in Table B1) were designed to have equal 
representation of peptides predicted for each HLA-allele to prevent intra-pool peptide competition 
for binding to the same HLA (Table B1). All peptides (> 80% purity) were synthesized by 
Proimmune, UK. The HPV-peptide pools were created by mixing 7-8 HPV16 candidate peptides 
by antigen, each at a concentration of 1 mg/mL per peptide in sterile 1X PBS. For individual 
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peptides, each peptide was reconstituted at 1mg/mL in sterile 1X PBS. Frozen PBMCs were 
thawed rapidly and stimulated with 10μg/mL pre-mixed HIV-negative control peptide pool, 
HPV16-peptide pools or pre-mixed CEF-positive control pool (all from ProImmune, UK) in 
biological triplicates in a sterile 96-well U-bottomed plate(Costar, Washington DC, USA). 
Recombinant human IL-2 (20U/mL), human IL-7 (5ng/mL) and 1μg/mL of checkpoint blockade 
antibodies anti-PD1 (clone J105, eBosciences, USA) , anti-CTLA4 (clone 14D3, eBosciences, 
USA) were added and cells were rested for two hours at 37C prior to peptide stimulation. On day 
5, half the media was removed and replaced with fresh IL-2 and peptide pool. On day 8, half the 
media was removed and fresh media, IL-2 and peptide was added to the cells and replated into a 
96-well multiscreen elispot plate for Elispot detection. Same procedure was repeated for 
individual epitope mapping and deconvolution using selected candidate epitopes as per the 
patient’s HLA-restriction (Fig. 4-3). 
B.3 Elispot detection of IFNϒ secretion 
Elispot detection assay was performed as previously described (Krishna & Anderson, 2016c). 
Briefly, sterile multiscreen Elispot plates, (Merck Millipore, Billerica, MA, USA) precoated 
overnight with 5μg/well anti-IFNg capture antibody (clone D1K, Mabtech, USA) in sterile 1X PBS. 
Eight days after stimulation, HPV+HNSCC PBMCs were subject to media change and IL-2, 
peptide (pools or individual) were added. Cells in each well were transferred to the Elispot plate 
and incubated at 37C 5% CO2 incubator for 48 hours. Plates were washed with elispot buffer 
(PBS + 0.5% FBS) and incubated with 1μg/mL anti-IFNg secondary detection antibody (clone 7-
B6-1, Mabtech, USA) for 2 hours at room temperature, washed and reincubated with 1μg/mL 
Streptavidin ALP conjugate for 1 hour at room temperature. The wells were washed again with 
elispot buffer and spots were developed by incubating for 8-10 minutes with detection buffer 
(33μL NBT, 16.5μL BCIP, in 100mM Tris-HCl pH 9, 1mM MgCl2, 150mM NaCl). Plates were dried 
for 2 days and spots were read using the AID Elispot reader (Autoimmun Diagnostika GmbH, 
Germany). Average number of spot forming units for the triplicates were calculated for each test 
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peptide/pool and subtracted from background (either HIV-control peptide pool or PBS-DMSO 
controls).  
B.4 RAPID-ELISA for E2, E6 and E7 seroreactivity in HPV+HNSCC patients 
RAPID-ELISA was performed as described previously (Anderson et al., 2015). Briefly, patient  
sera were diluted 1:100 and blocked with E. coli lysate. Each antigen was expressed from 
template cDNA and captured onto 96-well plates coated with anti-GST Ab (GE Healthcare, 
Piscataway, NJ) in duplicates. Horseradish peroxidase (HRP) anti-human IgG Abs (Jackson 
ImmunoResearch Laboratories, West Grove, PA) were added at 1:10,000, and detected using 
Supersignal ELISA Femto Chemiluminescent substrate (Thermo Scientific). Luminescence was 
detected as relative light units (RLU) on a Glomax 96 Microplate Luminometer (Promega, 
Madison, WI) at 425 nm. To control for nonspecific and GST-specific antibodies, the ratio of RLU 
for individual HPV-specific Abs to the RLU for the control GST-antigen was measured.  
B.5 Autologous APC generation from HPV+HNSCC patient PBMCs 
Autologous CD40L-activated B-cell APCs were generated from specific HPV+HNSCC patients by 
incubating whole PBMCs with irradiated (32 Gy) K562-cell line expressing human CD40L 
(KCD40L) at a ratio of 4:1 (800,000 PBMCs to 200,000 irradiated KCD40Ls) in each well. The 
cells were maintained in B-cell media (BCM) consisting of IMDM (Gibco, USA), 10% heat 
inactivated human serum (Gemini Bio Products, CA, USA), Antibiotic-Antimycotic (Anti-Anti, 
Gibco, USA). BCM was supplemented with 10 ng/mL recombinant human IL-4 (R&D Systems, 
MN, USA), 2μg/mL Cyclosporin A (Sigma-Aldrich, CA, USA), 1X insulin transferrin supplement 
(ITES, Lonza, MD, USA). APCs were re-stimulated with fresh irradiated KCD40Ls on days 5 and 
10, after washing with 1X PBS and expanding into a whole 24-well plate. After two weeks, APC 
purity was assessed by CD19+ CD86+ expressing cells by flow cytometry, and were generally 
used for  T-cell stimulation after >90% purity. APCs were either restimulated upto 4 weeks or 
frozen and re-expanded as necessary.  
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B.6 HPV-CTL stimulation by autologous APCs 
Antigen-specific T-cells were generated by stimulating HPV+HNSCC patient B-cell APCs by 
either peptide pulsing of specific HPV16-epitopes, or by transfecting whole antigen encoded in 
mammalian expression plasmid pCDNA3.2 (Invitrogen, CA, USA). Peptide pulsing of APCs were 
done under BCM 5% human serum, with recombinant IL-4. Transfection of APCs were done 
using the Lonza 4D Nucleofector, primary P3 buffer, program EO117 (Lonza, MD, USA) and 
incubated in BCM-10% human serum, IL-4 without any Anti-Anti. Twenty four hours later, on day 
1, APCs were washed and incubated with thawed whole HPV+HNSCC PBMCs at a ratio of 1:2 
(200,000 APCs : 400,000 PBMCs) in a 24-well plate in BCM supplemented with 20U/mL 
recombinant human IL-2 (R&D Systems, MN, USA), 5ng/mL IL-7 (R&D Systems, MN, USA). On 
day 5, partial media exchange was performed by replacing half the well with fresh B-cell media 
and IL-2. On day 10, fresh APCs were either peptide pulsed or transfected as described above in 
a new 24-well plate. On day 11, expanded T-cells were restimulated with peptide-pulsed, 
transfected APCs similar to day 1. T-cells were used for cytolytic assays or immunophenotyped 
after day 20.  
 
B.7 HPV-CTL cytotoxicity assays 
HLA-A*02:01 expressing HPV+HNSCC cell line SCC-104 was used for cytotoxicity assays. SCC-
104 cells were plated at a density of 50,000 cells per well in a flat bottom 96-well sterile treated 
plate (Corning, USA). Twenty four hours later, cells were pre-labelled with 0.5μM CellTracker 
Green CMFDA (ThermoFisher Scientific, MA, USA) for one hour, washed thrice with sterile 1X 
PBS. HPV-specific CTLs generated by either peptide pulsing or transfected antigens were pooled 
by HPV-antigen, washed and resuspended in BCM supplemented with 20U/mL IL-2 along with 
1μg/mL isotype IgG antibody, anti-PD1 antibody (eBosciences, USA), DMSO, and 1μM IDO-1 
inhibitor Epacadostat (Selleck Chemicals, MA, USA) in various combinations as described. HPV-
CTLs were added at ratio of 5:1 to SCC-104 cells and incubated for 48 hours at 37C, 5% CO2. 
The cocultured cells were harvested by trypsinization, neutralized with media supernatant from 
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each well containing dead cells and centrifuged for 850g, 10 minutes. Cell pellets were washed 
twice with sterile 1X PBS, resuspended with 1mL 1X PBS, and 2uL Propidium Iodide 
(ThermoFisher Scientific, MA, USA) and cell death was assessed by flow cytometry. All samples 
were acquired with Attune flow cytometer (ThermoFisher Scientific, MA, USA) in blue-violet 
configuration and analyzed using Attune-software.  
B.8 Flow cytometry staining for T-cell and tumor immunophenotyping 
Cells were washed once in MACs buffer (containing 1X PBS, 1% BSA, 0.5mM EDTA), 
centrifuged at 550g, 5 minutes, and re-suspended in 200μL MACS buffer. Cells were stained in 
100μL of staining buffer containing anti-CD137, conjugated with phycoerythrin (PE, clone 4B4-1; 
BD Biosciences, USA), anti-CD8-PC5 (clone B9.11; Beckman Coulter 1:100), anti-CD4 (clone 
SK3; BioLegend, 1:200), anti-CD14 (clone 63D3; BioLegend, 1:200) and anti-CD19 (clone HIB19; 
BioLegend,1:200), all conjugated to Fluorescein isothiocyanate (FITC) for exclusion gates, and 
either a combination of anti-PD1-Brilliant Violet 605 (BV605, clone EH12.2H7; BioLegend, 1:50) 
and anti-CD39-BV-405 (clone A1; BioLegend, 1:200) or anti-PD1-BV-605 and anti-TIM3-BV-405 
(clone F38-2E2; BioLegend, 1:50) for 30 minutes on ice. PD-L1 staining on HPV+HNSCC and 
cervical cancer cell lines were done using 5μL PD-L1 antibody (clone MIH1, ThermoFisher 
Scientific, MA, USA) in 100μL MACS buffer. Samples were covered and incubated for 30 min on 
ice then washed twice in 1x PBS, and resuspended in 1mL 1x PBS prior to analysis.  
B.9 Tetramer staining for T-cell immunophenotyping 
The following HLA-A*02:01 HPV16 tetramers were obtained from NIH Tetramer Core Facility at 
Emory University: TLQDVSLEV E2(93-101), YICEEASVTV E2(138-147), ALQAIELQL E2(69-77), 
KLPQLCTEL E6(18-26), TIHDIILECV E6(29-38), FAFRDLCIV E6(52-60), YMLDLQPET E7(11-
19), and YMLDLQPETT E7(11-20). Cells were washed (550g, 5 min) twice in MACS buffer with 
5% human serum. After washing, cells were re-suspended in 100μL staining buffer (MACS buffer, 
with 5% human serum and 1mM Dasatanib (ThermoFisher Scientific, MA, USA). Each of the 
eight HLA-A*02:01 HPV16 tetramers (NIH Tetramer Core, Emory University, Atlanta, USA), all 
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conjugated with phycoerythrin (PE) was added to each respective sample at concentration of 
1:100. Samples were incubated at room temperature for 30 minutes under dark. After incubation, 
cells were washed 2x in MACS buffer. Cells were stained in 100μL MACS buffer with anti-CD8-
PC5, anti-CD4-FITC, anti-CD14-FITC and anti-CD19-FITC for exclusion gates, and either a 
combination of anti-PD1-BV605 and anti-CD39-BV-405 or anti-PD1-BV-605 and anti-TIM3-BV-
405 for 30 minutes on ice. Samples were then washed twice in 1x PBS, and analyzed by flow 
cytometry. For flow cytometric analysis, all samples were acquired with Attune flow cytometer 
(ThermoFisher Scientific, MA, USA) and analyzed using Attune-software. Gates for expression of 
different markers and tetramers were determined based on flow minus one (FMO) samples for 
each color after doublet discrimination. Only samples with >50 CD8+Tetramer+ or CD8+CD137+ 
events were considered. Percentages from each of the gated population were used for the 
analysis. 
B.10 Cell lines and immunoblotting experiments 
Cervical cancer cell lines SiHa and Caski were obtained from ATCC (Manassas, VA, USA). 
HPV+HNSCC cell lines were obtained from the following sources: UPCI:SCC90 (SCC90) was 
obtained from ATCC (Manassas, USA), UM-SCC-47 (SCC47) and UM-SCC-104 (SCC104) from 
Merck Millipore (Billerica, MA, USA). 93-VU-147T (147T) cell line was a kind gift from Dr. 
Josephine Dorsman,VU Medical Center, Netherlands. All cell lines contained integrated HPV-16 
DNA, and were maintained in the following media: Caski was maintained in RPMI-1640 (ATCC) 
with 10% heat inactivated fetal bovine serum (FBS), SiHa in Eagle's Minimum Essential Medium 
(EMEM, ATCC, USA) with 10% FBS, SCC90 and, SCC47 in Dulbecco's Modified Eagle's 
Medium (DMEM, ATCC,USA) with 10% FBS, SCC104  cells were maintained in Iscove's 
Modified Dulbecco's Medium (IMDM, Gibco, NY, USA) with 10% human serum. Cells were 
harvested by trypsinization (0.25% Trypsin, GE Healthcare, IL, USA), and resuspended in 1mL 
RIPA buffer (Invitrogen, CA, USA) containing a cocktail of protease inhibitors (Roche Diagnostics, 
IN, USA). Equal amounts of cell lysates were loaded on a 4-20 % SDS–polyacrylamide gel 
(Invitrogen, CA, USA) and transferred to a Polyvinylidene fluoride membrane (GE Healthcare, IL, 
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USA). The membrane was blocked with 5% nonfat dry milk in PBS-1% Tween (PBST) for 1 hour 
at room temperature. Primary antibodies and concentrations were as follows: GAPDH (Cell 
Signalling Technologies, MA, USA, clone 14C10, 1:2000), IDO-1 antibody (ThermoFisher 
Scientific, clone PA5-29819, 1:1000), anti-HPV16-E7 antibody (Fitzgerald industries, MA, USA, 
clone 10-7987, 1:1000). Visualization was done with Dura Western Blotting Kit (Thermo Scientific, 
USA) according to the manufacturer’s instructions 
B.11 RNASeq data alignment 
RNA-Seq reads for each sample were quality checked using FastQC (version 0.10.1, Babraham 
bioinformatics, Babraham Institute, Cambridge, UK) and aligned to the human genome build 38 
(GRCh38, GCF_000001405.33_GRCh38.p7_genomic.fna) primary assembly and HPV16 
genome (GCF_000863945.1_ViralProj15505_genomic.fna) simultaneously using STAR (version 
2.5.2B). After alignment, variants were discovered following GATK Best Practices workflow for 
RNAseq (https://gatkforums.broadinstitute.org/gatk/discussion/3892/the-gatk- best-practices- for- 
variant-calling- on-rnaseq- in-full- detail). Raw RNAseq reads were pre-processed by adding read 
groups, indexing, marking duplicates and sorting, Split’N’Trim, reassigning mapping quality and 
base recalibration. 
B.12 HLA typing 
For MSSM-cohort, HLA-typing was performed by Proimmune HLA-tissue typing services, UK. For 
HLA-calling from RNAseq data (TCGA and UM cohorts), PHLAT (Bai et al., 2014) was used to 
infer the HLA typing of the three major MHC class I (HLA-A, -B, -C) alleles (Bai, Ni, Cooper, Wei, 
& Fury, 2014a). The method employs a read mapping based selection of candidate allele 
followed by a likelihood based scoring over all pairwise combinations of selected alleles and 
infers the first four digits with a high accuracy (Bai, Ni, Cooper, Wei, & Fury, 2014b). For HLA-
odds ratio calculations, HLA-allele typing from all 3 cohorts (MSSM, TCGA and UM) were 
combined resulting in 64 HPV-HNSCC (TCGA) and 77 HPV+HNSCCs. 
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B.13 HPV16 epitope-prediction from RNAseq data 
HLA types obtained from PHLAT were used to predict the epitopes binding to patient-specific 
HLA alleles. Binding affinities were predicted using IEDB recommended algorithm from the 
Immune Epitope Database (IEDB) tool (Moutaftsi et al., 2006b; Vita et al., 2014). Reference fasta 
files for HPV protein sequences were used to predict peptide lengths of 8, 9, 10, 11 for each 
patient’s allele and peptide combination. If the matching HLA allele of the patient did not exist in 
the current IEDB list, the closest allele was identified by keeping the first two digits the same and 
searching for the nearest available match for the third and fourth digit. To retain only high affinity 
binding epitopes with the patient-specific HLA alleles, epitopes with a binding affinity greater than 
500 nM were not considered in downstream analyses.  
B.14 RNASeq datasets and gene signature sources 
Transcriptome data for HNSCC patient samples (n = 119) were obtained from TCGA (TCGA-
cohort), and University of Michigan study (UM-cohort) (Cancer Genome Atlas Network, 2015; 
Zhang et al., 2016). In total, there were 34 and 18 HPV+HNSCC samples from TCGA-cohort and 
UM-cohort respectively. HPV-HNSCC dataset comprised of 18 tumors from UM-cohort and 49 
tumors from TCGA dataset that were both HPV-negative by p16 status and HPV-FISH. For 
ssGSEA analysis, immune signatures, comprising of 509 genes were obtained from previous 
studies(Mandal et al., 2016a; Şenbabaoğlu et al., 2016a). Additional gene signatures were 
obtained as follows : Custom HPV gene sets were grouped into HPV (All 8 HPV genes), HPV. 
Onco (E6, E7) and HPV.Early (E2, E4, E5). TIGIT gene signature (50 genes) was obtained from 
Johnston et al (Rooney, Shukla, Wu, Getz, & Hacohen, 2015a), TIL.Treg (309 genes) and 
Exhaust gene sets (49 genes) were obtained from De Simone et al (De Simone et al., 2016), and 
CYT (GZMA, PRF) from Rooney et al (Rooney, Shukla, Wu, Getz, & Hacohen, 2015b).  
B.15 ssGSEA analysis of HPV and immune gene signatures 
All RNAseq analysis from HNSCC transcriptomes was performed on log transformed transcripts 
per million Log2(TPM+1) from each sample, after exclusion of low expression genes (< 1 average 
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Log2(TPM+1) across cohort). As opposed to GSEA, ssGSEA computes a gene set enrichment 
score for the relevant gene signatures on a per sample basis, without the need for a phenotypic 
pre-classification of the dataset. Thus, each patient’s tumor can be analyzed by pre-defined 
immune signatures, and have been extensively validated in Şenbabaoğlu et al (Şenbabaoğlu et 
al., 2016b)(Şenbabaoğlu et al., 2016c)(Şenbabaoğlu et al., 2016b), Mandal et al (Mandal et al., 
2016b). ssGSEA scores were computed for each tumor sample using the R package GSVA,  and 
Z-transformed across the cohort prior to analysis. To assess impact of HPV-gene expression on 
immune signatures, a correlation matrix was built using the R-library Corrplot with the Z-
transformed ssGSEA scores and was displayed by hierarchical clustering of correlations. 
Correlation values are displayed in Table S4. Individual gene expression analysis was performed 
by unsupervised hierarchical clustering methods and was used for heatmap analysis. 
B.16 Statistical Analysis 
Categorical variables, such as Elispot data, and Flow cytometric data were summarized as SFUs, 
and percentages. Continuous variables (RNAseq data) were presented with mean with standard 
error of mean (SEM). Unpaired T-test with Welch’s correction was used for all categorical variable 
analyses, and for continuous variable analyses non-parametric  Mann-Whitney’s test was used. 
For heatmaps of T-cell frequencies and ssGSEA RNASeq analyses, Z-transformation to 
normalize the data across the cohorts.  R statistical software V3.4.0 and Prism software 
(GraphPad Software) were used for data managements and statistical analyses. Significance 
levels were set at 0.1 (*), 0.01 (**) or 0.001 (***) for all tests as indicated. 
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Figure. B1. HLA-B*40:01 has low HPV16-predicted binding peptides. Distribution of HPV16-
predicted binding 9-11mer peptides from all 8 HPV16-antigens (IED-consensus IC50 < 500nM) 
for HLA-A, B alleles in TCGA+UM cohort (n=694 peptides), ranked by number of predicted 
peptides/ allele. HLA-B*40:01 is shown in red. Pareto line representing cumulative distribution of 
peptide frequencies is shown as dashed line.  
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Figure. B2. PD-1/CTLA-4 blocking antibodies can enhance in vitro expansion of peripheral 
CTLs. Assessment of ex vivo PBMC stimulation protocol after 10 days with αPD1+αCTLA-4 
blocking antibodies on day 1, compared to purified isotype IgG day 1 in healthy donor. 
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Figure. B3. (A) HPV16-E2, E6 and E7 genes do not alter IDO-1 levels in HEK-293 cells. HEK-
293-LX cells were transfected using Lipofectamine 2000 with the indicated antigens and 48 hours 
later IDO-1 expression levels were measured by immunoblots. (B) Cell surface PD-L1 protein 
expression analyzed by flow cytometry in the 6 HPV16+ cell lines. Normalized mean 
fluorescence intensity of 10,000 events each indicated by different color. The erythroleukemic cell 
line K562 represents the negative control. Red asterisk indicates SCC-104 cell line used in 
cytolysis experiments.  
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Table B-1. Summary of all predicted candidate HPV16-E2, E6 and E7 epitopes used for 
experiments. Peptide pool information from each antigen, relevant information for the epitope’s 
information from HPV T-cell antigen database (http://cvc.dfci.harvard.edu/hpv/). Highlighted 
epitopes represent immunogenic CTL-reactive epitopes identified in this study. 
 
 
Position HLA Sequence Length
IEDB.
bind
NetMHC.
bind
Syfpeithi.
bind
IEDB.
Prot
ANN.P
rot
Bind 
percentile
Total 
percentile
E2(329-338) HLA-B*15:01 KSAIVTLTY 9 0.8 78.78 15 0.96 0.81 82.62 82.54
E2(329-338) HLA-B*57:01 KSAIVTLTY 9 0.55 116.59 14 1.15 0.64 81.78 81.96
E2(329-338) HLA-A*01:01 KSAIVTLTY 9 0.55 128.89 22 0.28 0.6 88.97 89.92
E2(329-338) HLA-A*11:01 KSAIVTLTY 9 1.35 151.72 15 0.61 0.53 82.39 84.93
E2(329-338) HLA-A*03:01 KSAIVTLTY 9 1.15 245.15 19 0.15 0.32 85.99 89.78
E2(329-338) HLA-B*35:01 KSAIVTLTY 9 3.1 266.25 11 -0.09 0.28 78.12 85.46
E2(93-101) HLA-A*02:01 TLQDVSLEV 9 0.5 9.82 24 0.2 0.29 90.88 92.64
E2(138-147) HLA-A*02:01 YICEEASVTV 10 0.8 125.98 26 -0.73 -0.69 92.5 89.87
E2(37-45) HLA-A*11:01 RLECAIYYK 9 0.65 50.91 17 -0.34 -0.56 84.49 87.15
E2(37-45) HLA-A*03:01 RLECAIYYK 9 0.4 152.21 24 -0.73 -1.04 90.81 87.45
E2(284-292) HLA-A*11:01 NTTPIVHLK 9 0.6 34.72 24 -0.12 -0.28 90.82 92.97
E2(101-110) HLA-A*24:02 VYLTAPTGCI 10 1.05 162.38 24 -1.06 -0.87 90.59 86.68
E2(207-215) HLA-B*07:02 SPEIIRQHL 9 0.7 73.94 21 0.13 0.12 88.06 91.91
E2(303-311) HLA-B*08:01 YRFKKHCTL 9 0.3 11.1 20 0.51 1.28 87.34 85.27
E2(303-311) HLA-B*27:05 YRFKKHCTL 9 0.3 119.83 27 0.89 0.25 93.57 91.65
E2(303-311) HLA-B*40:02 YRFKKHCTL 9 2.8 695.16 14 -1.2 -0.51 80.63 81.6
E2(147-155) HLA-A*01:01 VVEGQVDYY 9 34.5 228.27 26 0.39 0.25 81.18 86.22
E2(69-77) HLA-A*02:01 ALQAIELQL 9 3.6 213.45 23 0.17 -0.27 88.8 91.59
E2(310-318) HLA-A*02:01 TLYTAVSST 9 3.6 656.75 21 -2.19 -2.17 86.69 74.57
E2(267-276) HLA-A*03:01 ILTAFNSSHK 10 0.35 25.3 27 -0.71 -0.55 93.62 91.19
E2(267-276) HLA-A*11:01 ILTAFNSSHK 10 0.95 75.17 17 -1.11 -1.02 84.37 82.15
E2(103-112) HLA-A*11:01 LTAPTGCIKK 10 0.45 64.89 26 -0.59 -0.63 92.66 90.77
E2(103-112) HLA-A*03:01 LTAPTGCIKK 10 1.1 234.38 14 -1.3 -1.18 81.51 79.02
E2(218-227) HLA-B*07:02 HPAATHTKAV 10 0.35 16.59 20 0.01 0.18 87.32 91.71
E2(62-70) HLA-B*08:01 LAVSKNKAL 9 1.3 232.92 27 -0.84 -0.38 93.16 91.08
E2(62-70) HLA-B*35:01 LAVSKNKAL 9 4.3 666.47 13 -1.47 -0.84 79.24 78.36
E2(263-271) HLA-B*35:01 DSAPILTAF 9 2.6 166.28 12 0.55 0.09 79.26 85.07
E2(94-102) HLA-B*15:01 LQDVSLEVY 9 0.8 243.23 21 -0.3 0.3 87.91 90.42
E2(94-102) HLA-A*01:01 LQDVSLEVY 9 41 259.3 27 -0.2 0.27 79.89 86.12
E2(102-110) HLA-A*02:01 YLTAPTGCI 9 4.4 470.3 22 -1.22 -1.41 87.45 81.98
E2(191-199) HLA-A*02:01 QVILCPTSV 9 4.6 672.2 18 -1.86 -1.64 83.64 76.2
E2(297-306) HLA-A*02:01 TLKCLRYRFK 10 53.5 24400.31 9 -3.11 -3.07 42.84 40.94
E2(297-306) HLA-A*03:01 TLKCLRYRFK 10 0.45 85.36 21 -0.67 -0.62 88.14 87.78
E2(297-306) HLA-A*11:01 TLKCLRYRFK 10 1.05 86.84 16 -0.89 -0.63 83.43 84.04
E2(302-312) HLA-A*24:02 RYRFKKHCTL 10 0.55 120.86 20 0.11 0.32 87.18 90.66
E2(302-312) HLA-B*27:05 RYRFKKHCTL 10 10.6 122.95 15 0.73 0.32 79.32 83.46
E2(249-257) HLA-B*07:02 NPCHTTKLL 9 1.1 1802.85 21 -1.43 -1.55 86.74 80.14
E2(163-171) HLA-B*15:01 GIRTYFVQF 9 0.3 110.82 16 0.27 0.67 83.67 86.49
E2(163-171) HLA-B*08:01 GIRTYFVQF 9 1.8 365.55 18 -0.35 0.15 84.79 88.95
E2(158-167) HLA-B*15:01 YYVHEGIRTY 10 8.75 59.78 14 1.11 1.05 79.08 78.85
E2(158-167) HLA-B*35:01 YYVHEGIRTY 10 0.8 485.11 13 0.3 0.14 80.54 86.64
Prediction scores, percentiles
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Table B-1 continued 
 
 
Position HLA Sequence Length
IEDB.
Bind
NetMHC.
Bind
Syfpeithi.
Bind
IEDB 
Prot
ANN.
Prot
Bind 
Percentile
Total 
Percentile
E6(82-90) HLA-A*24:02 EYRHYCYSL 9 1.3 573.3 19 -0.68 -0.86 89.14 87.52
E6(82-90) HLA-B*08:01 EYRHYCYSL 9 1.3 588.7 18 -0.69 -0.4 88.12 88.7
E6(33-41) HLA-A*03:01 IILECVYCK 9 0.7 265.9 23 -1.28 -1.21 93.59 86.41
E6(33-41) HLA-A*11:01 IILECVYCK 9 0.55 35.9 18 -0.41 -0.49 88.74 89.83
E6(80-88) HLA-A*01:01 ISEYRHYCY 9 0.25 107.9 27 0.82 1.33 97.89 90.34
E6(59-67) HLA-B*15:01 IVYRDGNPY 9 0.7 46.1 18 0.88 0.76 88.69 86.85
E6(59-67) HLA-B*35:01 IVYRDGNPY 9 0.9 36.9 12 0.98 1.07 82.57 81.55
E6(59-67) HLA-B*57:01 IVYRDGNPY 9 2.75 6475.6 4 -1.27 -0.97 69.53 72.97
E6(18-26) HLA-A*02:01 KLPQLCTEL 9 1.8 227 24 -0.43 -0.1 94.26 94.61
E6(15-24) HLA-B*07:02 RPRKLPQLCT 10 1.5 496.2 22 -2.03 -1.56 92.16 81.18
E6(93-101) HLA-A*11:01 TTLEQQYNK 9 0.3 27.5 21 -0.44 -0.38 91.86 92.02
E6(68-77) HLA-A*11:01 AVCDKCLKFY 10 2.5 533.8 15 0.03 0.42 84.73 89.21
E6(87-95) HLA-A*24:02 CYSLYGTTL 9 0.75 189.4 20 -0.21 0.03 90.59 93.56
E6(44-52) HLA-B*15:01 LLRREVYDF 9 1.2 87.9 20 0.4 -0.11 90.51 92.44
E6(44-52) HLA-B*08:01 LLRREVYDF 9 1.5 427 19 -0.29 -0.36 89.17 91.08
E6(65-74) HLA-B*07:02 NPYAVCDKCL 10 4.1 2833.6 21 -1.43 -1.53 88.7 81.61
E6(29-38) HLA-A*02:01 TIHDIILECV 10 2.65 320.2 23 -1.2 -1.13 92.9 86.64
E6(69-77) HLA-A*01:01 VCDKCLKFY 9 0.95 4559.1 26 -0.98 -1.13 93.64 87.96
E6(67-76) HLA-B*35:01 YAVCDKCLKF 10 0.5 578.6 9 -0.3 -0.44 79.3 84.8
E6(67-76) HLA-B*15:01 YAVCDKCLKF 10 14.3 341.8 9 -0.07 -0.66 74.86 82.17
E6(119-126) HLA-B*07:02 CPEEKQRHL 9 2.5 893.3 20 -1.47 -1.91 89.54 80.44
E6(37-47) HLA-A*11:01 CVYCKQQLLR 10 1.9 348.8 24 -0.85 -1.01 94.14 89.25
E6(37-47) HLA-A*03:01 CVYCKQQLLR 10 1.15 377.7 21 -0.88 -0.36 91.34 90.04
E6(127-135) HLA-B*08:01 DKKQRFHNI 9 0.2 210.8 24 -1.04 -0.8 94.8 89.73
E6(52-60) HLA-A*02:01 FAFRDLCIV 9 2.3 115 20 -0.91 -1.04 90.13 86.48
E6(106-116) HLA-A*03:01 LLIRCINCQK 10 0.9 79.4 29 -0.85 -1.19 99.71 91.88
E6(106-116) HLA-A*11:01 LLIRCINCQK 10 1.5 196.5 17 -1.25 -1.5 87.31 81.61
E6(82-90) HLA-B*35:01 YGTTLEQQY 9 3 395.1 11 -0.11 0.08 80.61 87.77
Prediction scores, percentiles
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Table B-1 continued 
 
 
Position HLA Sequence Length
IEDB.
Bind
NetMHC.B
ind
Syfpeithi.
Bind
IEDB. 
Prot
ANN. 
Prot
Bind 
Percentile
Total 
Percentile
E7(15-23) HLA-B*15:01 LQPETTDLY 9 0.8 233.2 22 0.03 0.34 91.09 93.7
E7(15-23) HLA-A*01:01 LQPETTDLY 9 1.85 7312.4 17 -1.46 -1.5 81.2 77.08
E7(2-11) HLA-A*01:01 HGDTPTLHEY 10 0.45 413.9 28 -0.11 -0.55 96.8 95.92
E7(2-11) HLA-B*35:01 HGDTPTLHEY 10 2.05 3444.2 13 -1.03 -1.02 79.93 80.08
E7(2-11) HLA-B*57:01 HGDTPTLHEY 10 31.35 11936 10 -1.57 -1.37 61.57 65.39
E7(82-90) HLA-A*02:01 LLMGTLGIV 9 0.5 16 29 -0.12 -0.31 98 97.6
E7(82-90) HLA-B*15:01 LLMGTLGIV 9 8 860.8 10 -1.85 -2.29 76.83 69.57
E7(51-60) HLA-A*03:01 HYNIVTFCCK 10 2.2 4049.9 11 -2.21 -2.13 77.57 69.21
E7(51-60) HLA-A*11:01 HYNIVTFCCK 10 3.3 1212.9 11 -1.69 -1.62 79.12 74.39
E7(88-97) HLA-A*11:01 GIVCPICSQK 10 1.35 109 19 -1.04 -1.28 88.13 83.87
E7(88-97) HLA-A*03:01 GIVCPICSQK 10 1 156.6 24 -1.2 -1.54 92.98 85.04
E7(5-13) HLA-B*07:02 TPTLHEYML 9 1.7 505.2 20 -0.97 -0.98 88.7 85.75
E7(5-13) HLA-B*08:01 TPTLHEYML 9 4.4 1881.9 17 -1.54 -1.58 84.01 78.11
E7(5-13) HLA-B*35:01 TPTLHEYML 9 4.1 1139.5 20 -1.32 -0.58 87.47 85.25
E7(16-25) HLA-B*44:02 QPETTDLYCY 10 4.05 647.1 12 -0.19 -0.11 80.2 87.47
E7(16-25) HLA-B*35:01 QPETTDLYCY 10 0.6 653 22 -0.2 0.18 90.87 93.54
E7(7-15) HLA-A*02:01 TLHEYMLDL 9 2.1 64.9 24 -0.28 -0.16 92.67 94.37
E7(7-15) HLA-B*07:02 TLHEYMLDL 9 17 21631.5 12 -2.8 -2.6 61.73 55.34
E7(7-15) HLA-B*08:01 TLHEYMLDL 9 6.3 3016.1 18 -1.95 -1.44 83.56 76.75
E7(7-15) HLA-B*35:01 TLHEYMLDL 9 36 18002.2 11 -2.72 -2.79 56.88 51.96
E7(49-57) HLA-B*07:02 RAHYNIVTF 9 3.8 1801.2 9 -0.6 -0.75 76.65 80.99
E7(49-57) HLA-B*08:01 RAHYNIVTF 9 9 4103.7 13 -0.95 -1.12 77.17 78.33
E7(49-57) HLA-B*15:01 RAHYNIVTF 9 0.5 64.7 11 0.85 0.75 80.82 82.48
E7(49-57) HLA-B*57:01 RAHYNIVTF 9 0.6 233.8 14 0.29 0.25 83.53 88.48
E7(49-57) HLA-B*35:01 RAHYNIVTF 9 0.8 283.5 11 0.21 0.35 80.58 86.61
E7(85-93) HLA-A*02:01 GTLGIVCPI 9 4.4 107.2 21 -1.1 -1.37 89.02 83.79
E7(89-97) HLA-A*11:01 IVCPICSQK 9 0.45 66.9 21 -0.8 -0.67 90.36 88.74
E7(89-97) HLA-A*03:01 IVCPICSQK 9 0.55 182 31 -1.24 -1.42 99.78 89.46
E7(56-65) HLA-A*24:02 TFCCKCDSTL 10 4.4 5243 17 -1.68 -1.92 81.75 74.76
E7(44-53) HLA-B*35:01 QAEPDRAHY 9 4.9 462.8 12 0.13 -0.33 80.04 86.7
E7(11-19) HLA-A*02:01 YMLDLQPET 9 0.4 30.4 21 -0.59 -0.43 90.4 90.62
E7(11-20) HLA-A*02:01 YMLDLQPETT 10 1.45 236.8 19 -1.62 -1.49 88.01 80.55
Prediction scores, percentiles
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Table B-1 continued (Cross reactive epitopes) 
 
Patient HLA Epitope Sequence IC50  (ANN) Predicted HLA
A*68:01 E2(267-276) ILTAFNSSHK 66.98 A*03:01/A*11:01
A*68:01 E2(284-292) NTTPIVHLK 4.94 A*11:01
A*68:01 E2(297-306) TLKCLRYRFK 182.15 A*03:01/A*11:01
A*68:01 E2(37-45) RLECAIYYK 711.12 A*03:01/A*11:01
A*68:01 E6(106-115) LLIRCINCQK 183.06 A*03:01/A*11:01
A*68:01 E6(33-41) IILECVYCK 803.58 A*03:01/A*11:01
A*68:01 E6(37-46) CVYCKQQLLR 72.47 A*03:01/A*11:01
A*68:01 E6(93-101) TTLEQQYNK 58.08 A*11:01
A*68:01 E7(51-60) HYNIVTFCCK 505.69 A*03:01/A*11:01
A*68:01 E7(88-97) GIVCPICSQK 469.86 A*03:01/A*11:01
A*68:01 E7(89-97) IVCPICSQK 72.24 A*03:01/A*11:01
B*14:02 E2(147-155) VVEGQVDYY 492.79 A*01:01
A*32:01 E2(329-337) KSAIVTLTY 50.93 A*01:01/A*03:01/A*11:01/B*15:01/B*35:01/B*57:01
A*11:01 E6(68-77) AVCDKCLKFY 219.88 A*11:01
A*68:01 E2(103-112) LTAPTGCIKK 85.73 A*03:01/A*11:01
A*68:01 E2(284-292) NTTPIVHLK 4.94 A*11:01
A*68:01 E2(297-306) TLKCLRYRFK 182.15 A*03:01/A*11:01
A*68:01 E6(106-115) LLIRCINCQK 183.06 A*03:01/A*11:01
A*68:01 E6(37-46) CVYCKQQLLR 72.47 A*03:01/A*11:01
A*68:01 E6(93-101) TTLEQQYNK 58.08 A*11:01
A*32:01 E7(85-93) GTLGIVCPI 12.13 A*02:01
7027 A*03:01 E6(93-101) TTLEQQYNK 492.96 A*11:01
7030 A*03:01 E6(93-101) TTLEQQYNK 492.96 A*11:01
7007
7015
7019
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Table B-2. Gene signatures for ssGSEA used in this study.  HPV-Gene sets and immune 
signatures derived from for immunogenomic analyses 
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Table B-3. Clustered correlation matrix values for each gene-set correlations 
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Figure 1-2 Copyright permission 
Sri Krishna <Srikrishna@asu.edu>                                             Thu, Sep 28, 2017 at 11:36 AM  
 
  
Dear Sri Krishna 
We hereby grant you permission to reproduce the material detailed below at no charge in your 
thesis, in print and on ASU Electronic Theses and Dissertations and subject to the following 
conditions: 
1. If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must also be 
sought from that source.  If such permission is not obtained then that material may not be 
included in your publication/copies.  
2. Suitable acknowledgment to the source must be made, either as a footnote or in a 
reference list at the end of your publication, as follows: 
“This article was published in Publication title, Vol number, Author(s), Title of 
article, Page Nos, Copyright Elsevier (or appropriate Society name) (Year).” 
3. Your thesis may be submitted to your institution in either print 
or electronic form. 
4. Reproduction of this material is confined to the purpose for which 
permission is hereby given.  
5. This permission is granted for non-exclusive world English rights only. For other 
languages please reapply separately for each one required. Permission excludes use in an 
electronic form other than as specified above.  Should you have a specific electronic project in 
mind please reapply for permission. 
6. This includes permission for UMI to supply single copies, on demand, of the 
complete thesis.  Should your thesis be published commercially, please reapply for permission 
 
Yours sincerely 
 
Jennifer Jones, 
Permissions Specialist 
Elsevier Limited, a company registered in England and Wales with company number 1982084, whose 
registered office is The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom. 
